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Chapter 1
General Introduction
Background
Asthma and COPD (chronic obstructive pulmonary disease) are both entities o f obstructive 
airways diseases. In Dutch general practice the prevalence o f asthma and COPD is 
estimated to be approximately 1-5%^ Recent data from  the Dutch Continuous Morbidity 
Registration in four general practices located near Nijmegen demonstrate a prevalence 
o f asthma as well as COPD o f approximately 2% , which doubled over the past 15 years 
(see Table 1.1).2 Tirim anna et al also revealed an increase in the prevalence o f asthma 
and COPD in the Netherlands between 1977 and 19 9 2 , especially in m ilder cases o f the 
disease3, which are com monly treated in general practice. United States consensus
Table 1.1: The prevalence and incidence o f asthma and COPD in general practice 
according to the Continuous Morbidity Registration in the Netherlands (see text).2
Asthma 
prevalence % incidence %
CO P D
prevalence % incidence %
1971-1975 0.78 0.23 1.88 0.45
1976-1980 0.83 0 .18 2.14 0.28
1981-1985 0.86 0 .18 1.95 0.15
19 8 6 -19 9 0 1.37 0.27 2.11 0 .22
1 991-1995 1.91 0.30 2.60 0.30
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reports on asthma and COPD state a rising prevalence and rising mortality o f asthma, 
both o f 30% 4, and o f  COPD o f 30 and 40 %  respectively5 in the past two decades. 
Theoretically these alarm ing data point to the importance o f diagnosing and treating 
subjects with asthma and COPD as early as possible. These observations should be 
considered within the context o f the (Dutch) general practice research o f the past decades.
The benefits and potentials o f  early detection, monitoring and treatment o f patients 
with other chronic illnesses in general practice (in particular cervical cancer and 
hypertension) have been studied extensively.6-8 It would be interesting to know i f  early 
detection and treatment o f patients with asthma and COPD will be clinically effective. 
In fact ‘treatment’ in medical care is multifactorial, while evidence-based medicine 
evaluations often centre on one particular kind o f intervention.9 In asthma, for example, 
preventing exposure to allergens, and, in COPD, giving up sm oking have proved to be 
valuable ‘treatment’ options. This thesis focuses specifically on drug treatment o f 
asthma and COPD. Bronchial inflam m ation is considered to be the underlying cause o f 
clinical asthma and probably also o f COPD (see below). Recent (Dutch) consensus 
reports on asthma and COPD in general practice advise the prescription o f anti­
inflamm atory drugs, i.e. inhaled corticosteroids, as the cornerstone o f treatment, 
especially in asthm a.10'11 In this thesis research data about several aspects o f  treatment 
with inhaled corticosteroids are presented.
The eventual purpose o f clinical research is improvement o f patient care. A s the 
majority o f patients with (mild) asthma and COPD are treated in general practice12, this 
is by far the best domain for investigating aspects o f treatment. Part One o f this thesis 
presents data from  a general-practice-based intervention with inhaled corticosteroids, 
the so-called D IM CA project (DIMCA is an acronym for early Detection, Intervention 
and Monitoring o f Asthm a and COPD). The design and part o f the results o f  D IM CA 
have already been published.3,13-19 In this thesis I will investigate several aspects o f  early 
intervention with inhaled corticosteroids in patients with mild signs o f asthma or COPD 
without a clear diagnosis, participating in the D IM CA program m e.
The prescription o f inhaled corticosteroids as treatment o f choice has obviously 
proved to be beneficial in asthma, but, until now, not so in COPD. Questions about the 
optimal start, duration and dosage o f  treatment with inhaled corticosteroids rem ain 
unanswered where asthma and COPD patients are concerned. These questions 
constitute the basis o f Part Two o f this thesis.
In Part Three o f  the thesis the sum m ary and the general discussion is presented.
Clinical presentation and pathophysiology o f asthma
Asthm a is clinically characterized by bronchial sym ptom s and bronchial hyper­
responsiveness partly provoked by exposure to allergic or nonspecific stim uli.20 
In Figure 1.1, the dark grey zone represents the clinical manifestation o f asthma as a 
combination o f bronchial hyperresponsiveness, symptoms such as wheezing and 
dyspnea and atopy.
The m ucosa contributes to a large extent to m aintaining bronchial hyper­
responsiveness by release o f inflam m atory m ediators as histam ine and 
cytokines21 and by infiltration o f eosinophils.22 Chronic bronchial inflammation may 
result in damage and structural changes o f  the bronchial wall, also known as ‘airway
10
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re-modelling’.23 This process may have been responsible for the increased lung function 
decline that was demonstrated during 15 years in 1,095 adult patients with chronic asthma.24
Early treatment o f asthma with inhaled corticosteroids
Inhaled corticosteroids form  the cornerstone o f treatment o f bronchial inflammation, 
especially in asthm a.25 They were introduced in the 19 70 s as a new anti-inflammatory 
treatment for moderate to severe asthma, and were promoted for their safety compared 
to oral glucocorticoids.26 Inhaled corticosteroids reduce the infiltration o f inflammatory 
cells (such as m ast cells, m acrophages, T-lymphocytes and eosinophils) in the 
bronchial m ucosa27 and inhibit the release o f inflamm atory mediators from  these 
cells.25 Clinically, in the case o f asthma, inhaled corticosteroids reduce bronchial 
hyperresponsiveness and sym ptom s.28
The past ten years showed a gradual shift from  treatment with inhaled corticosteroids 
in moderate to severe asthma to treatment o f m ilder cases.28'29 Several reports on 
patients with asthma show that bronchial inflam m ation is already present in very mild 
stages o f the disease.21,30 Theoretically, rem odelling o f the airways as a result o f chronic 
bronchial inflam m ation may be prevented by treatment with inhaled corticosteroids 
as early as possible. It was shown that treatment with inhaled corticosteroids 
in patients with newly diagnosed asthma resulted in improvement o f m arkers o f 
airway inflam m ation31, preservation o f lung function32, and a reduction in hospital 
adm issions.33
Figure 1.1: Theoretical model o f the relationship between the main features 
contributing to or being at risk o f  the clinical manifestation o f asthma.
Bronchial
Hyp erresponsiveness Symptoms
= Asthma
= Asymptomatic Bronchial 
Hyp erresponsiveness
Atopy
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Clinical presentation and pathophysiology o f COPD
COPD is defined by irreversible bronchial obstruction and includes chronic bronchitis, 
small airways disease and em physem a.34 The disease is clinically characterized by the 
presence o f continuous chronic bronchial symptoms (dyspnea, productive cough). The 
bronchiolar changes and alveolar destruction are m ostly initiated by cigarette 
sm oking.35 In Figure 1.2 a sim plified model is presented, showing the contribution o f 
an increased perm anent airway obstruction, symptoms and sm oking to the clinical 
manifestation o f  COPD (dark grey zone).
The inflam m ation in bronchi and sm all airways is characterized by an increase in 
neutrophils and the production o f  mediators and proteolytic enzymes. These enzymes, 
generated by inflamm atory cells, and oxidants, inhaled with cigarette smoke, are 
regarded to be responsible for the destruction o f  the alveolar structures, resulting in 
em physem a.36 Both inflam m ation (leading to bronchial obstruction) and destruction 
are responsible for a progressive decline in lung function (represented by the FEVI, 
the forced expiratory volume in one second), while the physiological FEVI decline is
0 .02-0.03 L/year.37
Early treatment o f COPD with inhaled corticosteroids
Prescription o f inhaled corticosteroids in COPD is com mon in general practice38, 
although the role o f these anti-inflammatory drugs in COPD is not clarified. Inhaled 
corticosteroids have recently been shown to reduce the num ber o f  neutrophils in the 
bronchial m ucosa o f patients with COPD.39 On the other hand, Keatings et al showed 
that a 2-week treatment with 800  |j,g inhaled budesonide did not result in a reduction 
o f eosinophil and neutrophil activation m arkers in induced sputum  in 13 patients with 
COPD.40 The evidence o f their clinical benefit rem ains a matter o f  debate.41 Three 
long-term studies to be published, did not demonstrate a convincing influence o f 
inhaled corticosteroids on the long-term course o f lung function.42"44 Three other large 
long-term studies not yet published (EUROSCOP, ISOLDE and CO PENH AGEN CITY 
LUNG), in which patients with different stages o f COPD were treated with different 
dosages o f inhaled corticosteroids, also do not seem  to demonstrate a clinical relevant 
influence o f  inhaled corticosteroids on lung function decline.45 On the other hand, a 
recent six-monthly study o f patients with moderate COPD who were treated with 
high doses o f inhaled corticosteroids found sm all improvements in lung function, 
exacerbations and sym ptom s.46
In patients with COPD there is not yet clear evidence o f a preservation o f  lung 
function by early treatment with inhaled corticosteroids (in contrast to asthma). 
However, in persons at risk o f developing COPD, i.e. cigarette smokers, a form  o f 
inflam m ation has shown to be present.35 Theoretically, early treatment with inhaled 
corticosteroids could avoid increasing inflam m ation and hence prevent the occurrence 
o f irreversible changes in the bronchial wall.
Detection o f early stages o f asthma and COPD
I f  early intervention (with inhaled corticosteroids) were to prove efficacious, subjects 
would ideally have to be detected before the disease has manifested itself clinically. In
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such a very early stage, the ‘disease’ will be largely asymptomatic. To detect it at this 
stage, objective m easures o f the lung function will be required.
In asthma, asymptomatic bronchial hyperresponsiveness has shown to be a possible 
precursor o f the disease (light grey zone in Figure i . i ).47 Theoretically, in COPD, the 
observation o f  a sm all increase o f the FEVI decline with near normal lung function and 
without symptoms may indicate the start o f irreversible bronchial obstruction (light grey 
zone in Figure i.2).
Part one o f the thesis
In the D IM CA program m e bronchial hyperresponsiveness and an increased FEVI 
decline were chosen as objective early indicators o f  asthma and COPD respectively. 
It was hypothesized that these possible precursors, i f  not treated with inhaled 
corticosteroids, would lead to clinical cases. This was the m ain hypothesis o f the 
DIM CA program m e. Therefore, in these patients with m ild signs o f asthma and 
COPD the clinical effects o f inhaled fluticasone propionate, a relatively new inhaled 
corticosteroid, were assessed. The results o f this study - the intervention part o f the 
D IM CA program m e - presented in Chapter 3 form  the m ain body o f  Part One o f this 
thesis.
Inhaled corticosteroids, once started with, have to be taken daily over a long period o f 
time and may cause local adverse effects and, in higher doses, also systemic side-effects. 
The absence o f severe symptoms in very m ild cases in a screening program m e such as 
the D IM CA program m e, and the fear o f adverse effects, may influence the willingness 
to undergo early treatm ent.48 A lso, the occurrence o f side-effects o f  inhaled cortico­
steroids49 once treatment has started may decrease compliance rates. These issues are 
also investigated in the intervention part o f  the DIM CA programme. Chapter 2 describes
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the willingness to use inhaled corticosteroids in early stages o f asthma or COPD. 
Chapter 4 decribes the compliance to inhaled fluticasone propionate in subjects with 
early signs o f asthma and COPD.
Part two o f the thesis
This thesis does not only report on the experimental data from the DIMCA project, but 
also tries to put these data into a wider perspective. Questions about the optimal start, 
duration and dosage o f treatment with inhaled corticosteroids have to be resolved, 
where asthma and COPD patients are concerned. Meta-analysis was one o f the methods 
used for this purpose (Chapter 5 and 7).
A top-down strategy (start high, go low once control is achieved) is advised in 
recent consensus reports on asthma, also in patients who had never used inhaled 
corticosteroids ('corticosteroid-naive’ patients).50 However, this advice is not supported 
by clinical evidence. Chapter 5 describes a meta-analysis o f the effect o f inhaled 
corticosteroids on bronchial responsiveness (the hallmark o f asthma) in patients with 
‘corticosteroid-naive’ asthma.
In the light o f the possible adverse effects o f inhaled corticosteroids, it is important 
to assess i f  patients on inhaled corticosteroids can stop this treatment in a stable phase 
o f the disease. Chapter 6 deals with this problem, using data from a previous study of 
our research group concerning patients with mild asthma.
As I have already stated, the clinical effects, optimal dose and duration o f treatment 
with inhaled corticosteroids in COPD remains a matter o f debate. In Chapter 7, a meta­
analysis is performed o f studies assessing the long-term effect o f inhaled corticosteroids 
in patients with COPD. Only patients with a strict diagnosis o f COPD, i.e. without 
asthma features, were analysed. In order to minimize the influence o f publication bias, 
published as well as unpublished studies were checked. We found an unpublished 
French study, o f which we were able to use the original data for the meta-analysis.51 As 
a result o f our contacts with the French authors, we were also given the opportunity to 
analyse and publish the whole original data set in cooperation with Prof. J.Ph. Derenne 
and Prof. T. Similowski, the investigators in question. Chapter 8 presents the two-year 
clinical effects o f inhaled corticosteroids in a French group o f patients with moderate 
COPD.
Research questions
The research questions and corresponding chapters o f Part One and Part Two o f this 
thesis are:
Part one (data from  th e  DIM CA study)
Chapter 2 Is the w illingness o f patients with m ild signs o f
asthma or COPD to use inhaled corticosteroids* 
dependent on the fear o f  adverse effects?
Chapter 3 What are the clinical effects o f inhaled corticosteroids
in patients with ‘m ild signs o f  CO PD ’ or ‘m ild signs 
o f asthma’?
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Chapter 4 Are patients with early signs o f  asthma and 
COPD compliant during treatment with inhaled 
corticosteroids?
Part  two 
Chapter 5 
Chapter 6 
Chapter 7 and Chapter 8
What is the effect o f inhaled corticosteroids on 
bronchial responsiveness in ‘corticosteroid-naive’ 
asthma?
Is it possible to stop inhaled corticosteroids in a 
stable phase o f m ild asthma?
What are the clinical effects o f  inhaled corticosteroids 
in patients with moderate to severe COPD?
*In this thesis the words ‘corticosteroids’ and ‘steroids’ are identical. The m anuscripts
in which these words are used have been submitted to several journals, which use
either o f these words.
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Abstract
Treatment o f chronic airflow obstruction with inhaled corticosteroids at an early stage 
has been shown to preserve the lung function. We tested the hypothesis that 'fear o f 
corticosteroids’ may be an important reason for nonparticipation in the Detection, early 
Intervention and Monitoring program m e on Chronic obstruction pulm onary disease 
(COPD) and Asthm a (‘D IM CA’) project.
One thousand seven hundred and forty nine adult subjects from  i0  general practices 
were invited to participate in the several parts o f the ‘DIM CA’ program m e. Refusers 
were questioned about the reason(s) for nonparticipation.
Together the screening, monitoring and three drug interventions o f the study showed 
on average 25-35% refusers. The most frequent reasons for nonparticipation were 
absence o f pulm onary symptoms and lack o f time. For those invited to take part in one 
o f the three drug interventions, ‘dislike o f medication’ was the m ost important reason 
for nonparticipation (33, 45 and 67%  o f the refusers). ‘Fear o f corticosteroids’ specifically 
was the reason for nonparticipation in 8%  o f the refusers on the basis o f ‘dislike o f 
medication’.
We concluded a specific fear o f corticosteroids was not a m ajor obstacle for early 
intervention with inhaled corticosteroids.
Introduction
Inhaled corticosteroids are considered as first-line treatment in asthm a.I Treatment with 
inhaled corticosteroids in adult patients with newly detected asthma has been shown to 
preserve the lung function.2 In chronic obstructive pulm onary disease (COPD), inhaled 
corticosteroids may prove to be beneficial to subgroups o f COPD patients in the 
short-term,3 but the long-term effects are still under investigation.4 To be able to treat 
asthma and COPD at an ‘early’ stage, detection o f subjects with few symptoms m ight be 
necessary.
Inhaled corticosteroids are promoted for their relative safety, though local side-effects 
such as hoarseness and oral candidiasis, and when used in high doses, also systemic 
side-effects such as suppression o f  serum  cortisol levels, have been described.5 In 
their study, Bosley et al6 discussed psychological factors associated with poor compliance 
in asthma. They reported that in some asthmatic patients an unjustified fear o f 
corticosteroids or an overemphasis o f the side-effects o f  corticosteroids have been 
recognized as a possible reason for underusage o f these drugs. We hypothesized that 
‘fear o f corticosteroids’ was the m ain reason for nonparticipation in our large Detection, 
Monitoring and early Intervention program m e with inhaled corticosteroids in COPD 
and Asthm a. (‘D IM CA’) study.
Methods
‘DIM CA’ d esig n  and  r efu sers
In I9 9 I, a random sam ple o f i,749  apparently healthy adult subjects from  i0  general 
practices in the area o f Nijmegen, the Netherlands were invited by letter to participate 
in a screening program m e on signs and symptoms o f asthma and COPD. Six hundred 
and four subjects with m ild signs/sym ptom s were subsequently invited to participate in
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a 2 yr monitoring program m e with quarterly lung function m easurem ents. Two 
hundred and fifty two patients showed an increased lung function decline or bronchial 
hyperresponsiveness during the study period and they were invited by letter to 
participate in one o f  three randomized, double-blind, placebo-controlled intervention 
trials with an inhaled corticosteroid (fluticasone, 500 |j,g daily). Subjects could only 
participate in one trial.
‘Drug intervention i ’ (duration i yr) included patients selected within 6 months o f 
monitoring with undetected COPD. ‘Drug intervention 2 ’ (duration 2 yrs) started 
after i yr o f monitoring and included patients with a rapid decline in lung function and 
signs o f  bronchial hyperresponsiveness. After the 2 yr monitoring period, patients with 
a m oderately increased decline in lung function or with signs o f  bronchial 
hyperresponsiveness were included in ‘Drug intervention 3 ’ (duration i yr for patients 
with bronchial hyperresponsiveness and 2 yrs for patients with an increased decline in 
lung function). In the letters o f invitation for the screening, monitoring and trials, the 
reason for selection was explained. Subjects invited for the trials were also inform ed in 
writing about the effects and possible side-effects o f fluticasone. Written inform ed 
consent was obtained from  all participants o f the trials. Refusers were defined as 
subjects who were considered eligible for the screening, m onitoring or one o f  the 
drug interventions, but who actively refused to participate after a m ailing and one phone 
call, urging participation.
M easurem en ts
In I9 9 6 , all refusers received by mail a multiple choice questionnaire concerning the 
reasons o f nonparticipation by mail (Table 2.i). The questionnaire had been developed 
especially for this study. Subjects were allowed to give more than one reason for non­
participation. The final question in the questionnaire asked whether the decision to not 
participate would change i f  this program m e was not an experiment but part o f  routine 
medical care. The refusers who did not respond to the questionnaire were sent one 
reminder. In order to gain m ore specific details about the reasons for refusal, refusers 
who had given perm ission in the questionnaire were phoned again and reasons for 
refusal explored in a structured standardized interview.
Results
The refusal rates were: 34%  (95% confidence interval (CI) 32-36%) for the screening; 
25%  (95%  CI 2i-29% ) for the monitoring; 35% (95% CI 23-49%) for Drug intervention 
i; 33%  (95%  CI 23-44%) for Drug intervention 2; and 28%  (95% CI 20-37%) for Drug 
intervention 3. Refusers did not differ from  participants with respect to age or sex. The 
refusers o f the monitoring part had a higher level o f  education than the participants.
Two hundred and sixteen (52%) o f the 4 II subjects who were sent a questionnaire 
completed and returned the questionnaire immediately. Another 28 (7%) subjects 
responded after a rem inder (Table 2.i). The overall response rates in the different stages 
were 48-94% . The m ain reason for refusing to participate in one o f  the stages o f 
‘DIM CA’ was the absence o f respiratory symptoms (33-67% o f the refusers). Time 
constraints were mentioned by 5-49% o f the refusers. Additional in-depth interviews in 
46  subjects identified that work and children were critical reasons for nonparticipation.
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Table 2.1: The response to the postal questionnaire mailed to all refusers o f the Detection, early Intervention and Monitoring program­
me on Chronic obstructive pulmonary disease and Asthma (‘DIMCA’ project), and the reasons for refusing to participate.
Refusers of  
screening (n=5o6)
Refusers of 
monitoring (n=i5i)
Refusers of Drug 
intervention! (n=ig)
Refusers of Drug 
intervention 2 (n==26)
Refusers of Drug 
intervention 3 (n=33)
Male
%
Age
yrs
Male
%
Age
yrs
Male Age 
% yrs
Male
%
Age
yrs
Male
%
Age
yrs
Refusers mailed 208* 39
n=99
4 9 + 14
n=99
125+ 31 46+ 13 19 39 4 6 + 12 26 27 45+ 14 33 42 4 6+11
Removed/ died 32 No 
data
No
data
16 25 39 + 10 0 0 2 0 50+9
Non-responders 
(after reminder)
77 No 
data
No
data
28 21 43+ 13 7 43 53± i ° 5 4 0 35+11 0
Responders 
(after reminder)
99  39 4 9 + 14 81 35 48+13 12 33 4 2+ 11 21 24 48+13 31 45 4 6+11
Reasons for refusing to participate
No com plaints 41 (41) 30  (37) 4  (33) 14  (67) 14  (45)
Lack o f  time 29 (29) 4 0  (49) 5 (42) 1 (5) 9 (29)
Dislike o f testing 
or research
49  (49 ) 18  (22) 1 (8) 3 (14) 8 (2 6 )
Dislike o f m edication^ Not asked Not asked 4  (33) 14  (67) 14  (45)
Other reasons^ 35 (35) 51 (63) 5 (42) 13  (62) 18  (58)
Age data are presented as m ean+SD . Data concerning reasons for refusal to participate are presented as absolute num ber and percentage o f  responders in parenthesis. *: 
unfortunately, personal data o f  298 nonresponders to the original invitation for the screening were not available; + : 26 refusers o f monitoring were not contacted by mail for 
practical reasons; only the refusers o f  the intervention group were asked; including ‘no transport’ , ‘family circum stances’ , ‘forgot the reason for refusal’ , ‘other illness 
prior to the study/pregnant’ , ‘fear the study would show  a d isease ’ , ‘ long-term duration o f  study’
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Dislike o f testing or research was stated by 8-49%  o f all refusers.
For those invited to one o f the three drug interventions, dislike o f  using medication 
em erged as the most import reason for non-participation (33-67% o f the subjects). 
Twenty three subjects o f  the intervention group w ere interview ed in m ore 
depth. General dislike o f  medication and general worries concerning side-effects were 
m entioned m ost often (15 (65%) o f the refusers to intervention). Only 2 (8%) subjects 
m entioned fear o f (side-effects by) using corticosteroids specifically. Finally, 54% o f 
all refusers stated that they would participate in a project like ‘DIM CA’ i f  it was part o f 
routine medical care.
Discussion
The absence o f pulm onary symptoms, lack o f  time and dislike o f medication were 
the m ain reasons for refusal to participate in an early detection and intervention 
program m e with inhaled corticosteroids in asthma and COPD (‘D IM CA’ project). A  
specific ‘fear o f corticosteroids’ was found to be a relatively m inor reason for refusal.
In every step o f  the ‘D IM CA’ project, one out o f every three subjects eligible did not 
participate. This rate is comparable with nonparticipation rates in several screening 
program m es in older patients concerning breast or uterine cervical cancer, colonic 
cancer and coronary heart disease, ranging 20-69% 7.
Only those subjects who gave perm ission to be phoned for additional information 
about their refusal were phoned. Therefore, the in-depth-interview results about the 
determinants of refusal, including the fear of corticosteroids, may have been distorted 
in some way.
The absence of pulm onary complaints was a m ain reason for refusal to enter one of 
the three parts of the project. Absence of complaints is likely to be an understandable 
reason for absence o f motivation. In a colorectal cancer screening program m e 83%  o f 
the refusers found the procedure unnecessary, because there were no sym ptom s.8 Lack 
o f time is mentioned as an important reason for refusal to screening studies.9"14 In the 
present study, one out of three refusers cited lack of time, especially due to work and 
fam ily com mitments. A  possible solution to this problem may be flexibility in time o f 
appointment (evening, weekend). Dislike o f the test is one o f  the m ain reasons for non­
participation in preventive screening program m es. 9>10>14>15 In two gynaecological m ass 
screening program m es, refusers thought the examinations were more unpleasant 
compared to the participants.10-15 In the present study, only a few refusers had a specific 
aversion to the lung function tests.
The present study showed a high rate of general dislike of medication. This is not an 
unexpected finding, because most o f the subjects o f  the ‘D IM CA’ study showed only 
m ild bronchial symptoms. Several studies have shown that the fear o f side-effects o f 
drugs is a com mon reason for refusal to be treated with hormonal replacement 
therapy16-18, diazepam19 and aspirin20, or to be vaccinated.21'22 The general aversion 
to drugs in our study was accompanied by only a small rate of specific fear of 
inhaled corticosteroids. It is our experience that in the clinical practice patients often do 
not consider inhaled drugs as ‘real m edicines’ like tablets. Furthermore, inhaled 
corticosteroids may not have the sam e impact as oral prednisone, which is popularly 
known as a ‘kill or cure rem edy’.
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Results o f the first drug intervention study o f  our ‘D IM CA’ project show there are 
indications that treatment with inhaled corticosteroids may preserve the lung function 
in undetected COPD.23 However, the costs and effectiveness o f early detection and 
preventive treatment with inhaled corticosteroids in (largely asymptomatic) asthma 
and COPD have to be weighed carefully before a large scale prescription o f inhaled 
corticosteroids may be advisable.
This is the first (experimental) study describing obstacles in im plem enting a 
screening and early intervention strategy with inhaled corticosteroids in chronic 
obstructive pulm onary disease and asthma in general practice. The absence o f 
pulm onary complaints and lack o f time as well as a general resistance to medication 
were the m ain determinants o f nonparticipation in a relatively healthy and active 
population. However, in contrast to our hypothesis, doctors do not have to fear 
that inhaled corticosteroids in particular are an obstacle to participation in early 
pharmacological intervention in asthma or chronic obstructive pulm onary disease.
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Abstract
Early treatment with inhaled steroids may prevent (irreversible) bronchial obstruction in 
patients with asthma and chronic obstructive pulm onary disease (COPD). From a 
theoretical perspective, one could argue that treatment with inhaled steroids should 
be started as soon as the first clinical indications o f asthma or COPD appear. We 
investigated the clinical effects o f fluticasone propionate in subjects showing ‘m ild signs 
o f COPD’ or ‘m ild signs o f asthma’ without a clinical diagnosis.
All subjects were detected in a two-phase detection program  in the general adult 
population and had been monitored for two years. Subjects with a moderate increase in 
decline in FEVI o f more than 4 0  m l/year (i.e. m ild signs o f COPD) were invited for a 
two-year randomized placebo-controlled trial with fluticasone 250 |jg b.i.d. via Rotadisk® 
versus placebo. Subjects who showed signs o f bronchial hyperresponsiveness (PC20- 
histam ine o f < 8 m g/m l and/or reversibility o f bronchial obstruction > 10 %  o f FEVI 
predicted, i.e. m ild signs o f asthma) were invited fo r a one-year randomized placebo­
controlled trial. The FEVI was assessed every three months, PC20 histam ine every six 
months at a lung function laboratory. Symptoms were recorded weekly by the patients. 
In the ‘CO PD ’ trial the m ain outcome param eter was the course o f postbronchodilator 
FEVI, in the ‘asthm a’ trial the PC20 histamine. A  multivariate repeated m easurem ent 
analysis was performed.
In the ‘CO PD ’ trial, 48 subjects (24 fluticasone, 24 placebo) participated. The overall 
course o f  FEVI during the study was not beneficially changed by fluticasone in 
com parison with the placebo group. However, after 3 m onths o f  study the 
postbronchodilator FEVI had increased significantly with +I82 m l(SE=64 ml, p=0.004) 
in the fluticasone group in com parison with the placebo group. In the ‘asthma’ trial, 
29 subjects (I4 fluticasone, I5 placebo) participated. Bronchial hyperresponsiveness 
was not influenced by fluticasone in com parison with placebo. In both trials, there 
were no significant differences in symptoms between the fluticasone and placebo 
treated patients.
In conclusion, fluticasone propionate (250 |j,g b.i.d.) did neither reverse the 
deterioration in FEVI in subjects with m ild signs o f  COPD during two years o f 
treatment, nor improve the level o f PC20 histam ine in patients with m ild signs o f 
asthma during one year o f treatment.
Introduction
Bronchial inflam m ation is the m ain cause o f bronchial hyperreactivity and symptoms 
in asthma and also plays an important role in the genesis o f irreversible bronchial 
obstruction in patients suffering from  chronic obstructive pulm onary disease (COPD)^ 
Inhaled steroids are considered to be the cornerstone o f the treatment o f asthm a,2 
and perhaps also o f the treatment o f (subgroups o f patients with) COPD.3 I f  the 
inflamm atory process o f the bronchial wall continues, irreversible changes will occur - 
and thus increasing obstruction- like inflam m atory cell infiltration, goblet cell 
hyperplasia, basement m em brane thickening and airway smooth m uscle hyperplasia 
and hypertrophia, a process called ‘airway rem odelling’.4
Even newly detected asthma patients have already shown symptoms o f airway 
mucosal inflam m ation.5 In these patients, early anti-inflammatory therapy with inhaled 
steroids has shown to preserve lung function,6 and thus theoretically to prevent airway
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remodelling. Therefore, recent guidelines on asthma advise treatment with inhaled 
steroids in mild (persistent) stages.2'7 There are also indications that inhaled steroids 
decrease the progressive lung function decline (>80 ml/year) in subjects with m ild to 
moderate COPD.8 Theoretically, treatment with inhaled steroids should be started as 
soon as the first clinical features o f asthma or COPD appear.
Mild abnormalities in lung function are not always accompanied by bronchial 
sym ptom s.9 In such cases, subjects with early indications o f COPD (like increased lung 
function decline) or asthma (like signs o f bronchial hyperresponsiveness) should be 
detected early by monitoring lung function, in order to make succesfull treatment 
possible. On the other hand, the (small) clinical effects may be overshadowed by a 
num ber o f adverse effects o f  the early introduction o f inhaled steroids, such as local 
side-effects,I°  medicalization and the increased cost o f healthcare costs for subjects with 
a low level o f symptoms.
The efficacy o f  early treatment with inhaled steroids was investigated in an 
‘experimental design’ in two groups o f subjects with m ild signs o f  COPD or asthma. 
Patients were selected from  an undiagnosed population sample, who had finished the 
detection and two-year monitoring part o f DIM CA. D IM CA is an acronym for 
Detection, Intervention and Monitoring o f COPD and asthma.
Methods
Patien ts
The two-stage detection program  o f D IM CA was presented elsewhere.”  Figure 3.I 
roughly shows the patient flows in DIM CA. There was no evidence o f recruitment or 
selection bias during the two parts o f the detection program .”  For the first stage o f the 
DIM CA detection program , a random sam ple o f undiagnosed adult subjects from  I0 
general practices in the area o f Nijm egen were invited to participate in a screening 
program . Screening consisted o f  a symptoms questionnaire and a lung function 
assessm ent. Subjects with a positive screening result started a 2-yr monitoring 
period, which was the second stage o f the detection. Every 3 months, lung function 
(including reversibility), bronchial responsiveness, exacerbations and symptoms were 
assessed. Subjects with a moderate or severe bronchial obstruction or bronchial 
hyperresponsiveness during the first year o f monitoring were invited to participate in 
one o f two trials with inhaled fluticasone propionate (DIM CA I and 2).
Results o f D IM CA I have been reported elsewhere.“ ^3 When after the 2-yr 
monitoring period subjects did not show any signs or symptoms they were considered 
healthy ('false-positives’). Subjects with persisting mild signs o f COPD or asthma 
after two years o f m onitoring were recruited fo r an intervention with inhaled 
fluticasone propionate 250 |j,g b.i.d. Subjects with a moderate increase in decline in 
(prebronchodilator) FEVI o f more than 40  m l/yr after the monitoring were invited to 
participate in a 2-yr trial, D IM CA 3a ('mild signs o f CO PD ’). A  criterion o f ‘chronic 
cough and/or sputum  production at least three months a year during the two-year 
m onitoring’ in subjects with a m easured (prebronchodilator) FEVI decline o f  40-80 
m l/yr was added to m inim ize the possibility o f false-positives.I4 A  second, mutually 
exclusive, group o f subjects was invited (DIM CA 3b, ‘m ild signs o f asthm a’) for a I-yr 
trial i f  they fulfilled at least two o f the following three inclusion criteria assessed during the
2-yr monitoring period: i )PC20 histamine < 8 m g/m l (> 2x o f 3 yearly measurements),
3^
Figure 3.1: Patient flow in DIMCA and trial profile o f  DIMCA 3a and 3b.
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2)reversibility in FEVI > I0%  o f FEVI predicted (> ix o f 9 quarterly measurements), 3)>
I exacerbation per year or > I attack o f dyspnea/wheezing during the two-year monitoring 
period. Exclusion criteria o f both trials were diagnosed asthm a or COPD, other 
pulm onary diseases, a history o f serious clinical systemic disease likely to interfere with 
the objectives o f the study (congestive heart failure), pregnant or lactating women, 
wom en o f childbearing age who are not taking adequate contraceptive precautions, use 
o f £  blocking agents, patients unable to use the diskhaler or the peakflowmeter, known 
or suspected hyperreactivity to inhaled £  agonists. From all patients who fulfilled the 
selection criteria and participated, a written inform ed consent was obtained. The study 
was approved by the local ethical committee.
T ria l  d esig n s  an d  treatm en t
Besides the different duration o f  D IM CA 3a (2 years) and 3b (i year) the study protocols 
were highly similar. Two separate double-blind, randomized, placebo-controlled studies 
were performed. In D IM CA 3a, subjects were stratified for FEVI decline (40-80 m l/yr 
versus >80 ml/yr). Patients in each study were randomized to either treatment with 
fluticasone propionate (Flixotide®) 250 |j,g b.i.d via R o ta d isk ®  or placebo. Participating 
fam ily physicians were aware o f the official Dutch guidelines on treatment o f asthma 
and COPD in general practice, including a quit-smoking recommendation at the start 
o f the study. Also at the start o f the study, all participants were inform ed o f a drug 
compliance study: this was done by counting the (full and empty) disks returned. Each
3-monthly lung function visit a package o f 50 R o ta d isk s®  (each containing four 
dosages o f the study drug, enough for I00  days) was supplied. Patients were instructed 
to rinse their mouth after the use o f the dry powder inhalations. In addition, the 
inhaler technique was checked at each visit and subjects were asked about their 
compliance. I f  the inhaler technique was insufficient or subjects stated non-compliance, 
they received new inhaler instructions or were encouraged to take the drug twice daily.
Patients were not allowed to use pulm onary medication other than an inhaled 
short-acting bronchodilator i f  needed (salbutamol (V entolin®), terbutaline (B rican yl®) 
or ipratropium bromide (Atrovent®) in case o f  acute bronchial symptoms. In case o f an 
exacerbation, the family physician in attendance was instructed to treat in a standardized 
way with a I0-day course o f  prednisone and a broad spectrum antibiotic. Subjects 
with aggravating (pulmonary) disease or suffering from  serious adverse effects which 
interfered severely with the trial protocol were withdrawn from  the study. Information 
about serious and m inor adverse events was collected and reported.
M easurem en ts
At the start o f the studies and half-yearly thereafter, all patients visited a lung function 
centre for assessm ent o f lung function, bronchial responsiveness and symptoms. After
3, 6, 9, I5, i 8 and 2I months, lung function and symptoms were m easured at the 
fam ily practice. During the study, subjects kept a weekly report in which they recorded 
the m orning and evening peak flow (PEF) and bronchial symptoms.
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Spirometry
At the start o f the studies and after 6, I2, I8 and 24 months, spirometry (FEVI, FIV I, 
FVC, M EF25, MEF50, MEF75) was perform ed by a trained lung function assistant at 
the lung function center using a Microspiro H I-298 (Chest Corp., Japan).^ During 
the sam e perform ance, static lung function parameters (IVC, RV and TLC) were 
m easured with a wet Gould spirometer^6 At intermediate quarterly visits, spirometry 
was perform ed in the fam ily practice using a hand-held turbine spirom eter (Microplus, 
SensorMedics; USA). The practice nurses were thoroughly trained. According to the 
ATS criteria, the FEVI corresponding with the highest sum  o f FEVI and FVC out o f 
three satisfactory forced expiratory maneuvres was chosen for analysis.I7 At the fam ily 
practice, FEVI’s that deviated more than i0 %  from  the m ean o f three FEVI maneuvres 
were excluded from  analysis. The postbronchodilator FEVI was assessed I5 minutes 
after administration o f four puffs o f 20 0  |jg V en to lin ®  with a spacer (Volum atic®) 
at the lung function center and at the fam ily practice. Airway reversibility was 
expressed as the increase in FEVI as a percentage o f FEVI predicted^6 M easurements 
were only perform ed in exacerbation-free periods and not within 8 hours o f  use o f  a 
bronchodilator.
PC20 histamine
The PC20 histam ine was assessed half-yearly in the lung function center according to 
the method o f  Cockcroft.18.. The concentration o f  histam ine provoking a 20 %  fall in 
FEVI (PC20) was calculated by linear interpolation o f adjacent data point which were 
log2 transformed.
PEF level and diurnal variation
The PEF was assessed weekly by the subjects with the M in iw rig h t®  peakflowmeter. 
Three m aneuvres were recorded in the m orning and in the evening. The highest 
m orning and evening PEF were used for analysis. The diurnal variation was assessed 
weekly by the following formula: {evening PEF m inus m orning PEF} divided by the 
m ean PEF o f these two measurem ents.
Exacerbations
Exacerbations were recorded by the fam ily physician. A n exacerbation was defined as at 
least two positive answers to the following three items: i)increased complaints o f cough 
and/or wheezing and/or dyspnea, 2)change in color o f phlegm , 3)increased use o f 
bronchodilators, modified from  Brand et al.19 W hen the period between two successive 
visits for an exacerbation was less than four weeks, it was considered to be the sam e 
exacerbation.
Symptoms, 'episode o f increased symptoms'
Four symptoms (cough, dyspnea, wheezing and phlegm) were recorded weekly by the 
patients in their reports. Each symptom was recorded on a scale ranging from  0 to 3
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(from 0: no complaints, to 3: all days and/or nights past week). The total weekly score 
was assesssed (0-I2). When at least one o f the following items within the weekly report 
was indicated, an episode o f increased symptoms was considered to be present: I) 
increased cough, wheezing or dyspnea, 2)change in color o f  phlegm, 3)increased use o f 
bronchodilators, 4)having a cold. When in the following week no item was indicated, the 
episode was considered to be finished.
Rescue medication
Each quarterly visit, the number, dose and days o f use o f  bronchodilating rescue 
inhalations were recorded.
Compliance and inhaler technique
All full and empty disks were returned and counted. Individual compliance rates 
were determined by expressing the dosage taken (number o f  dosages provided m inus 
num ber o f dosages left) as a percentage o f the amount prescribed during the study 
period.
The inhaler technique was checked half-yearly at the lung function laboratory. Four 
essential items (breathe out before inhalation, head upright, deep and strong inhalation 
and holding breath for 5 seconds) were added to a total score ranging from  0 (very bad) 
to 4 (very good). A  score o f at least 3 was considered sufficient.
Functional status
Functional status was assessed by m eans o f  ‘COOP/WONCA-charts’20 at the quarterly 
visits in the fam ily practice (0, 3, 6, 9, I5, i8  and 2 i mo). Within each o f the six charts 
o f i) ‘fysical fitness’, 2) ‘feelings’, 3) ‘daily activities’, 4) ‘social activities’ and 5) ‘changes 
in health status’ and 6) ‘general health’ the Figure (i out o f 5 Figures) that best fitted 
their current status had to be chosen. Each o f the Figures had a score ranging from  i 
(very good) to 5 (very bad).
Eosinophils
In D IM CA 3b, blood eosinophils were counted at the start and after i2  months o f the 
trial in the lung function laboratory. Values were expressed in num ber xi09 per liter.
Smoking behaviour
Sm oking history was assessed at the start o f the trial and expressed as the num ber o f 
pack years; num ber o f cigarettes/day multiplied by years smoked and divided by 20. 
Changes in sm oking behaviour during the study (number o f cigarettes/day) were recor­
ded every three months.
Allergy
At the start, all subjects underwent a skin allergy test with i6  allergens (pollen, house
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dust mite, fungi, pets). Subjects were considered allergic when the wheal o f at least one 
allergen exceeded 2/3 o f  the histam in control.
A nalysis
The statistical package o f  SAS was used in all analyses2  PC20 values were log2 
transformed, eosinophil values were transform ed by the natural logarithm (ln) in the 
analyses.
In D IM CA 3a, the m ain outcome param eter was the course o f postbronchodilator 
FEVI. With 3-monthly m easurem ents o f the FEVI, the study duration had to be at least
2 years to assess a reliable course in the FEVI I4 Secondary outcome parameters were 
prebronchodilator FEVI and PC20 histamine.
In D IM CA 3b, the level o f PC20 histam ine was the m ain outcome parameter. A  i-yr 
study was estimated to be long enough to assess possible changes in the level o f the 
PC20 histamine accurately. Secondary effect measures were pre- and postbronchodilator 
FEVI and the PEF.
Intention-to-treat analysis was perform ed in both DIM CA 3a and D IM CA 3b. In all 
the analyses, the effect o f fluticasone compared to placebo was considered statistically 
significant with p<0.05.
The effect o f fluticasone versus placebo on all prim ary and secondary outcome 
parameters was m easured with a multivariate repeated m easurem ent technique, in 
which patient, treatment and time effects were analyzed separately. In individual 
patients, one follow-up assessm ent o f the independent variable had to be perform ed for 
inclusion in the analysis.
The effect o f fluticasone in com parison to placebo on the MEF values and symptoms 
were also analyzed separately by a repeated m easurem ent analysis. Changes in 
eosinophil counts were tested with the independent Student’s t-test. Differences in 
functional status scores per item between the fluticasone and placebo group were 
assessed with the Wilcoxon Ranktest (Z-score). Differences in the number o f exacerbations 
and episodes o f increased symptoms between the actively treated and placebo group 
were compared by m eans o f the Poisson test.
The following independent covariates were used in the models with the prim ary and 
secondary outcome param eters FEVI and the PC20: age, height, sex, baseline FEVI, 
baseline PC20 and baseline airway reversibility, num ber o f pack years, presence o f 
allergy. Also the following effect m odifiers, which could possibly have influenced the 
course o f FEVI or PC20 during the study, were added to the model: the num ber o f 
exacerbations, the num ber o f  cigarettes smoked daily, the use o f bronchodilators and 
compliance to the trial drug during the study. In a backward selection procedure only 
independent variables with p < 0.05 were m aintained in all models.
Power calculation
We assum ed that the within-patient variation o f  the FEVI m easurem ent was I0 0  ml. 
DIM CA 3a: In a group o f 28 subjects with m ild to moderate COPD, a decrease in the 
FEVI decline from  I6 0  m l/year to I00  m l/year during treatment with inhaled steroids 
was shown.8 Therefore, the m inim al detectable difference was set on 60 ml. In a
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subgroup o f I6 patients who had finished the two-year monitoring period early, the 
m ean SD o f the FEVI decline was 66 m l.22 Thus with an alpha=0.05 and a power=0.8, 
the num ber o f evaluable patients needed was i6  (one-tailed test). Taking into account a 
withdrawal o f  i0 % , i8  patients per treatment arm had to be recruited.
DIM CA 3b: A n increase in FEVI level o f  approximately 450 m l after 6 months o f 
treatment with inhaled steroids (beclomethasone 800  |j,g daily) was demonstrated in a 
group o f patients with m ild to moderate asthm a.8 We estimated our m inim al detectable 
increase in FEVI level after one year o f study to be at least I00  ml. With an alpha=0.05 
and a power=0.8, the num ber o f evaluable patients needed was 28 (one-tailed 
test). Taking into account a withdrawal o f i0% , i6  patients per treatment arm had to be 
recruited.
Results
Pa rtic ipa n ts versu s n o n -participan ts
Seventy four subjects o f DIM CA 3a and 45 subjects o f DIM CA 3b (which, i f  extrapolated, 
is i9 ,4%  o f the general population” ) met the inclusion criteria. Twenty-one o f these 74 
and i2  o f these 45 subjects refused participation in the trial concerned. The major 
reason for refusal in both trials was a ‘general dislike o f medication’ . Other main 
reasons for refusal were ‘lack o f tim e’ and ‘dislike o f testing’. A n extensive description 
o f reasons for non-participation to all different parts o f  the D IM CA program  was 
published elsewhere.23 In D IM CA 3a, five subjects were excluded by the investigator 
before randomization (2 used 8 blockers, 2 moved away and I wanted to have a child). 
Four subjects were excluded before randomization to DIM CA 3b on the basis o f using £  
blocking agents (2 subjects) or inhaled steroids (2 subjects). The clinical characteristics o f 
the participants in both trials were comparable with the non-participants in all clinical 
relevant parameters.
Pa tien t  c h aracteristics
Table 3.I shows the baseline characteristics o f  D IM CA 3a. Beside a significantly higher 
num ber o f pack years in the fluticasone group, the trial groups were fully comparable at 
baseline. Despite randomization, in D IM CA 3b the baseline FEVI as a percentage o f 
FEVI predicted was significantly h igher in the fluticasone group than in the placebo 
group (Table 3.2).
Fu l fil m en t  of in terv en tio n
In D IM CA 3a, I2 (of the 48) subjects stopped prematurely with the treatment (6 
fluticasone, 6 placebo), and in D IM CA 3b, four (of the 29) subjects (2 fluticasone, 2 
placebo) (Figure 3.I). The most important reasons o f drop-out were throat irritation (see 
section Adverse Events) and dislike o f medication in absence o f symptoms. These 
reasons did not differ between the fluticasone and placebo group within either trials.
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Table 3.1: DIMCA 3a. Baseline characteristics (SD are given in parentheses).
Fluticasone Propionate, n==24 Placebo, n=24
A ge (yr) 4 6(1o) 4 7 (11)
Height (cm) 1 7o (7) 172(10 )
M ale/Fem ale 12 / 12 1 3/11
FEVn pre (L) 3 0 5( 0 70) 3.17(0 .76)
FEVn pre (%pred.) 95(l8) 98 (17)
FEVn pre/VC (%) 75(lo) 77(6)
FEVn post (L) 3.16(0.68) 3.1 9 (o.79)
FEVn post (%pred.) 98 (15) 9 9 (l8)
FEVn decline during m onitor stage (ml/yr) -10 9 (4 6) -124(66)
PC20 histam ine (m g/m l), geom etric mean 14 .2 9.2
Airway reversibility (% o f  FEV-, pred.) 4 .0 (5.1) 3.0 (4 .0 )
M EF25 (%pred.) 76 .7 (30 .6) 83(21.2)
M EF50  (%pred.) 65.6(27 .4 ) 68 .5(24 .1)
M EF75 (%pred.) 
Sym ptom s
62.5(60.6) 5 7 5 (2 0 -6)
1 7 (1.5) 1 .3(1.3)
Allergy (Y/N/no test) 8/15/1 10 /13/1
Pack years 11.9 (9 .5)*p = 0.02 5.8 (8 .4 )
Sm oker (yes/no) 12 / 12 8/16
Cigarettes/day 16 (8 )n = 12 1 5(11)n=7
Table 3.2: DIMCA 3b. Baseline characteristics (SD are given in parentheses).
Fluticasone Propionate, n = i4  Placebo, n=i5
A ge (yr) 4 6(i2) 4 8(1o)
Height (cm) i 73(i 2) 170(8)
M ale/Fem ale 6/8 4 /11
FEVn pre (L) 3 .20(0 .91) 2 .67 (0 .65)
FEVn pre (%pred.) 9 7 (io )*p = o .o i2 8 7(10 )*
FEVn pre/VC (%) 76(10) 69(8)
FEVn post (L) 3.32(° . 88) 2.81(0.65)
FEVn post (%pred.) io i( io )* * p = o .o i4 91(9)**
FEVn decline during m onitor stage (ml/yr) +18(48) + 2(43)
PC20 histam ine (m g/m l), geom etric mean 8.2 7.0
Airway reversibility (% o f  FEV-, pred.) 3 7 (3 i ) 5.2 (4 .7)
PEF mo (l/min) 47 9 (97) 44 1(68)
PEF ev (l/min) 47 9 (96) 4 59 (69)
Diurnal PEF variation (l/min) 3.4 (3.2) 4 .6 (2 .4 )
MEF50 (%pred.) 6 2 .9 (20 .0 )***p = 0 .0 4 7 4 9 .2 ( 14 .2 )** *
Sym ptom s o .8 ( i.3) 1.3(1.6 )
Allergy (Y/N/no test) 6/5/ 3 4 /11
Pack years 7 .6 (i0 .9) 8.1(8.0)
Sm oker (yes/no) 4 / i0 6 /9
Cigarettes/day i 9 (5)n =4 11(9 )n = 6
Blood eosinophil count (x io 9/L) 0 .i3 0 .17
38
Figure 3.2: DIMCA 3a: Course o f pre- and 
postbronchodilator FEVj (%pred.) and PC20 
histamine o f the fluticasone group versus the 
placebo group. Difference scores, SE and number of 
measurements at each point in time in the study were 
presented. For reasons of clearness the measurements at 
the family practice at 6 and 18 months were omitted from 
the Figure. Two-year estimates (with 95% c.i. and p-value) 
of the effect of Fluticasone Propionate versus Placebo on 
the variable presented were calculated with repeated 
measurement analysis. FP = fluticasone, PL = placebo, LC 
= assessment in lung center, otherwise in the family 
practice.
Figure 3.3: DIMCA 3b: Course o f pre- and 
postbronchodilator FEVj (%pred.) and PC20 
histamine o f the fluticasone group versus the 
placebo group. Difference scores, SE and number of 
measurements at each point in time in the study were 
presented. For reasons of clearness the measurements at 
the family practice at 6 months were omitted from the 
Figure. One-year estimates (with 95% c.i. and p-value) of 
the effect of Fluticasone Propionate versus Placebo on 
the variable presented were calculated with repeated 
measurement analysis. FP = fluticasone, PL = placebo,
LC = assessment in lung center, otherwise in the family 
practice.
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Effects on lu n g  fu n ctio n  and  PC20
In D IM CA 3a, repeated m easurem ent analysis showed no overall statistically significant 
difference in the course o f postbronchodilator FEVj between the fluticasone and 
placebo group (Figure 3.2). However, after 3 months o f  study the postbronchodilator 
FEVj had increased significantly with + 182 m l in the fluticasone group in comparison 
to the placebo group (SE=64 ml, p=0.004). The prebronchodilator FEVj showed a 
comparable course (Figure 3.2). The PC20 did not show significant overall effects o f 
fluticasone versus placebo (Figure 3.2).
In D IM CA 3b, no significant effects o f fluticasone compared to placebo were shown 
on the PC20 and the FEVj (Figure 3.3). In D IM CA 3b, neither a significant effect o f 
fluticasone compared to placebo was shown on the m orning PEF (Figure 3.4), nor on 
the evening PEF or diurnal variation.
In both trials, baseline MEF values were slightly im paired (Table 3.1 and 3.2). 
However, fluticasone did not modify the course o f M E F ^ , MEF50 and MEF75 versus 
placebo.
Effects on exacerbatio n s, episo d es of in c rea sed  sym ptom s, sym pto m s, use  of 
escape bro n ch o dilato r  d r u g s, an d  blood eo sin o ph il  count
In D IM CA 3a, 6 exacerbations occurred in five patients o f the fluticasone group, and in 
the placebo group 4 (in three patients). In the fluticasone group, 127 episodes o f 
increased symptoms occurred in 18 patients, in the placebo group 57 such episodes were 
counted in 17 patients (p=0.000i, Poisson-test). The m ean duration o f the episodes was
2 weeks in the fluticasone group and 4 weeks in the placebo group.
In D IM CA 3b, no exacerbations occurred. In the fluticasone group, 19 episodes o f 
increased symptoms occurred in eight patients (with a m ean duration o f 3 weeks) 
versus 26 episodes in the placebo group in seven patients (with a m ean duration o f 4 
weeks), p=0.45, Poisson-test.
Symptoms did not differ significantly between fluticasone and placebo in both trials. 
In addition, in both trials no differences were observed between the fluticasone and 
placebo group according to the use o f  escape bronchodilator drugs during the trial (in 
D IM CA 3a, six placebo and five fluticasone patients used such a drug, in D IM CA 3b two 
placebo and two fluticasone patients).
Blood eosinophil count was not influenced by fluticasone compared to placebo in 
D IM CA 3b.
Effects on fu n ctio n al  status
In DIM CA 3a, the baseline COOP/WONCA chart scores varied from  ‘not im paired’ 
(i.2(SD  0.6) according to ‘social activities’) to ‘slighly im paired ’ (2.4(SD  1.2) 
‘general health’). The majority o f patients o f both the fluticasone and placebo groups 
perceived no overall change o f the different item s o f the COOP/WONCA charts score. 
No statistical significant differences between fluticasone and placebo were shown with 
regard to each item o f the general health status. In D IM CA 3b, the sam e pattern o f 
COOP/WONCA scores was observed.
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A dverse events d u r in g  in terv en tio n
In D IM CA 3a, four serious adverse events occurred, o f which none was considered to 
be related to the trial drug. One patient o f the fluticasone group developed polymyalgia 
rheumatica requiring prednisone. This patient was withdrawn from  the study. Another 
patient o f the fluticasone group had a period o f severe headache and was hospitalized. 
In the placebo group, one patient suffered from  polyposis nasi and one from  a uterus 
leiomyoma, both requiring hospitalization. Fourteen (29%) subjects reported (minor) 
adverse events that could be related to the trial drug (6 in the fluticasone group: dry 
throat, itching cough after inhalation o f trial drug, throat pain {stopped use o f trial 
drug for that reason}, scraping throat, retching, hoarseness; 8 in the placebo group: 
hoarseness {stopped}, dry cough, itching throat, itching cough {stopped}, irritation o f 
pharynx (4X), {2 stopped}).
In D IM CA 3b, one patient in the placebo group suffered from  a serious adverse effect 
which required hospitalization: angina pectoris-like complaints. In 8 o f the 29 subjects 
(28%), (oral) side-effects o f the trial drug were reported, 5 o f the fluticasone group (1 
with hoarseness, 2 with throat irritation {one patient stopped use of trial drug for that 
reason}, 1 with a dry mouth, 1 with loss o f  taste) and 3 o f the placebo group (1 with 
itching cough, 2 with painful throat {1  stopped}).
In both trials, no cases of oral candidiasis were identified.
C o m plian ce  an d  in h a l e r  tec h n iq u e
In D IM CA 3a, compliance was 72%  o f the prescribed dose (range 7 to 102% ), showing 
no difference between the fluticasone and placebo group. In DIM CA 3b, compliance 
was 71%  (range 8-99% ). The subjects in the fluticasone group showed statistically lower
4 1
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compliance rates (58{SE=8}%) than those in the placebo group (83{SE=4}% , p = o .o ii). 
In D IM CA 3a, the inhaler technique was insufficient on one assessm ent (of five) in 4 
o f the 24 participants o f the fluticasone group, and in 3 o f  the 24 participants o f 
the placebo group. Two o f the 29 participants o f  D IM CA 3b (both belonging to the 
fluticasone group) showed an insufficient inhaler technique on one assessm ent (of 
three) in the study.
Discussion
This study showed that a long-term inhaled steroids treatment o f subjects with m ild 
signs o f COPD (moderately increased lung function decline) or m ild signs o f asthma 
(indications o f  bronchial hyperresponsiveness) did not influence the course o f lung 
function or bronchial hyperresponsiveness, respectively.
The FEVI was the m ain outcome param eter o f D IM CA 3a. The slowly progressive 
FEVI decline (>40 ml/yr) was not reversed by treatment with fluticasone in comparison 
to placebo, although a slight significant increase o f FEVI after 3 months o f  study was 
shown. A  short-term increase o f  the FEVI during treatment with inhaled steroids, 
followed by a progressive decline parallel to placebo was also reported in two large 
multicenter studies in patients with diagnosed (moderate to severe) COPD, the 
EURO SCOP and ISOLDE trial (oral presentations ERS 1998).
In m ild asthma, bronchial hyperresponsiveness is supposed to be a m ore accurate 
indicator o f inflam m ation than the FEVI, because bronchial obstruction may be the 
consequence o f bronchial hyperresponsiveness,24 especially in early asthma. In D IM CA 
3b, the PC20 histam ine increased with approximately h a lf a dose step during treatment 
with fluticasone in com parison to placebo. However, this increase was not statistically 
or clinically significant. The diurnal or m orning PEF did not improve either by 
treatment with fluticasone versus placebo. Also, the high baseline level o f  FEVI (95-98% 
pred.) did not change during treatment with fluticasone versus placebo. Unfortunately, 
the randomization had not succeeded according to the FEVI, which was significantly 
lower in the placebo group than in the fluticasone group. It may be argued that the room 
for improvement was so sm all in the fluticasone group that it was hard to show any 
positive effect on FEVI. Also, a type 2 error might have occurred, because the trial did 
not include the 32 subjects needed as prescribed by the power calculation.
In both trials, additional analyses with interaction term s of the treatment with 
allergy, reversibility o f  obstruction, PC20 histam ine and sm oking behaviour did not 
reveal subgroups with significant clinical effects o f fluticasone compared to placebo on 
the m ain outcome parameters.
As far as the perform ance o f  FEVI m easurem ents with a portable spirometer25 can 
be validated in the fam ily practice, this perform ance was reliable. A  sam ple o f  io %  
o f assesm ents o f the FEVI in the fam ily practice showed a reproducibility o f 4%  on 
average. Also, reanalyzing the data with only the assessm ents on the lung function 
center did not change the m ain conclusions.
Although the FEVI has been widely accepted as the golden standard o f  bronchial 
obstruction and thus o f the state o f bronchial obstruction in COPD or asthma, the value 
o f the m easurem ent o f FEVI in very early stages o f  asthma and COPD is doubtful, 
especially in the presence o f only small deviations o f FEVI. It was hypothesized that
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patients with m ild obstructive airways disease, whose pathophysiologic abnormalities 
are linked to the small airways, may be underdiagnosed if  spirometry which m easures 
flow rates at low lung volumes ( F E F ^ ^ ^ )  is not perform ed.26 Indeed, at the start o f 
both the trials the MEF values were slightly im paired (approximately 65%  o f predicted 
values), indicating (mild) obstruction o f the peripheral airways. However, both in 
DIM CA 3a and 3b no effect o f fluticasone in com parison to placebo was shown on 
M EF25, M EF50 and M EF75.
In COPD, other clinical characteristics o f progression or monitoring o f treatment 
like ‘quality o f life ’ attract more and more attention.27 In D IM CA 1 (investigating 
undetected subjects with a persistently reduced lung function) it was shown that 
seeking help from  the fam ily physician was associated with im pairm ents in the quality 
o f life and not with respiratory symptoms or a reduced lung function.28 Significant 
disturbances in the quality of life may also occur with near normal spirometry in 
patients with COPD.27 Nevertheless, in D IM CA 3a the generic health status as 
m easured with the COOP/WONCA-charts did not show any clear im pairm ent at the 
start of the study. This result reflects that a (subjectively) healthy group was selected. 
Consequently, it is no surprise that no improvement during treatment with fluticasone 
in com parison with placebo was found.
Recent placebo-controlled trials in COPD showed that treatment with 10 0 0  |j,g 
fluticasone propionate daily increased the lung function level in six m onths29 and 1500 
|j,g beclomethasone or 16 0 0  |j,g budesonide daily decreased the decline in FEVI during 
two years.30 Perhaps the daily dose o f 500 |j,g fluticasone in our study was too low to 
achieve a reversal in the progressive lung function decline in D IM CA 3a.
A s already stated, although subjects o f DIM CA 3a ('mild signs o f  COPD ’) were 
selected on the basis o f an increased decline o f (prebronchodilator) FEVI (on average 
-120 ml/year), they only suffered from  m ild disturbance o f  FEVI (95-98%pred.). During 
the subsequent two-year treatment period, the prebronchodilator (as well as the 
postbronchodilator) FEVI declined less progressively: in the fluticasone group the 
(uncorrected) decline was -63 m l/yr versus -78 m l/yr in the placebo group (difference 
not significant), which may have been caused by ‘regression to the m ean’ . In the 
placebo group a statistical significant difference between the 4-year course o f  pre- and 
postbronchodilator FEVI (-63 m l/yr versus -44 ml/yr, p = 0 .0 ii) was observed, which may 
point to an increase o f some (reversible) bronchial inflammation. In the fluticasone group 
such difference was not shown, which may indicate som e anti-inflammatory effect of 
fluticasone on the reversible inflamm atory components of bronchial obstruction in 
these patients with m ild signs o f COPD.31 This hypothesis was supported by additional 
analysis o f reversibility in FEVI. At the end o f  the trial the airway reversibility tended to 
be h igh er in  the placebo group than in  the fluticasone group (difference 
+2.3% (SEi.2% )).
In D IM CA 3b, patients were selected on the basis o f  signs o f bronchial hyper­
responsiveness during the m onitoring period. Asym ptom atic bronchial hyper­
responsiveness is a w ellknow n ph enom enon.32 T h is m ay partly explain our 
negative results. On the contrary, Zhong et al showed that 10  out o f 50 students with 
asymptomatic bronchial hyperresponsiveness developed asthma in the following two
years.33
Only few exacerbations occurred during the trials. Therefore, we chose to introduce 
a new variable ‘episode of increased sym ptom s’. The m ean duration of the episodes
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were slightly shortened in D IM CA 3b by treatment with fluticasone in com parison to 
placebo, but no beneficial effect of fluticasone in com parison to placebo was shown on 
the frequency of obstruction-related symptom episodes. Symptoms and the use of
bronchodilators during the study were not affected either by treatment with inhaled 
fluticasone versus placebo, probably also because of the m ild disturbances at baseline.
Fluticasone propionate is a new inhaled steroid, promoted for its higher local 
potency and thus less systemic side-effects than earlier inhaled steroids.34 Thirty 
percent o f the subjects perceived som e side-effect o f  fluticasone in a moderate daily dose 
o f 500 |jg, especially oral complaints. However, this percentage was not different from 
the subjects o f  the placebo groups. The occurrence o f side-effects was not related to the 
level o f  compliance during the trials (on average 70%  o f the prescribed dose). The lower 
level o f compliance in the fluticasone group o f D IM CA 3b could not be fully explained. 
However, reanalyzing the data with only the compliant subjects did not change the 
results.
W hen we translate the results of this study into the fam ily practice, we conclude that 
there is no reason for establishing inhaled steroids in subjects with ‘m ild signs o f 
COPD ’ or ‘m ild signs o f  asthm a’ without a clear diagnosis. Family physicians should 
therefore be encouraged to focus on adequate treatment and follow-up of patients when 
a diagnosis o f (mild) COPD or asthma has been established. A  general screening o f the 
population in order to detect undiagnosed (mild) asthma or COPD is not supported by 
this observation.
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Abstract
In a prospective study, we investigated the long-term compliance to fluticasone 
propionate (FP) by dry powder inhalation (R otadisk®) in subjects with early signs o f 
asthma and COPD without an established diagnosis.
Subjects were selected from  a large screening program  on early stages of asthma and 
COPD (‘D IM CA’ program) in the general practice. Forty eight adult subjects with ‘early 
signs o f CO PD’ (slightly increased FEV i decline o f >0.04L/yr) and 29 adult subjects 
with ‘early signs o f asthm a’ (signs o f  bronchial hyperresponsiveness or reversibility) 
participated to a random ised placebo-controlled trial with fluticasone propionate 
(F lixotide® 500|J.g daily) versus placebo with a duration o f two years or one year 
respectively. Compliance was m easured by counting R o ta d isk s®  returned. By m eans o f 
a questionnaire participants were asked about perceived effects and/or side-effects of 
the trial drug.
The m ean overall individual compliance rates o f 72%  (range 7 to i02% ) in the ‘early 
COPD’ trial and 7 i%  (range 8 to 99%) in the ‘early asthma’ trial were m aintained 
throughout the study. Perceived effectiveness (i2%  o f the participants) or side-effects 
(30% o f the participants) o f the trial drug were not related to compliance. The willingness 
of patients to use the trial drug in daily practice if  efficacy would be proved was 
statistically significantly related to compliance during the trial (p=0.0i7).
It was concluded that the compliance rates found were relatively high in patients with 
symptoms o f m ild asthma or COPD without an established diagnosis. Conviction o f the 
importance of treatment influenced compliance more positively than perceived (side-) 
effects. These results again em phasize the importance of patient education in 
establishing early treatment with inhaled corticosteroids.
List o f abbreviations
BH R = bronchial hyperresponsiveness 
COPD = chronic obstructive pulm onary disease
D IM CA = Detection, Intervention and Monitoring program  o f COPD and Asthm a 
FEVi = forced expiratory volum e in one second 
FP = fluticasone propionate
PC20 histam ine = provocative concentration o f histam ine inducing a 20%  drop in FEVi 
Introduction
The clinical effect of a drug is not only dependent on the specific action of the drug, but 
also on the patient’s way o f using it. Hence, compliance is an important factori In case 
of chronic disorders, extensive literature reviews show compliance levels of up to 50%  
o f the prescribed drugs.2'3 ‘Clinical characteristics’ (age, sex, severity o f the disease) have 
not shown a strong relationship, but factors such as the ‘doctor-patient relationship’ , 
‘simplicity of the regim en’ and ‘patient health beliefs that the disease is serious’ seem 
to be important determinants o f compliance.4,5
Recent guidelines on asthma encourage the prescription of inhaled corticosteroids 
for asthma, and perhaps for COPD as well, in fam ily practice as soon as possible in 
order to prevent irreversible loss o f lung function.6,7 In the light o f the determinants o f
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compliance stated above, such preventive therapy with inhaled corticosteroids may only 
succeed if  patients trust their doctor in prescribing the right drugs when necessary, the 
regim en is simple and patients believe that the prognosis of their asthma or COPD is 
serious enough to justify the long-term daily use of inhaled corticosteroids. Generally, 
inhaled corticosteroids have to be taken twice daily with the use o f a dry powder inha­
ler device or a metered dose inhaler. Inhaled corticosteroids do not give im m ediate 
relief o f symptoms, and may cause local side-effects like throat irritation.8 In patients 
with low or even absent symptoms, these factors may com prom ise com pliance when 
the ‘treament is perceived to be worse than the disease’ . Therefore, patient education 
seem s o f utmost importance to achieve m axim al compliance rates.9
We investigated the long-term compliance to the inhaled corticosteroid fluticasone 
propionate (FP) by dry powder inhalation (R otadisk®) in an experimental study in 
subjects with early signs of asthma and COPD without an established diagnosis. 
Reasons for non-compliance stated by the patients were assessed. Finally, the ‘perceived 
effectiveness and side-effects’ of the trial drug, ‘ease of u se ’ of the inhaler and 
‘w illingness of patients to use the trial drug in daily practice after proved efficacy’ were 
investigated and related to compliance during the study.
Method
Patien ts
The trials in which compliance was m easured were part o f the ‘D IM CA’ project, a large 
Detection, Intervention and Monitoring study in COPD and Asthm a in fam ily practice. 
A n extensive design and purpose o f the study was presented elsewhere i0. Figure 4 .i 
shows the trial profile. In short: a random sam ple o f i,749 apparently healthy adult 
subjects from  i0  fam ily practices in the area of Nijm egen were invited to participate in 
a screening program  on signs and symptoms of asthma and COPD, followed by a 
two-year surveillance o f  those with possible signs and/or symptoms. Subjects with a 
moderately severe bronchial obstruction or bronchial hyperresponsiveness during the 
first year of monitoring were invited to participate in one of two trials with FP versus 
placebo (DIM CA i or D IM CA 2). Subjects who, during the surveillance period, showed 
‘early symptoms o f CO PD ’ (increased FEVi decline o f >0 .04  L/yr) or ‘early symptoms 
o f asthm a’ (bronchial hyperresponsiveness (PC20 histam ine < 8 mg/ml) and/or 
reversibility o f obstruction (increase in FEVi > i0 %  as a percentage o f the FEVi predicted 
after application o f  800  |j,g inhaled salbutamol) were recruited for a trial with FP versus 
placebo with a duration o f two years (DIM CA 3a) or one year (DIMCA 3b) respectively. 
From all the patients who met the selection criteria and participated, a written inform ed 
consent was obtained. The study was approved by the local ethical committee.
Study  d esig n
Both trials were randomised, double-blind and placebo-controlled studies. A ll subjects 
were treated with the inhaled corticosteroid FP (Flixotide®) R o ta d isk ®  2dd250 |j,g or a 
placebo by the D isk h a le r® . At the start o f the trials, the patients were given detailed 
information about the anti-inflammatory action of the trial drug, the chance of getting 
a placebo, possible local adverse effects (throat complaints) and the importance o f using
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Figure 4.1: Trial profile o f the 'early COPD' (DIMCA 3A) and 'early asthma' 
(DIMCA 3B) trials in the DIMCA project.
invited: 1749
- age 25-70  years
- no corticosteroid dependence
age 4 3 ,2  (11 .8 ) % fem ale 5 5 .3  
FEV1 % pred 9 6 .4  (14 .6 ) 
packyears 8.1 (11 .2 )
Second stage: 
2-year Monitoring
First stage: 
Screening
1155 participants
384 participants
74 patients with 
'early COPD'
I
randomised 48
1
36 finished 
intervention protocol
45 patients with 
'early asthma'
I
randomised 29
I
25 finished 
intervention protocol
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the drug daily. The clinical effects of FP versus placebo in both the trials will be 
reported later.
M easurem en ts
At the start of the study, patients were told by the investigator that compliance 
measurem ents would take place during the whole study. At each three-monthly visit 
lung function and symptoms were assessed. In addition, at each visit a fixed amount of 
study medication (200 dosages o f  FP or placebo {50 R o ta d isk s®} for i0 0  days) was 
provided. The next visit, all full and empty disks had to be returned. In absence of the 
patients, all boxes were counted manually. On each occasion subjects were encouraged 
to continue the daily inhalation scheme (i inhalation 2 times a day) and the inhalation 
technique was checked and problems with the study drugs were discussed. At each 
six-monthly visit, subjects were asked by m eans of a structured questionnaire whether 
they had succeeded in taking the inhalations as prescribed, and if  not the reason for this 
('forgotten’ {especially in absence o f sym ptom s}, ‘absence o f sym ptom s’, ‘no tim e’, 
‘side-effects’ or ‘m iscellaneous’ {holidays, illness, irregulair services}). At the end o f the 
study or after dropping out subjects were questioned by telephone, by m eans of a 
structured questionnaire, whether they had perceived the trial drug as ‘effective’ , and 
whether they had perceived ‘side-effects’ of the trial drug. They were also asked about 
the ‘ease of u se ’ of the inhaler and whether they were willing to use the trial drug in daily 
practice if  it would show to be effective in preventing lung damage in the long-term.
A n alysis
A n intention-to-treat-analysis was perform ed, m eaning that all avaliable full and empty 
packages returned were analyzed until subjects finished the study or dropped out. When 
a complete box was not returned it was considered m issing and not analyzed.
Individual compliance rates (%) were determined by expressing the dosages taken 
(number of dosages provided m inus the num ber of dosages left) as a percentage of the 
amount prescribed during the study period. Patients were considered to be compliant if  
the arbitrary overall compliance rate during the study period was at least 70% .
In order to investigate a time trend in compliance during the study, individual 
three-monthly compliance rates were assessed.
With the use of the univariate ANOVA-test, compliance rates to the trial drug were 
related to ‘perceived effectiveness and side-effects’ , the ‘ease of use of the inhaler’ and 
the ‘willingness to use the trial drug in daily practice’ i f  the trial drug would show 
effectiveness.
One subject of the ‘early COPD’ trial stopped the drug use as early as within three 
m onths of study, and did not return the box. The compliance rate of this patient was not 
analyzed therefore.
Results
Forty-eight subjects participated in the ‘early CO PD ’ trial (DIM CA 3a), 29 subjects in the 
‘early asthm a’ trial (DIM CA 3b). In Table 4 .!, the m ain baseline characteristics are
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shown, indicating only sm all deterioration in FEVi , reversibility o f obstruction and PC20 
histamine, the latter especially in the ‘early asthm a’ group. Thirty-six subjects finished 
the two-year ‘early CO PD ’ trial and 25 subjects finished the one-year ‘early asthma’ trial 
(Figure 4.i). Throat complaints and unwillingness to take medication daily were the 
m ain drop-out reasons. No difference in num ber and reason o f dropping out was shown 
between the FP and placebo groups o f both trials.
Table 4.1: Baseline characteristics o f the 'early COPD' (DIMCA 3a) and ‘early 
asthma’ (DIMCA 3b) trials. Standard deviations or ranges are given in parentheses. Explanation 
of characteristics: FEVi%pred. = forced expiratory volume in one second (L) as a percentage of the 
predicted value (which depends on age, sex and height), allergy: present when > i of i6 common 
allergens appear to be positive (skin test), pack years = (number of cigarettes smoked daily divided by 
20) x (number of years smoked), PC20 histamine: concentration of histamine necessary to induce a 
20% drop in FEVi), reversibility %FEVipred.: increase in FEVi after administering 800 |ig salbutamol 
(expressed as a percentage of FEVipred.), symptoms: wheezing, dyspnea, cough, productive cough in 
the past three months, each item adding i point in a score of 0-4.
DIM CA 3a 
(n=48)
DIM CA 3b
(n=29)
A ge (yr) 4 7 (29 -71) 4 6(30-70)
M ale/fem ale (n) 25/2 3 10 / 19
FEVn% pred. 96 (17) 93 (11)
Allergy +/- (n) 18/28/2 10/16/3
Sm okers (%) 4 2 37
Pack years (mean number) 9 (0-29) 7 (0-31)
PC20 histam ine (mg/ml) 1 1 3(5 7 ) 5 3 (3-5)
Reversibility %  FEVnpred. 3 (5) 5(3)
Sym ptom s 1 .5( 1 .4 ) 0 .6(0.9)
Bronchodilators y/n (n) 6/4 2 2/27
Within each o f the trials 95%, o f all boxes supplied to the patients were returned. The 
packages returned contained 88 percent, full or empty of the full disks supplied in the 
‘early CO PD ’ trial (FP 90% , placebo 86% ), and 86%  in the ‘early asthma’ trial (FP 87%, 
placebo 85%).
Counting disks showed overall individual compliance rates ranging from  7%  to i0 2%  
in the two-year ‘early CO PD ’ trial (mean compliance rate 72%) and 8 to 99%  in the 
one-year ‘early asthma trial (mean rate 7i% ). Figure 4.2 shows a comparable pattern o f 
division of overall individual compliance rates in the ‘early CO PD ’ trial compared to the 
‘early asthm a’ trial. Sixty-two percent (29 o f  47) o f the participants o f the two-year ‘early 
COPD’ trial and 69%  (20 o f 29) o f the participants o f the one-year ‘early asthm a’ 
trial had individual compliance rates of at least 70% . Within the ‘early COPD’ trial, 
compliance rates between the FP and placebo group were comparable (7i an 73% 
respectively). In the ‘early asthma’ trial, the subjects in the FP group showed statistically 
significantly lower overall compliance rates (58(SE=8)% than in the placebo group 
(83(SE=4)%, p = 0 .0 ii).
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Figure 4.2: Overall individual compliance rates to inhaled FP (% o f prescribed FP) 
with respect to the trials (DIMCA 3a and 3b).
■ 3A 'early COPD’ (n = 48, data about n =47) 
□ 3B 'early asthma’ (n =  29)
0-20 21-40 41-60 61-80 81-100 > 1 00  
Overall individual compliance rate (%)
During the two-year ‘early CO PD ’ trial, the three-monthly compliance rate o f all 
participants decreased slightly from  8o(SE=4)%  to 7i(SE=8)%  (Figure 4.3). Only during 
months 12 and 15, decreases were statistically significant compared to the start o f  the 
trial. In the one-year ‘early asthma’ trial compliance decreased slightly, not statistically 
significant, from  75(SE=5)% to 73(SE=6)% . When only the compliance rates were 
analyzed in subjects who completed the trial drug protocol ('explanatory analysis’), 
approximately the sam e pattern o f decrease was shown (from 84% (SE=4% ) to 
7i% (SE=8% ) and from  79% (SE=4% ) to 73% (SE=6% ) respectively).
In 128 (66%) o f all 195 six-monthly registrations on compliance, available subjects 
participating in each o f both trials stated that they had been fully compliant during the 
preceding six months. The m ean compliance rate to the trial drug in these patients was 
86%  o f the prescribed dose during this period, compared to 62%  in patients admitting 
they had not been fully compliant during the past six months. The stated reasons for 
non-complying were ‘forgotten’, especially in absence o f  symptoms (42%), ‘absence o f 
sym ptom s’ (3%), ‘no tim e’ (14%), and ‘m iscellaneous’, holidays, illness, irregulair 
services (26%). Fifteen percent o f the reports about non-compliance concerned 
‘side-effects’. The reasons of non-compliance were comparable between both trials or 
the use o f FP versus placebo.
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Figure 4.3: Change o f compliance with inhaled FP (% o f percentage FP) during 
DIMCA 3a and DIMCA 3b. Standard errors are presented. The number of packages returned at 
each particular point in time in the study are depicted (the number of patients participating in the trial 
drug protocol at each particular point in time are given in parenthesis). Within both trials, compliance 
rates at each assessment were tested with baseline compliance (paired t-test), in case of significance 
(p<0.05), this is indicated in the Figure below.
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For practical reasons, only 74 o f the 77 participants o f both trials were questioned by 
telephone after finishing the study or dropping out. Nine o f the 74 patients (12%) 
questioned (four from  the ‘early COPD’ and five from  the ‘early asthm a’ trial) had 
perceived some effectiveness o f the trial drug (less pulm onary symptoms like dyspnea 
or cough), six o f which also reported some side-effects especially throat complaints. A  
total o f 22 (30%) percent o f the 74 participants in the trials who were questioned reported 
side-effects o f the trial drug, which they related to the trial drug (painful or irritated 
throat, loss o f taste, headache). This percentage was approximately the sam e within both 
trials and trial drug arms. The perceived effectiveness and/or side-effect o f the trial drug 
was not related to individual overall compliance rates (Table 4.2). No significant 
differences appeared between both o f the trials or the FP or placebo group.
Handling the D isk h a le r®  caused seven o f the 74 participants some problems (three 
o f the ‘early CO PD ’ trial and five o f the ‘early asthm a’ trial). For example, two subjects 
found it difficult to perform  the different actions, one patient had a visual disability and 
consequently problems with the num bers on the R o ta d isk ®  indicating the num ber o f 
unused dosages (4 to 1), one subject simply preferred a tablet. Patients who found the 
inhaler easy to use tended to be more compliant than subjects who had som e problem 
with using the inhaler (Table 4.2).
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Table 4.2: Relationship o f'p e rce iv e d  effectiveness or side-effects o f  the trial drug', 'handling the D is k h a le r ® ' and 'w illingness to 
u se the trial d rug in daily practice w h en  efficacy is proved' with com pliance rates. Results pertain to 74 participants questioned by 
telephone (SD  =  standard deviation o f  the com pliance rates).
Number of patients Individual CO M PLIA N CE
'Perceived effectiveness or side-efFects of trial drug' (4 missing data) rate Mean (% ) SD
No effect, no side-effect 48 74 24
Effect, no side-effect 3 62 40
Effect, side-effect 6 73 26
No effect, side-effect 16 7° 24
ANOVA-test: p =  0.82
Number of patients Individual CO M PLIA N CE
'Handling Diskhaler®' (5 missing data) rate Mean (% ) SD
Easy 65 75 22
Not easy 7 61 32
ANOVA-test: p =  0.13
Number of patients Individual CO M PLIA N CE
'Willingness to use the trial drug in daily practice' (3 missing data) rate Mean (% ) SD
Yes 55 73 22
No 6 46 38
Probably 13 82 20
ANOVA-test: p =  o .o i j
\J-\
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Fifty-five o f the 74 patients questioned (74%) stated they would be willing to inhale 
the trial drug daily i f  it would be strongly advised by the fam ily physician as a m eans to 
prevent lung damage in the long-term. Thirteen subjects hesitated about being treated 
with the trial drug i f  judged necessary by the fam ily physician and six subjects would 
only start treatment when the severity o f symptoms would justify daily inhalation. 
Subjects who stated they were not willing to use the trial drug in daily practice i f  it was 
proved effective were significantly less compliant than subjects who hesitated or were 
willing to use the drug in case o f proved effectiveness (Table 4.2). Four o f  the five 
‘definite’ refusers came from  the ‘early asthm a’ trial (2 FP, 2 placebo).
Discussion
Two out o f three patients with early signs o f  COPD or asthma without an established 
diagnosis appeared to be compliant during long-term treatment with FP, although 30%  
o f the patients perceived side-effects and only 12%  perceived effectiveness o f  FP. One o f 
ten subjects had some problem s with the use o f the dry powder inhaler. Only one 
o f twelve subjects would refuse the treatment with FP in the daily practice, even i f  
prevention o f irreversible loss o f  their lung function would be proved. In these patients, 
compliance rates were significantly lower than in patients who realized, i f  efficacy would 
be proved, the disease could be serious enough to justify preventive treatment with 
inhaled corticosteroids.
The m ean overall compliance rate to FP was 72% . One may suppose that patients 
with a very m ild degree o f the disease, as in our study are less compliant than patients 
with m ore severe form s o f the disease. However, there are insufficient consistent 
clinical data to support this view.11,12 Earlier clinical trials with inhaled corticosteroids 
reported compliance rates o f 60-80%  in moderate asthma patients13,14 and 80-85%  in 
moderate COPD patients.15,16 However, the assessm ent periods in these studies with 
inhaled corticosteroids were relatively short (12 weeks to six months)13-16 or assessm ents 
were done at the start o f  the study.15,16 Only one clinical study was published m easuring 
the compliance to a bronchodilator during a two-year study period.17 In this two-year 
study in 3,923 patients with m ild to moderate COPD, the overall compliance to 
ipratropium bromide or placebo by metered dose inhaler was comparable to our study, 
being approximately 70 % .17 These data support the finding in two asthma trials with 
both preventive and symptom-relieving inhaled drugs that compliance may not be 
drug-dependent but rather patient-dependent.13,14
Compliance decreased only slightly, and not statistically significantly, during the 
two-year study period. Forgetting to take the study drug, m ainly because o f a lack o f 
symptoms, was the m ain reason for non-compliance as stated by the patient. In the 
Lung Health study, the phenom enon o f a slowly decreasing compliance rate has also 
been shown, also with forgetting as the m ain reason o f non-compliance stated.17 Local 
adverse effects (oral complaints like irritation, cough, candidiasis and hoarseness o f 
the voice) are well-known side-effects o f the use o f inhaled corticosteroids, and may 
influence long-term compliance. Indeed, in 30%  o f the subjects studied local effects 
were reported by the patients. However, in accordance to the literature,11,12 in our study 
adverse effects turned out to be not an important reason for non-compliance (stated in 
only 15%  o f the reports on non-compliance). Moreover, both the perceived inability o f
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the study drug to reduce bronchial symptoms i f  present (in almost 90%  o f the 
participants o f  our study), as well as the perception o f side-effects were not related to the 
level o f compliance. Additional analyses showed that no relationships were found 
between most o f the patient characteristics and compliance (sex, sm oking behaviour, 
lung function and symptoms). Only a higher age was related to a higher level o f 
compliance, which has been suggested by some authors.4 These results support the 
growing opinion that not only patient characteristics but also perceived effectiveness o f 
the drug or adverse effects do not determine compliance gross.11,12
Well-known determinants o f compliance are a sim ple treatment regim en, a good 
patient-doctor relationship and patient understanding o f  the rationale for treatment.5 
Patients in our trial had to inhale twice daily. Compliance has shown to increase when 
the daily num ber o f  intakes decreases from  4 to 2 .18 Only 10 %  o f  the subjects studied 
reported problem s with the inhaler, although a study o f Petrie et al showed that patients 
preferred the T u rb o h aler®  to the D isk h a le r®  because it was more convenient to carry 
and easier to use.19 Subjects in our study who found the D isk h a le r®  easy to use tended 
to be more compliant than subjects who did not. The investigators also inform ed all 
participants orally and in writing about the purpose o f  the trial and the action, and 
possible adverse effects, o f the trial drug, and repeated their m essage regularly during 
the study. They also tried to build up a good relationship with individual patients 
during the study by inform ing regularly about their health status. Although not the 
purpose o f the study, perhaps all these efforts to help patients to fulfill the study 
protocol enhanced their compliance. Contrary to this, the investigators o f the Lung 
Health Study hypothesized that stronger prompting might discourage subjects who 
wished to discontinue using the drug.17 In our study, a statistical significant relationship 
was found between the willingness to be treated with the trial drug when efficacy would 
be proved on one hand and compliance as has been assessed during the study on the 
other hand. This result supports the opinion that when patients believe their disease is 
serious enough to justify daily treatment, their compliance will be higher than when 
they are sceptical about the severity o f  their disease and hence about the profit o f 
treatment. Thus, in accordance to recent opinions, education seem s to be the keyword 
in enhancing compliance, especially in m ild asthma.20
One has to be cautious with the translation o f the results o f this study into general 
practice. In clinical studies, compliance rates are higher than in general practice, 
mainly because o f  a selection o f subjects which have shown to be com pliant.1 First, 
In our ‘D IM CA’ study all subjects had been monitored for as long as for two years and 
had all shown compliance to the assessm ent protocol so far. Secondly, one out o f three 
subjects had refused to participate in each o f the parts o f ‘D IM CA’.21 The m ain reasons 
for refusal were ‘lack o f  sym ptom s’ and ‘lack o f tim e’ in this relatively healthy and 
active group o f patients.21 This may have caused an overestimation o f the rate o f 
compliance m easured when translated into general practice. However, 54% o f the 
refusers is willing to use FP i f  its effect is proved and treatment with FP is part o f 
routine clinical care.21 Moreover, 74%  o f the subjects who participated in the trials o f 
this study are willing to be treated with FP in daily practice unconditionally i f  such is 
advised by their fam ily physician.
Compliance rates pertain only to subjects during the time they were actually 
participating in the trial drug protocol. However, 16 o f the 77 participants (21%) dropped
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out during the study. In general practice these subjects would be indicated as ‘non- 
com pliers’ . This may have caused a slight overestimation the overall compliance in ‘real 
life ’ .
H alf o f  the patients received placebo inhalations throughout the study. Placebo 
treatment may have caused an underestimation o f  the perceived effects or side-effects 
o f FP. However, no differences were found in the perception o f clinical effects or side- 
effects between placebo and FP. Therefore, the lower compliance rate in the FP group in 
com parison to the placebo group in the ‘early asthma’ trial could not be fully explained.
Counting disks as an objective m easure o f compliance may cause an overestimation 
o f actual compliance depending on whether patients will return all issued medication 
packages.22 Therefore, in this study the patients were asked to return empty disks as 
well. This way, the acceptable percentage o f almost 90%  o f the prescribed disks were 
returned, full or empty. O f course, it rem ained unclear whether the m issing disks were 
dumped empty or full. And, counting disks periodically does not give insight into the 
daily pattern o f  use o f  the trial drug like as much as electronic monitoring o f compliance.23
At the start o f the study, the investigators also told patients frankly that compliance 
would be m easured throughout the study in order to assess ‘feasibility’ aspects. Telling 
patients that compliance will be measured is known to increase compliance significantly 
in com parison to m easuring the compliance blindly.24 This may have caused an 
overestimation o f compliance in ‘real life ’ to some extent, because patients did not want 
to disappoint the investigator.
Finally, the questionnaire about the willingness to use the drug in daily practice and 
perceived (side-) effects o f the study drug was supplied at the end o f the trial. Recall bias 
can therefore not be fully excluded.
The first analyses o f  D IM CA 1 (which m easures the effect o f FP in subjects with 
undiagnosed COPD) show that there are indications that FP may preserve the lung 
function.25 Since our study o f patients with early signs o f asthma or COPD without a 
diagnosis has shown satisfactory compliance, non-compliance in subjects with a clear 
diagnosis o f asthma and COPD will only be a relative barrier in establishing treatment.
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Abstract
Background: Inhaled corticosteroids are the most efficacious anti-inflammatory drugs in 
asthma. International guidelines also advocate the early introduction o f inhaled 
corticosteroids in corticosteroid naive patients. A study was undertaken to assess the 
effects o f inhaled corticosteroids on bronchial hyperresponsiveness in patients with 
corticosteroid naive asthma by conventional meta-analysis.
Methods: A Medline search o f papers published between January 1966 and June 
1998 was performed and 11 papers were selected in which the patients had no history 
o f treatment with inhaled or oral corticosteroids. Bronchial responsiveness to 
bronchoconstricting agents was considered as the main outcome parameter. Doubling 
doses (DD) o f histamine or methacholine were calculated.
Results: The total effect size o f inhaled corticosteroids (average daily dose 1000 |jg) 
versus placebo in the 11 studies was +1.16 DD (95% confidence interval (CI) +0.76 
to +1.57). When only the eight short term studies (2 to 8 weeks) were analysed the effect 
size o f the bronchoconstricting agent was +0.91 DD (95% CI +0.65 to +1.16). No 
relationship was found between the dose o f inhaled corticosteroid used and the effect 
on bronchial responsiveness.
Conclusion: This meta-analysis in patients with corticosteroid naive asthma 
indicates that, on average, high doses o f inhaled corticosteroids decrease bronchial 
hyperresponsiveness in 2-8 weeks. It remains unclear whether there is a dose-response 
relationship between inhaled corticosteroids and effect on bronchial hyperresponsiveness.
Introduction
Asthma is a chronic inflammatory disease o f the airways.1 Inflammatory cells (mast 
cells, eosinophils, lymphocytes and macrophages) are present even in patients with mild 
asthma.2 Levels o f bronchoconstrictor mediators such as histamine and prostaglandins, 
which are known to be associated with inflammation, are also increased in mild 
asthma.3 Inhaled corticosteroids are the most effective anti-inflammatory drugs.1 
There are indications that early introduction o f inhaled corticosteroids may prevent 
remodelling o f the airway epithelium in patients with asthma and thus irreversible loss 
o f lung function.1 Recently revised international consensus reports on asthma therefore 
advocate the administration o f inhaled corticosteroids not only in moderate and severe 
asthma, but also in mild asthma.1'4 One o f the new recommendations o f rapid control 
o f mild asthma is to start treatment with higher daily doses o f inhaled corticosteroids 
(up to 1000 |jg) than in earlier reports (200-400 lig).5,6 Surprisingly, no systematic 
reviews on the effects o f inhaled corticosteroids in patients with mild corticosteroid 
naive asthma are available to support this recommendation. Hatoum et al performed a 
meta-analysis o f the effects o f treatment with inhaled corticosteroids in patients with 
mild chronic asthma based on five published articles,7 and found a significant increase 
in the peak expiratory flow (PEF) after treatment. However, PEF was the only main 
outcome parameter used. No measure indicative o f bronchial inflammation was 
included. Furthermore, the previous use o f inhaled corticosteroids was not an exclusion 
criterion o f the meta-analysis. It is therefore possible that in all cases the asthma was 
‘mild’ because o f a (previous) successful treatment with inhaled corticosteroids.
We have therefore performed a meta-analysis o f all randomised controlled studies of
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inhaled corticosteroids in patients with corticosteroid naive mild asthma. Patients 
with mild asthma have nearly normal spirometric values and few symptoms, while 
significant bronchial inflammation is present. Bronchial hyperresponsiveness (BHR), 
which is considered by many as an indirect measure o f inflammation, was therefore 
used as the main clinical outcome parameter o f the meta-analysis. We also assessed 
the minimum dose o f inhaled corticosteroid and the minimal duration o f treatment 
required to obtain a significant improvement in BHR.
Methods
Inclusion and exclusion criteria
Studies were only included i f  they reported trials on the clinical effects o f inhaled 
corticosteroids in corticosteroid naive mild asthma as indicated in the title or abstract, i f  
they followed a randomised controlled design, and i f  they had a duration o f at least two 
weeks. Exclusion criteria included a history o f treatment with inhaled corticosteroids, 
absence o f the assessment o f BHR or the absence o f adequate data about the BHR 
(either original data or effect size with standard errors in both the inhaled corticosteroid 
and placebo groups).
Selection procedure
A Medline search was performed for papers published between January 1966 and June 
1998 with the following ‘free-text’ words: ‘beclomethasone’, ‘budesonide’, ‘fluticasone’,
‘triamcinolone’, ‘flunisolide’, ‘inhaled (cortico)steroid(s)’, ‘asthma(tic)(s)’, ‘mild’, ‘moderate’, 
‘ (cortico)steroid naive’, ‘newly detected’, ‘newly diagnosed’, ‘non(cortico)steroid dependent’. 
The search yielded 258 English references. All abstracts o f the retrieved references were 
checked manually. Thirty nine papers concerned the pathophysiology of inhaled 
corticosteroids, 24 were general reviews or consensus reports about on corticosteroids, 
and 20 discussed the adverse effects o f inhaled corticosteroids. One hundred and 
three papers presented the effects of inhaled corticosteroids in various conditions such 
as rhinitis and pregnancy and tolerance to £  agonists. Seventy two papers included 
controlled as well as uncontrolled clinical trials o f the clinical effects o f inhaled 
corticosteroids in mild asthma. The reference lists o f these studies were also checked for 
additional references.
By this method, 58 randomised controlled clinical trials assessing the effects of 
inhaled corticosteroids in patients with ‘mild to moderate asthma’ could be selected,8-65 
all but one o f which8 had a duration o f two or more weeks. The method section o f 39 
o f the remaining 57 papers stated that some o f the patients included had a history of 
treatment with inhaled or oral corticosteroids.9-47 These studies were excluded from the 
systematic analysis. In three studies48-50 BHR had not been measured and these were 
excluded Four o f the 15 selected studies51-54 contained data on the bronchoconstricting 
agent which were incomplete to estimate the true effect size (and SE) o f inhaled 
corticosteroids versus placebo and therefore were not included in the analysis. Eleven 
studies were therefore left for inclusion in the meta-analysis. None o f these studies 
assessed dose-response relationships.
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Quality assessment of the controlled studies selected
All i i  clinical trials selected for the review were checked by means o f a criteria list for 
quality assessment o f randomised clinical trials based on a recent Delphi consensus.66 
When the method section contained information about a specific item on the Delphi list 
a score o f one point was given. In the absence o f information or i f  there was a negative 
answer to a specific question zero points were given. The total score ranged from o to
9, a higher score representing a higher quality. Arbitrarily, studies with a score below 6 
were jugded to be o f insufficient quality and were not reviewed.66
Evaluation of bronchial responsiveness (BHR)
Bronchial hyperresponsiveness to bronchoconstricting agents was considered as the 
main outcome measure. The assessment o f BHR differed widely between the studies, 
depending on the method (methods according to Hargreave,52'55 Eiser,5^ 57 Chai,65 
Sterk58, Yan,64 or the test method not mentioned5^ 59-62), the bronchoconstricting agent 
(histamine, methacholine, propanolol), and the expression method used (PD20, PC^, or 
PD35 in mg/ml, |j,g or |j,mol). Each o f the agents was administered from the lowest 
concentration up to the minimal concentration inducing a specific fall in forced 
expiratory volume in one second (FEVi). To compare the effects o f inhaled corticosteroids 
on BHR between the studies, doubling doses (DD) o f the triggers (log2 transformed) 
were calculated (if not already done in the study). An increase o f i DD of the trigger after 
treatment with inhaled corticosteroids meant that double the amount o f the trigger 
was needed to achieve the same fall in FEVi. In studies in which more than one irritant 
was used for the assessment o f BHR only the most common irritant (histamine, 
methacholine) was evaluated.56,59,62,65
Procedure of the meta-analysis
In each study within the trial groups the difference in dose steps was determined by 
final minus baseline assessment. When values were expressed as logi0 we used the 
formula logi0(final assessment) minus logi0(baseline assessment) divided by logi02. To 
determine the SD o f the differences, variances o f the independent observations were 
used. When the variables x  and y were considered, the variance was: var(x-y) = var(x) + 
var(y) -  2 x covariance (xy), or, in another formula: var(x-y) = var(x) + var(y) -  2 x 
correlation coefficient x SD(x) x SD(y). This correlation coefficient could only be 
assessed within the studies in which all individual data were presented. The mean 
of these coefficients was used as an ‘estimated’ correlation coefficient within the 
remaining studies. The SD was assessed as the root o f var(x-y).
Assessment o f the overall effect size was based on the method o f DerSimonian and 
Laird.67 The effect size o f inhaled corticosteroids versus control was assessed by 
subtracting the independent effects (effect o f inhaled corticosteroid compared to 
placebo, unpaired t test). In Figure 5.i the effect size within each study is presented in 
DD with 95% confidence intervals (CI) and p values. The estimate was assessed under 
the condition o f homogeneity. In case o f significance (X2 test, p<0.05) the estimate 
was assessed under the condition o f heterogeneity. Reasons for heterogeneity were 
investigated, i f  appropriate.
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The doses o f inhaled corticosteroids used were related to the effect sizes in two 
different ways. Firstly, an univariate regression analysis was used to relate increasing 
doses o f inhaled corticosteroid to the effect size o f BHR and, secondly, a Wilcoxon rank 
test was used to compare the effect size o f high doses (> iooo |jg daily) and low doses 
(<iooo |jg daily) o f inhaled corticosteroids. It is doubtful whether a dose o f 600 |jg daily 
is ‘low’ for children, so we also assessed the dose-response relationship omitting the two 
studies in children.
To determine whether inhaled corticosteroids would be able to decrease bronchial 
responsiveness in short-term studies we repeated the above analysis using only studies 
with a maximum duration o f 2-8 weeks.
Results
Quality of studies
All i i  studies selected were o f sufficient quality to be reviewed. Four studies were rated 
as being o f high quality (score o f 8)57'58'6I'64 and the remaining seven were o f sufficient 
quality. Most o f the ii  studies failed to give an explicit description o f the method of 
concealed treatment allocation or intention to treat analysis.
M ethod of studies
Table 5.i shows study populations, eligibility criteria, design and intervention o f the ii 
studies. Two studies were performed in children with atopic asthma.56,57 One study 
recruited i03 patients and was a long term study.6i Patient numbers in the other studies 
varied from io  to 40 subjects. Eligilibity criteria differed widely between the studies, 
although all studies excluded subjects who had previously received regular treatment 
with inhaled corticosteroids. The duration o f most o f the studies varied from two weeks 
to three months. One study lasted six months,57 and another for two years.6i 
Nine studies compared the effects o f inhaled corticosteroids with placebo and six 
with £ 2 agonists. The average daily dosage o f inhaled corticosteroids (budesonide or 
beclomethasone) used was ioo o  |jg (range 400-2000 |jg).
Effects on BHR
Baseline BHR levels were in the mild asthmatic range in five o f the studies58,60-63 and 
in the moderate asthmatic range in the remaining studies (Table 5.2).
The overall effect BHR of inhaled corticosteroids compared with control was measured 
by accumulating the separate effect sizes o f the ii  selected studies. For that purpose the 
original individual data55,59,65 or mean logi0 values, doubling doses, or geometric mean 
with SE or 95% CI o f histamine or methacholine were substracted56-58,62-64 or assessed 
on the basis o f the graphics6o,6i for all studies separately.
Effect sizes were all in favour o f the inhaled corticosteroid treatment, ranging from 
+0.44 to +2.40 DD of the bronchoconstricting agent (Table 5.2). However, Figure 5.i 
shows that in five o f the ii  studies the inhaled corticosteroid did not have a significant 
effect on BHR compared to placebo.55^ 8-60,65
The total effect size o f inhaled corticosteroids versus placebo o f the ii  studies was
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Table 5.1: Randomised controlled clinical trials on the effects o f inhaled 
corticosteroids in patients with corticosteroid naive asthma.
Study No. o f  patients, 
age, diagnosis
Duration 
o f  asthm a
Main eligibility 
criteria
Design and 
duration
Intervention, 
daily dose
Ryan55 10 , 22-38 y, controlled 
non-steroid 
dependent asth m a
Not specified Variability in FEV., > 20 % , 
BHR, only bronchodilators
DB, CO, 
4  w eeks
4 0 0  i g  BDP vs. 
placebo, MDI
B aets56 31, 7-14  y, mild 
atop ic asthm a
Not specified FEV, > 75% pred, 
crom oglycate and/or 
bronchodilators, no 
dependence on (oral) 
corticosteroids
DB, P,
2 m onths
6 0 0  i g  BUD vs. 
placebo,
MDI + spacer
Kerrebijn57 19 , 7-16  y, allergic 
asthm a
Not specified PD 20 m ethacholine < 150  
^.g, FEV, > 8o% pred , no 
continuous m edication
DB, P,
6 m onths
6 0 0  i g  BUD vs. 15 0 0  
i g  terbutaline, MDI
00ID
B 16 , 19-38 y, mild atopic Not specified 
asthm a
N on-sm oking, FEV, > 
8o% pred , PC 20 
m ethacholine i-7m g/m l. 
No inhaled or oral 
corticosteroids in the past
DB, P,
4  w eeks
8 0 0  |ig BUD vs. 
placebo, Turbohaler
Fuller59 10 , 18-45 y, atopic, 
mild asthm a
Not specified Requiring only irregular 
therapy with inhaled ^  
agon ists
DB, CO, 
3 w eeks
12 0 0  i g  BUD vs. 
placebo,
MDI + spacer
Laitinen60 14 , 21-59 y, newly 
d iagn osed asthm a
7,4 m onths 
(range 2-12)
No previous regular 
treatm ent
DB, P,
3 m onths
12 0 0  i g  bud vs. 750  i g  
terbutaline,
MDI + spacer
H aahtela61 10 3 , 15-64 y, newly 
detected asthm a
sym ptom s 
< 12  m onths
Sym p tom s < 1 year, never 
used regular m edication, 
FEV, reversibility > 15% , 
PC15 h istam ine <32 mg/ml, 
no history of regular 
treatm ent or treatm ent 
with co rtico stero id s  or 
crom oglycate
DB, P, 
2 years
12 0 0  i g  BUD vs. 750 i g  
terbutaline,
MDI + spacer
O 'C on n or62 12 , 20 -27  y, mild 
asthm a
Not specified BHR, atopy, only occasional 
sym ptom s controlled by ^  
agonist, FEV1 > 80% pred
DB, CO, 
2 w eeks
16 0 0  i g  BUD vs. 
placebo, Turbohaler
v£6
n
>
10 , 20-46 y, mild 
stable ashm a
Not specified FEV1 > 8 0% pred , atopic 
non-sm oking, occasional 
sym ptom s controlled only 
by ^ 2  agon ist
DB, CO, 
2 w eeks
16 0 0  i g  BUD vs. 
placebo, Turbohaler
Vathenen64 40 , 18-45 y, mild to 
moderate asthm a
> 2 years FEV1 > 50% pred , PD 20 
histamine < 4  ^.mol, current 
non-sm okers, no treatm ent 
other than an inhaled ^  
agonist
DB, P,
6 w eeks
16 0 0  i g  BUD vs. 
placebo,
MDI + spacer
W iebicke65 25, adults,
asym ptom atic  or mild 
asthm a
Not specified FEV1 > 75% pred, no regular 
m edication required, 
non-sm okers, BHR present.
CL 
(D
, 
e 
CD 
5 
O 
co
2 0 0 0  i g  BDP + 8 0 0  i g  
salbutam ol vs. placebo 
+ 8 0 0  i g  salbutam ol, 
MDI + spacer
DB = double-blind, P = parallel, CO = cross-over, BDP = beclom eth ason e d ipropionaat, BUD = budesonide, MDI = metered 
dose  inhaler, BH R = bronchial hyperrespon siven ess, FEV-, = forced expiratory volum e in one second; PC20  or PD 20  = 
concentration or do se  o f  provocative agent required to reduce FEV, by 20 %  ore m ore; DD = doubling dose.
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Table 5.2: Randomised controlled clinical trials on the effects o f inhaled 
corticosteroids in patients with corticosteroid-naive asthma.
Study Major outcome 
measures
Mean baseline 
BHR (range o f 
doses applied)
Mean
baseline
fev i
Effects on BHR 
(inhaled 
corticosteroids 
vs. control)*
Effects on lung 
function (inhaled 
corticosteroids vs. 
control)
Effects on symptoms, 
ß2 agonists and 
bronchial epithelium / 
eosinophils (inhaled 
corticosteroids vs. 
control)
Ryan55 PC 20 histam ine 0.5 mg/m l 
histam ine 
(0 .0 125-16 )
3.18  i + 0 .4 4  DD
(P = a 1 4)
f e v i = No data
Baets56
(Dinamih82PH
50 ^ g  histam ine 
(10-1280)
90% pred +1.55 DD 
(p < 0 .00 l)
FE V ,+  (97% ), 
m orning PEF + 
(2ol/m in)
f e v i =
Sym p tom s =, 
ß2 agon ists  -
Kerrebijn57 PD 20 metha- 
choline
38 |ig
m ethacholine
(10-1280)
95% pred +2.33 DD 
(p< 0 .00 1)
f e v i = Sym p tom s =
Bel58 PC20  metha- 
choline, max 
airw ay narrowing 
m ethacholine
3.6 mg/m l 
m ethacholine 
(0.25-256)
94% pred + 0.65 DD 
(p = 0 .23  )
f e v i = No data
Fuller59 (Dinmi
-2 
c 
.!£ 
c
D
ra
P
b
0 .2 8  ^.mol 
histam ine 
(0.06-16)
89% pred + 1.0 0  DD 
(p = 0 .21)
FEV, =, PEF + 
(35-50 L/min)
Sym p tom s =
Laitinen60 PC15 hist, FEV,, 
PEF, sym ptom s, 
biopsy: bronchial 
epithel, inflam m . 
cells m ucosa
2.9 m g/m l hist 
(1.0-32)
89% pred + 0 .7 0  DD 
p=0.25
FEV, =, PEF + 
(50L/min)
Sym p tom s =, 
ß2 agon ists  =, 
structure airway 
epithelium  +, 
lym phocytes -, 
eosinphils -
Haahtela61 e,
- Î
 
¿gÈS
P
F
s
a
7 .0  mg/m l 
histam ine 
(1.0-32)
86% pred + 1 .10  DD 
(p< 0 .00 1)
FEV, =, PEF + 
(30l/m in)
I 
1 pg 
£ 
I
n
CO 
C
O
.
O'Connor62 PC20  metha- 
choline/ M BS/ 
AM P
1.4  m g/m l 
m ethacholine 
(0.125-32)
96% pred + 1 .17  DD 
(p = 0 .0 09 )
N o data No data
Evans63 Peripheral blood 
eosin op h ils, PC20 
m ethacholine
0 .13-2 .23  mg/m l 
m ethacholine 
(0.125-32)
drepr69 + 0.88  DD 
(p< 0 .00 1)
N o data No data about 
sym pto m s/
P2 agon ists, 
eosinophils -
Vathenen64 PD 20 histam ine, 
FEVv  PEF, sym p ­
tom s, ^ 2  agon ists
0 .37  ^m ol 
histam ine 
(0.03-32)
95% pred + 2 .4 0  DD 
(p = 0 .003)
FEV, + (98%), 
PEF + (40L/m in)
Sym p tom s -, 
P2 agon ists  -
Wiebicke65 PC10 0  sRaw 
h istam ine/m etha- 
choline, PV75 
sRaw  hypervent/ 
SO 2
0 .2  mg/m l 
histam ine 
(0.01-8 .0)
90% pred + 0 .6 4  DD 
(histam ine or 
m ethacholine) 
(p = ° . 28)
N o data No data
BHR = bronchial resp on siven ess; DD = doubling do se ; FEV, = forced expiratory vo lum e in one second ; PEF = peak 
expiratory flow; Raw = specific airw ays resistance; S O 2 = oxygen saturation; PC2Q , PD 2Q; = concentration or do se  o f  
provocative agent required to preduce a fall in FEV, o f  20 %  or m ore; HDM = house dust mite. A ccording to effects o f 
inhaled corticosteroids versus control group on lung function and sym ptom s: '+ ' o r '-' m eans statistically significant 
increase or decrease  (p<0.05), '= ' m eans no statistically significant difference *  See Figure 5.1.
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Figure 5.1: Effect size o f inhaled corticosteroids on bronchial responsiveness in 
doubling doses o f bronchoconstricting agent with 95% confidence intervals and 
p values. The effect size within each selected study and the overall estimate are presented. Daily doses 
of inhaled corticosteroids are given. BUD = budesonide; BDP = beclomethasone; *studies in children; 
#only studies in adults; ## only studies of < 2 months.
- 1 0  1 2  3 4
Doubling dose
+1.16 DD (95% CI +0.76 to +1.57, test of heterogeneity) which was statistically significant. 
The confidence intervals o f the effect size in the study o f Baets et al in children did not 
fall within the confidence interval o f the total effect size when assessed under conditions 
o f homogeneity (p = 0.014). To determine whether heterogeneity could be explained 
by the variation in age we also assessed the total effect size without the two studies in 
children56>57 but the total effect size remained statistically significant (+0.88 DD of the 
bronchoconstricting agent (95% CI +0.64 to +1.14)).
A univariate regression analysis was used to measure any dose-response relationship 
between the dose o f inhaled corticosteroid on the level o f BHR. This analysis showed no 
statistically significant relationship (regression coefficient -0 .0 0 7  DD/100 |jg, p = 0.87). 
Correcting for study duration did not improve the relationship between the dose of 
inhaled corticosteroids and a decrease in BHR, nor was there a statistically significant 
effect found when the patients were divided into two groups according to the dose of 
inhaled corticosteroids (<1000 |jg daily, 4 studies, total effect +1.25DD; > 1000 |jg, seven 
studies, total effect +1.13 DD; p = 0.92, Wilcoxon rank test). This difference in effect was 
somewhat higher than in the previous analyses (p-values ‘fell’ to p = 0.29 and p = 0.11, 
respectively) when the two studies in children (600 |jg daily) were excluded.
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We were also interested to determine whether inhaled corticosteroids were able to 
decrease BHR during short term treatment. A positive result was seen in four o f the 
eight studies with a relatively short duration o f 2-8 weeks.56>62-64 and a negative result 
was seen in the other four.55>58>59>65 We combined the separate study effects in these 
short term studies to assess the overall effect size o f inhaled corticosteroids compared 
with control on BHR. The effect size under the condition o f homogeneity was +0.91 DD 
(95% CI +0.65 to +1.16) o f the bronchoconstrictor in favour o f the inhaled corticosteroid 
(p = 0.14). We also related the effect sizes o f individual studies to the dose o f inhaled 
corticosteroids used in the short-term studies by univariate regression analysis wich 
gave a regression coefficient o f +0.02 DD/100 |jg (p = 0.38). Correcting for study 
duration did not improve the relationship between the dose o f inhaled corticosteroids 
and decrease in BHR. A comparison o f low dose (<1000 |jg, 3 o f 8 studies) versus high 
dose inhaled corticosteroids also showed a lack o f correlation between the dose used and 
the level o f BHR (+0.88 DD versus +1.21 DD, respectively; (p = 0.55, Wilcoxon rank test).
Discussion
Inhaled corticosteroids are increasingly considered as first line treatment for asthma, 
even in milder stages o f the disease.1'4 The degree of BHR is considered to be indirectly 
related to degree o f bronchial inflammation. This meta-analysis in patients with 
corticosteroid naive asthma indicated that, on average, high doses o f inhaled corticosteroids 
(mean dose 1000 |jg, range 400-2000 |jg daily) decreased BHR significantly within 
2-8 weeks. This finding supports recent consensus reports asthma recommending 
the use o f relatively high initial doses o f inhaled corticosteroids in mild bronchial 
inflammation.1,4 There were insufficient studies to determine whether doses below 
1000  |jg daily would have been able to produce the same result.
Inhaled corticosteroids have been shown to be the most effective inhaled anti­
inflammatory agents available in asthma and there are indications that the early 
introduction o f inhaled corticosteroids may prevent loss o f lung function.68 In mild 
(corticosteroid naive) asthma the advantages o f inhaled corticosteroids have to be 
weighed against the disadvantages. Local side effects such as oral candidiasis and 
systemic side effects such as adrenal suppression have been reported, especially with 
higher doses o f inhaled corticosteroids.69 It is also important to recognise that control 
o f BHR is an outcome wich patients with few bronchial symptoms may not consider 
important and this may hamper patient-compliance.
A few comments on the method o f the meta-analyse have to be made. The purpose 
o f the study was to assess the first-time treatment effect o f inhaled corticosteroids on 
bronchial inflammation so we searched the literature for studies o f ‘corticosteroid naive’ 
asthma. This may have led to confusion about the severity and duration o f asthma o f the 
studies included. Firstly, corticosteroid naive asthma is not necessarily mild, and 
patients with moderate to severe asthma could have been corticosteroid naive. Baseline 
BHR and FEV: in most o f the studies suggested mild to moderate asthma. 
Unfortunately, the duration o f asthma was not stated in many o f the studies so asthma 
o f recent onset as well as longer standing ashtma (mild or moderate) might have been 
present.
The method o f assessment o f BHR varied widely between the studies. In order to
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compare different measurements o f BHR the effects were presented in doubling doses 
o f the trigger. Although the DD is often used as a clinical and epidemiological effect 
parameter, the comparison between the different studies may have resulted in some 
bias. However, both histamine and methacholine are the best validated substances for 
provocation testing.70
Type 2 errors could have occurred as a number o f studies analysed might not have 
had enough power. A conventional meta-analysis was therefore performed to obtain a 
tighter estimate o f the effect size than that obtained by several smaller (and possibly 
underpowered) studies. However, we are aware o f the fact that such an analysis may not 
totally overcome these shortcomings o f individual studies.
We performed a meta-analysis despite the diversity o f the studies included. The 
studies contained populations o f different ages (children and adults), asthma of 
different duration (less than one year to unspecified), and o f slightly different severity, 
the use o f different inhaled corticosteroids, different dosages o f inhaled corticosteroids, 
and different study durations (two weeks to two years). These differences might have 
influenced the reliability o f the results to some extent. However, the direction o f effect 
sizes was always the same, and the different dosages and duration o f the studies made 
it possible to estimate dosage and time effects o f drug activity.
In this study the measurement o f BHR as a hallmark o f inflammation in asthma was 
the primary outcome parameter o f the effects o f inhaled corticosteroids in patients with 
corticosteroid naive mild asthma. The clinical relevance o f an overall effect size of 
approximately 1 DD of the trigger after treatment with inhaled corticosteroids o f patients 
with corticosteroid naive asthma is not yet clear. This difference is thought to be 
clinically relevant in patients with moderate and severe asthma.71 In those with 
corticosteroid naive asthma the improvement in BHR may be o f greater importance 
because, in most cases, there is less room for improvement than in moderate and 
severe asthma. There are indications that bronchial inflammation precedes bronchial 
obstruction and thus probably symptoms in asthma.72 Patients with corticosteroid 
naive (mostly mild) asthma may have nearly normal spirometric parameters and few 
symptoms on testing. Improvements with treatment are therefore difficult to obtain. 
Measurement o f BHR was therefore chosen as an indicator o f bronchial lability. 
Nevertheless, in half o f the 11 studies analysed there was a significant improvement in 
lung function (PEF and/or FEV:) after treatment with inhaled corticosteroids.56,59-61,64 
Three o f the six studies in which symptoms or the use o f bronchodilators were 
evaluated reported a statistically significant decrease in one o f these parameters after 
treatment with inhaled corticosteroids.56,61,64
Most studies showed a clinically significant decrease in BHR after treatment with 
high doses o f inhaled corticosteroids compared with the control drug. However, only in 
the two-year study by Haahtela et al in patients with corticosteroid naive mild asthma 
did long term treatment with a high dose o f inhaled corticosteroids eventually cause 
BHR to return to ‘non-asthmatic’ levels.61 Although the first six weeks o f treatment 
with inhaled corticosteroids contributed most to the effect on BHR, the PC^ histamine 
increased gradually during the two year study. A gradual decrease in the level o f BHR 
during 12-24 months o f treatment with inhaled corticosteroids was also reported in two 
studies in patients with moderate asthma.73,74 The six-month study by Kerrebijn et al 
and the three month study by Laitinen et al also found that the first 6-8 weeks of
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treatment with inhaled corticosteroids contributed most to the decrease in BHR.57^ °  
In the light o f these results we suggest that the dose could probably be tapered after 
six weeks to a lower dose (200-400 |j,g), both to avoid adverse effects and gradually to 
diminish the inflammation in the long term.
No relationship between the dose o f inhaled corticosteroids and the level o f BHR was 
found. It is possible that the only low dose study included in the analysis55 (400 |J.g 
daily) was too short to show an optimum improvement within the study period o f four 
weeks, so we cannot fully exclude the possibility o f a dose-response effect. 
Unfortunately, no studies were analysed in which dose-response relationships were 
tested. Larger and more long term studies are urgently needed in patients with 
corticosteroid naive asthma to assess the effects o f first time with inhaled corticosteroids 
at different dosages and periods o f treatment on both BHR and lung function and 
symptoms.
In conclusion, this meta-analysis has indicated that, on average, high doses of 
inhaled corticosteroids (mean dose 1000 |j,g, range 400 to 2000 |j,g daily) decreased 
BHR within 2-8 weeks in patients with corticosteroid naive asthma. It remains unclear 
whether lower doses o f inhaled corticosteroids can achieve the same results. In the 
meantime it may be wise to follow the recent treatment protocols o f consensus reports 
on asthma advocating a top-down strategy with inhaled corticosteroids once control of 
symptoms has been achieved.
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Abstract
Background: This study investigated i f  long-term therapy with inhaled corticosteroids 
could be discontinued in mild asthma when patients are in a clinically stable phase of 
the disease. Data were derived from a 2-year randomized controlled, bronchodilator 
intervention study in family practice.
Methods: The experimental (stop-steroid) group consisted o f 19 asthmatic patients 
who had used inhaled corticosteroids daily during at least the year preceding this study 
and who stopped using these drugs because o f participation in the bronchodilator 
intervention study. The control (no-steroid) group consisted o f 70 patients with asthma 
who had not used corticosteroids in the year preceding the study. At the start o f the study 
(8 weeks after stopping steroids), the two groups were completely comparable in all 
relevant characteristics. During the 2-year study, patients were treated only with a 
bronchodilator (salbutamol or ipratropium bromide). Outcome measures were: 
exacerbations, symptoms, annual decline in forced expiratory volume in 1 second 
(FEVj), annual change in nonspecific bronchial responsiveness (PC20-histamine) and the 
need for additional corticosteroid therapy because o f symptoms o f increased airway 
obstruction.
Results: In the stop-steroid group, 12 o f 19 patients (63%) dropped out during 
the study period because o f a deterioration o f their clinical condition and need for 
additional (inhaled) corticosteroid treatment. In the no-steroid group, only eight 
patients dropped out for this reason (11%). In the stop-steroid group, who did not 
use steroids for at least 1 year, the annual FEV: decline was much larger than in the 
cimparison subjects (165 versus 40 ml/yr).
Conclusion: Stopping maintenance treatment with inhaled corticosteroids may not be 
advisable in all patients with mild asthma. Instead o f stopping or interrupting 
treatment, family physicians are advised to determine the minimal effective daily dose 
o f inhaled corticosteroids for each individual patient that provides adequate control of 
the disease.
Introduction
The current understanding that inflammation is a major pathophysiologic mechanism 
of asthmai has resulted in a shift in treatment policy towards the early introduction of 
inhaled corticosteroids.2,3 In addition, some recent studies4-6 have suggested that inhaled 
corticosteroids can improve the long-term outcome o f asthma. The tendency toward 
early use o f inhaled steroids is strengthened by the finding in two independent studies 
that continuous therapy with bronchodilators, the usual alternative to steroid treatment, 
may have adverse effects on the control o f asthma7 and on the progression o f asthma.8 
Since continuous therapy with bronchodilators may be detrimental, treatment with 
inhaled corticosteroids is probably the only currently available therapy that has been 
shown to improve the long-term course o f asthma.
Since the majority o f patients with asthma are treated in family practices,9 'I0 
family physicians will be prescribing this therapy for a growing number o f patients. 
An important question for family physicians and patients is whether treatment with 
inhaled corticosteroids can be interrupted or stopped when patients are in a stable phase 
o f the disease. Since inhaled steroids do not have a direct symptom-relieving effect, 
patient compliance with this medication is a major problem,ii and patients may even
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ask their family physician to stop maintenance treatment with inhaled steroids when 
their asthma is stable. Although inhaled steroids have relatively mild side-effects, oral 
candidiasis, hoarseness, and irritation o f the oropharynx may occur, and systemic effects 
may develop when doses o f 800 |j,g or more are used.12 All these aspects make the above 
question very relevant.
I f  corticosteroids ‘cure’ the underlying mechanisms o f asthma and chronic bronchitis 
to some extent, steroid treatment can probably be interrupted. I f  they only suppress 
inflammation temporarily, discontinuing o f steroids might be difficult. Some information 
is available about the effects o f stopping treatment with inhaled corticosteroids in 
patients referred for specialist treatment. In one study with moderate-to-severe asthmatic 
children, stopping inhaled steroids appeared to cause trouble.13 Haahtela et al showed 
that discontinuation o f treatment with inhaled steroids in mild asthma often was 
accompanied by exacerbation o f the disease and may have resulted in irreversible loss 
o f lung function.14 In another study with mild asthmatic adults, it was shown that 
improvements in asthma caused by 1 year’s use o f inhaled steroids could be maintained 
for at least 3 months after stopping steroid treatment.15 No studies have been performed 
in patients from family practice who had not been referred for specialist treatment. 
Since most o f these patients probably have mild asthma, it seems relevant to investigate 
the possibilities o f stopping inhaled steroids in these patients.
This study assessed the effects o f stopping treatment with inhaled corticosteroids on 
long-term control and progression o f asthma in a family practice. Data o f 89 patients 
with asthma from a previous published large intervention study were evaluated.8
Methods
Patients
The study population consisted o f 89 asthma patients who entered a 2-year randomised 
controlled study o f bronchodilator therapy in family practice.8 Figure 6.1 shows 
enrollment o f the subjects. Patient selection, and the inclusion and exclusion criteria of 
the intervention study have been described in detail elsewhere.8 Twenty-nine family 
physicians were asked to select all their patients aged 30 or older with symptoms of 
asthma or chronic bronchitis. Inclusion criteria included only patients with a mild- 
to-moderate airway obstruction (forced expiratory volume in 1 second [FEV:] or 
FEVj/EVC at least two standard deviations below their predicted value16 but more 
than 50% o f the predicted value) and/or bronchial hyperresponsiveness to histamine 
(provocative concentration o f histamine that produces a 20%  fall in FEV: [PC20], and 
PC20 < 8 mg/ml). Exclusion criteria were: dependency on corticosteroids, chronic heart 
failure, malignant disorders, or other life-threatening diseases. Only patients with 
airway reactivity due to asthma were included. The criteria for the diagnosis o f asthma 
were based on the standards o f the American Thoracic Society.17 Asthma was defined as 
the combination of: 1) reversible obstruction (FEV: increased by more than 15% o f the 
baseline value 60 minutes after the administration o f 80 |j,g ipratropium bromide and 
400 |j,g salbutamol), 2) bronchial hyperresponsiveness to histamine (PC20 < 8 mg/ml), 
3) dyspnea, and 4) allergy and/or wheezing.
The experimental (stop-steroid) group had 19 asthmatic patients who had 
continuously used (inhaled) corticosteroids daily during at least 1 year preceding the
8 l
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study and stopped because o f participation in the bronchodilator intervention study. 
These patients had been given permission by their physician to stop corticosteroids, and 
they entered an 8-week washout period before the start o f the bronchodilator study, 
during which inhaled corticosteroid treatment (and other pulmonary medication) 
was stopped. During this period, only as-needed inhaled salbutamol or ipratropium 
bromide were prescribed. No patients had an exacerbation during this washout period 
and were therefore not excluded from the study.
Figure 6.1: Enrollment o f study subjects. A total of 524 patients were selected at the start of 
the 2-year bronchodilator trial; 300 patients did not participate in the study for several reasons (see 
arrows). Of the 224 patients who eventually took part in the bronchodilator trial, only patients with 
asthma (n=8<9) were used in this study. No dropouts occurred in the 8-week washout period. At the 
start of the study, the stop-steroid group had 19 asthmatic patients. Due to dropout after 1 and 2 years 
of study, only 10 and 5 patients remained, respectively. The no-steroid group had 70 asthmatic patients. 
After 1 and 2 years of study, only 62 and 54 patients remained, respectively.
n = number of patients
FEVj = forced expiratory volume in 1 second
Stop-steroid groupBronchodilator
trial
Asthma
/  1 
/  19
1
10
1
5
n=89
►1
. 8 week washout
\ \  70 62 54
Chronic
--------------- 1--------- --------- 1
bronchitis No-steroid group
n=135 1 1 1
start 1 year 2 year
*■ refused n=5 9
excluded by G.P. for reasons other than 
pulmonary disease n=156
+• FEVj < 50% predicted n=80
no airflow obstruction or bronchial 
hyper responsiveness n=5
The control (no-steroid) group consisted o f the remaining 70 asthmatic patients who 
had not used inhaled corticosteroids in the year preceding the study. The clinical 
characteristics o f the stop-steroid and no-steroid groups are shown in Table 6.1. At the 
start o f the study, the two groups had no significant differences.
The study was approved by the Medical Ethics Committee o f the University of 
Nijmegen. All patients gave informed consent.
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Outcome measures
The stop-steroid and no-steroid groups were followed for 2 years while receiving 
standard bronchodilator treatment. The main outcome measure during this period 
was the annual decline, i f  any, in FEVr  On the basis o f earlier research,6'8 it was 
determined that the minimum detecTable difference in FEV: decline was 120 ml/yr, 
with an individual standard deviation o f the FEV: decline o f 100 ml. With an alpha of 
.05 and a power o f .8 the number o f patients who could be evaluated had to be at least 
10 in each study group.
Secondary outcome measures during this period were: the number o f exacerbations, 
severity o f symptoms and annual change in nonspecific bronchial responsiveness 
(PC20-histamine). An important outcome measurement and endpoint in this study was 
the need for corticosteroid therapy due to too severe or too many exacerbations. The 
category ‘too severe exacerbations’ was defined as exacerbations not sufficiently treated 
by a 10-day course o f oral prednisone, adding broad spectrum antibiotics i f  necessary. 
The category ‘too many exacerbations’ was more than two exacerbations annually.
Table 6.1: Patiënt characteristics.*
Variable Experimental 
'Stop Steroid’ Group
Control
'No-steroid
N u m b e r 19 70
A g e , y e a r s 5 6  ( 12 ) 51 ( 12 )
G e n d e r , m a le / fe m a le 6/-13 35/35
S y m p t o m  s c o r e 4 . 6  ( 1 .5) 4.9  ( 1 .7)
#  o f  p a c k s / y e a r  o f  s m o k in g 1 2 ( 1 0 ) 1 2  ( 16 )
S m o k e r s ,  y e s / n o / n o  d a ta 2 /8 /9 27/ 38/5
A lle r g y ,* *  y e s / n o / n o  d a ta 5 / 6 / 8 24/40/5
F E V n % p r e d ic t e d 71 ( 19 ) 7 2  (20 )
F E V n/IV C , % 6 2  ( 15) 6 1 ( 1 1 )
R e v e rs ib ility  FE V v  %  p re d ic te d 17 ( 10 ) 14  ( 1 1)
P C 2 0 - h is ta m in e , m g /m l .6 1.3
*  C h a r a c t e r is t ic s  a r e  o f  th e  1 9  p a t ie n t s  o f  th e  s to p - s t e r o id  g r o u p  ( c o n t in u o u s  u s e  o f  in h a le d  c o r t ic o s t e r o id s  
d u r in g  th e  y e a r  p r e c e d in g  th e  s tu d y ) ,  a n d  th e  7 0  p a t ie n ts  o f  th e  n o -s te r o id  g r o u p  (n o  u s e  o f  c o r t ic o s t e r o id s  
d u r in g  th e  p r e - s tu d y  p e r io d ) . S t a n d a r d  d e v ia t io n s  o r  r a n g e s  a r e  in p a r e n t h e s e s .  D if fe r e n c e s  in d ic h o to m ic  
v a r ia b le s  w e r e  s ta t is t ic a l ly  c o m p a r e d  u s in g  th e  c h i- s q u a r e  t e s t  a n d  w e r e  c o m p a r e d  in n o r m a lly  d is t r ib u te d  
v a r ia b le s  u s in g  th e  th e  u n p a ir e d  S t u d e n t 's  t t e s t .  N o  s ta t is t ic a l ly  s ig n if ic a n t  d i f fe r e n c e s  w e r e  p r e s e n t .
* *  A lle rg y  w a s  d e f in e d  a s  a t  le a s t  o n e  p o s it iv e  t e s t  o u t  o f  s e v e n  R A S T  ( R a d io  A lle r g o  S o r b e n t  T e s t s ) .
F E V 1 - F o rc e d  e x p ir a to r y  v o lu m e  in 1 s e c o n d  a s  a  p e r c e n t a g e  o f  th e  p r e d ic te d  v a lu e  
IV C  - In s p ira to ry  v ita l c a p a c it y
P C , 0 - h is t a m in e  - P r o v o c a t iv e  c o n c e n t r a t io n  o f  h is t a m in e  (th e  d o s e  o f  h is t a m in e  p r o d u c in g  a  2 0 %  fa ll in 
F E V 1 ) . G e o m e t r ic  m e a n  P C 2 0  is g iv e n .
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Measurements 
Respiratory symptoms
The severity o f respiratory symptoms (cough, phlegm, dyspnea) was assessed weekly by 
each subject on a scale o f 0-4 and recorded in a diary. A score o f ‘4 ’ indicated worst 
symptoms and ‘0 ’ indicated no symptoms. The total score was computed by adding the 
cough, phlegm, and dyspnea scores (maximum 4 points each) to yield a total score. The 
highest (most symptomatic) possible score was 12.
Exacerbations
Exacerbations were defined according to Fletcher et al,l8 with modifications o f Boman 
et al19 as the occurence o f mucopurulent sputum, cough and at least one o f the 
following symptoms: general malaise, symptoms o f common cold, fever, dyspnea, 
increased sputum production, increased sputum thickness, foul-tasting sputum, or 
increased difficulty o f expectoration. In case o f an exacerbation, a 10-day tapering-down 
course o f oral prednisone was given (25, 25, 20, 20, 15, 15, 10, 10, 5, 5 mg).
FEV1, PC20-histamine and reversibility of airway obstruction
No bronchodilating medication was taken for at least 8 hours before the assessments of 
airway obstruction. Measurements o f FEV1 were performed with the Microspiro HI-298 
spirom eter® (Chest Corporation, Japan) by two qualified laboratory technicians.20 
Patients had to perform three satisfactory forced vital capacity (FVC) maneuvres on all 
occasions. Data were taken from the curve with the highest sum of FVC and FEVr  The 
bronchial responsiveness to histamine was measured using the method described 
by Cockcroft et al21 and expressed as the PC20-histamine value. After the FEV1 had 
returned to baseline value, the increase in FEV1 60 minutes after the inhalation o f both 
400 |jg salbutamol and 80 |jg ipratropium bromide was assessed.
Smoking behaviour
The number o f cigarettes per day was recorded by the patients in a weekly report. The 
smoking history was retrospectively assessed and quantified in pack years.
T reatment during  two-year follow-up
All patients received bronchodilator therapy alone during the 2-year study period, either 
continuously (salbutamol 400 |jg or ipratropium bromide 40 |jg, four times daily) or on 
demand (only dry powder capsules o f salbutamol 400 |jg or ipratropium 40 |jg during 
complaints or exacerbations).8 No inhaled steroids or cromoglycate were permitted. 
Patients using salbutamol during the first year crossed over to ipratropium bromide 
during the second and vice versa.8
A nalysis
The scores o f cough, phlegm, and dyspnea were combined in the total symptom score.
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The annual FEVI decline was determined by linear regression o f FEVI over the course 
o f time (maximum of seven measurements). PC20 values were 2log transformed prior 
to analysis. The annual changes o f PC20 were estimated by linear regression of 
2logPC20 in the course o f time (maximum of five measurements).
The influence o f stopping treatment with inhaled corticosteroids on the outcome 
variables was assessed by multiple analysis o f variance (MANOVA), adjusting for age, 
gender, height, smoking, pack years, allergy, initial PC20 and FEVP reversibility of 
obstruction, and bronchodilator treatment during the study.22 The relation between 
clinical characteristics and the annual FEVI decline after stopping treatment with 
steroids in the stop-steroid group was also investigated by means o f MANOVA.
The effects of stopping steroids on decline in lung function and change in bronchial 
hyperresponsiveness, exacerbations, and symptoms were only investigated in subjects 
who could stop using steroids for at least 1 year (explanatory analysis, no intention- 
to-treat analysis).
Results
In the stop-steroid group, 12 o f the 19 patients (63%) dropped out during the 
2-year study period because o f a deterioration o f their clinical condition and need for 
additional (inhaled) corticosteroid treatment, vs only eight o f the 70 patients (11%) in 
the no-steroid group (chi-square=20.i, P<.000i). O f the 12 dropouts from the stop- 
steroid group, eight needed additional corticosteroids during the first 6 months of the 
bronchodilator trial (Table 6.2).
Table 6.2: Number o f dropouts, period o f dropout, and reasons for dropout during 
the 2-year study*.
Experimental 
'Stop-steroid’ 
Group n =i9
Control 'N o-steroid ’
Group
n=70
n (%) n (%)
0 - 6  m o n t h s  •  T o o  s e v e r e  o r  t o o  m a n y  e x a c e r b a t io n s  
( n e e d in g  s te r o id s )
•  O th e r  r e a s o n s * *
2) 
) 
(4 
(6
00
1 (5)
4  (6)
6 - 12  m o n t h s  •  T o o  s e v e r e  o r  t o o  m a n y  e x a c e r b a t io n s  
( n e e d in g  s te r o id s )
•  O th e r  r e a s o n s * *
0  (0) 
0  (0)
0  (0) 
0  (0)
1 2 - 2 4  m o n t h s  •  T o o  s e v e r e  o r  t o o  m a n y  e x a c e r b a t io n s  
( n e e d in g  s te r o id s )
•  O th e r  r e a s o n s * *
4  ( 2 1)
4  (6)
1 (5)
4  (6)
*  - in both the stop-steroid and no-steroid groups
* *  - Lack o f  m otivation, em igration, m alignancy, side effects o f  bronchodilator study m edication
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When the patients who could continue bronchodilator without inhaled steroids during 
at least i year were analyzed, the following data were found (Table 6.3). The annual FEVI 
decline was larger in the stop-steroid group (165 ml/yr) than in the no-steroid group (40 
ml/yr) (P=.022). No differences between groups were found with respect to symptoms, 
exacerbations, and the annual change in PC20.
No feature could predict the effect of stopping inhaled corticosteroids at the start 
o f the study. Allergy, initial FEVI and PC20, reversibility o f obstruction, and smoking 
behaviour before and during the study were all unrelated to the difference in annual 
decline in FEVI in the stop-steroid and no-steroid groups.
Table 6.3: Effects o f stopping treatment with corticosteroids.
Experimental 
'Stop-steroid’ Group 
n = io
Control
'No-steroid ’ Group 
n =  62
P value
FE V 1 d e c lin e , m l/ y e a r l6 5 (5° ) 4 °  (2o ) . ° 2 2
P C 2 0  d e c lin e , d o u b lin g  d o s e / y r .33 (. 6 2) .33 (° . 22 ) 1 . 0 0 0
E x a c e r b a t io n s , n u m b e r / y e a r ^  (.3) .8  (° . 1) .2 1 6
S y m p t o m  s c o r e 2 . °  (.5) 2 .2  ( ° .3 ) .6 9 7
T a b le  s h o w s  th e  e f fe c t  o f  s t o p p in g  t r e a t m e n t  w ith  c o r t ic o s t e r o id s  o n  s y m p t o m s ,  e x a c e r b a t io n s , th e  a n n u a l 
d e c l in e  in FEV-, ( fo rc e d  e x p ir a to r y  v o lu m e  in 1 s e c o n d ) ,  a n d  P C 2 0  (p r o v o c a t iv e  c o n c e n t r a t io n  o f  h is t a m in e  
p r o d u c in g  a  2 0 %  fa ll in F E V 1 ) in p a t ie n ts  w ith  m ild  a s t h m a  w h o  c o u ld  s to p  u s in g  c o r t ic o s t e r o id s  a t  le a s t  
d u r in g  1 y e ar . S t a n d a r d  e r r o r s  o f  th e  m e a n  a r e  in p a r e n t h e s e s .  D iffe r e n c e s  w e r e  t e s t e d  b y  m e a n s  o f  th e  
u n p a ir e d  S t u d e n t 's  t te s t .
Discussion
Long-term treatment o f asthma with inhaled corticosteroids is becoming increasingly 
important for family physicians. Two recent guidelines about the therapeutic 
management of asthma advocated the early introduction of inhaled corticosteroids in 
subjects with asthma.2-3 Since most patients with asthma are treated in primary 
care9-10 and indications for the use o f inhaled corticosteroids are increasing, family 
physicians will have to prescribe this kind of therapy for a growing number of patients. 
For family physicians, an important therapeutic question about treatment with inhaled 
corticosteroids is whether maintenance therapy with these drugs can be discontinued 
when adequate control of the disease has been achieved. This question has not yet been 
addressed in a long-term follow-up study in patients selected from family practice. 
Therefore, it seemed appropriate to study the ability to stop steroid therapy under close 
observation, as we did in this study.
This study shows that it is difficult to stop treatment with inhaled corticosteroids in 
patients with mild asthma. O f the 19 patients in whom steroids were stopped, 12 (63%) 
needed additional corticosteroids during the 2-year study period, mostly during the 
first 6 months after stopping. This percentage was much higher than in the group of
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subjects not using steroids regularly (11%). In the patients who stopped steroids 
and were able to continue treatment with bronchodilators alone (without inhaled 
steroids) for at least 1 year, the annual decline in ventilatory function was much higher 
than in the no-steroid group. However, no increased deterioration in bronchial 
hyperresponsiveness was found in the patients stopping inhaled corticosteroids. 
Perhaps the PC20 had already declined during the washout period just before the start 
o f the study.23'24
The high percentage o f patients who needed additional corticosteroid therapy and 
the large decline o f FEV: in the patients stopping treatment with steroids suggests that 
inhaled steroids do not cure but only suppress underlying disease processes. It even 
suggests the existence o f a ‘rebound’ increase in airway inflammation and a consequent 
excessive increase in airway obstruction after the withdrawal o f steroids. Short-term 
studies in asthma demonstrated a decline in FEV: and an increase in nonspecific 
bronchial responsiveness after withdrawal or dose reduction15 o f inhaled steroids.23"25 
One long-term study in patients with asthma referred to specialist treatment also 
showed a decline in FEV: level after stopping inhaled budesonide14. After stopping 
treatment with oral steroids or replacement by inhaled corticosteroids, fatal asthma26 
and severe asthma relapse27 may occur as late as 4-8 months after discontinuation. 
Fortunately, none o f the stop-steroid group in our study had fatal or near-fatal asthma 
after cessation o f steroids. The syndrome o f pseudorheumatism (myalgia, arthralgia, 
joint swelling, etc.) in some asthmatic patients stopping treatment with oral steroids28 
might also suggest a rebound increase in systemic and local inflammatory processes.
In origin, this study had another research question, and the information presented in 
this report represents a reanalysis o f study data. A disadvantage o f such a re-analysis is 
that the study protocol was not specifically designed for the purpose for which we used 
it. Therefore, the research reported here can only serve as an observational study. As a 
consequence, the study (stop-steroid) and comparison (no-steroid) groups do not really 
have an experimental-control relationship. Measuring dropouts as an outcome might 
have interfered with the main outcome measures o f the study (FEVjdecline, 
PC20decline etc.), since the study was unblinded and not randomized. Patients in 
the stop-steroid group had already taken an inhaled steroid for at least 1 year and could 
easily drop out during the study on the basis o f this pre-study medication experience. 
However, despite the many dropouts in the from the experimental (stop-steroid) group, 
we were still able to show a significantly faster decline o f FEV: in this group than in the 
no-steroid group (165 vs. 40 ml/yr). A better design to answer this paper’s question 
would have been a randomized, controlled, double-blind study in which one group of 
patients would continue and another group would discontinue the medication. Before 
firm conclusions can be drawn about the possibility o f stopping inhaled steroids, such 
a study is absolutely necessary.
In spite o f this limitation, we believe this study suggests that physicians should be 
careful in their decision when to stop inhaled steroids in patients with asthma. For 
this study, we selected only those patients who had mild degrees o f airway obstruction 
(FEVj was 75% of the predicted value), mild symptoms, and who, in the opinion o f the 
responsible family physician, could potentially stop the use of inhaled corticosteroid 
therapy. No measured differences were detected in characteristics at the start o f the 
study between the patients who had used inhaled corticosteroids and those who had not, 
8 weeks after stopping the steroid treatment. During this 8-week washout period, we
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observed whether the symptoms were well controlled by bronchodilators alone and i f  no 
exacerbations or signs o f increasing airway obstruction developed. I f  patients had not 
responded well to this bronchodilating therapy alone, they would have been excluded 
from the study. However, this did not occur.
As mentioned earlier, at the start o f the study the stop-steroid and no-steroid groups 
were identical for all erlevant characteristics. As a consequence, their needs for steroid 
therapy should also be identical. Therefore, the use o f steroids seems to pose a risk in 
patients in that future discontinuation o f the drug is associated with a deterioration in 
lung function. The majority o f the stop-steroid group had been referred to the lung 
specialist before the start o f the use o f steroids. Therefore, we could overtake the mean 
initial FEVj o f this group o f patients. The mean FEV: percentage predicted was 71%, the 
same level as at the start o f the study. However, the reason for referral in the stop- 
steroid group could have been an unstable (steroid-dependent) asthma. Theoretically, it 
is possible that the deterioration in lung function o f the stop-steroid group was caused 
by this fact. In that case, an 8-week washout period would not have been long enough 
to eliminate the protective effect o f steroids in the airways. Nonetheless, this study’s 
data suggest that if a physician is considering stopping inhaled steroid therapy in a 
patient with apparently mild (stable) asthma, the patient must be monitored closely for 
at least 6 months after stopping.
Conclusions
Stopping maintenance treatment with inhaled corticosteroids in patients with mild 
asthma might be troublesome. In this observational study, about 60%  of the patients 
needed additional inhaled corticosteroids after discontinuation of the drug, most of 
them during the first 6 months after stopping. In the patients who could continue 
without corticosteroids during at least 1 year, the annual decline in ventilatory function 
was much larger than in the comparison group. Instead o f stopping inhaled steroids, 
family physicians are advised to determine the minimal effective daily dose of inhaled 
corticosteroids that provides adequate control of the disease in individual patients.
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Abstract
Background: The role o f inhaled corticosteroids in the long term management of 
chronic obstructive pulmonary disease (COPD) is still unclear. A meta-analysis o f the 
original data sets of the randomised controlled trials published thus far was therefore 
performed. The main question was: ‘Are inhaled corticosteroids able to slow down the 
decline in lung function (FEVI) in COPD?’
Methods: A medline search o f papers published betwen 1983 and 1996 was 
performed and three studies were selected, two of which were published in full and one 
in abstract form. Patients with ‘asthmatic features’ were excluded from the original data. 
Ninety five o f the original 140 patients treated with inhaled corticosteroids (81 with 1500 
|j,g beclomethasone daily, six with 1600  |j,g budesonide daily, and eight with 800 |j,g 
beclomethasone daily) and 88 patients treated with placebo (of the inital 144 patients) 
were included in the analysis. The effect on FEVI was assessed by a multiple repeated 
measurement technique in which points of time in the study and treatment effects 
(inhaled corticosteroids compared with placebo) were investigated.
Results: No baseline differences were observed (mean age 6 i years, mean FEVI 45% 
predicted). The estimated two year difference in prebronchodilator FEVI was +0.034 
l/year (95% confidence interval (CI) 0.005 to 0.063) in the inhaled corticosteroid group 
compared with placebo. The postbronchodilator FEVI showed a difference o f +0.039 
l/year (95% CI -0.006 to 0.084). No beneficial effect was observed on the exacerbation 
rate. Worsening o f the disease was the reason for drop out in four patients in the 
treatment group compared with nine in the placebo group. In the treatment group 
six o f the 95 subjects dropped out because o f an adverse effect which may have been 
related to the treatment compared with two o f the 88 patients in the placebo group.
Conclusions: This meta-analysis in patients with clearly defined moderately severe 
COPD showed a beneficial course o f FEVI during two years o f treatment with relatively 
high daily dosages of inhaled corticosteroids.
Introduction
The role o f anti-inflammatory therapy (inhaled corticosteroids) is still unclear in the 
management o f patients with stable chronic obstructive pulmonary disease (COPD). 
In contrast to asthma, several international consensus reports on the management 
of COPD mention that the evidence for beneficial effects of inhaled corticosteroids 
on lung function and symptoms has not yet been established.^2 In asthma, inhaled 
corticosteroids have beneficial effects by reducing inflammation in the airways. Although 
inflammation seems to be present in the airway walls o f patients with COPD (in terms 
of macrophages, T cells, and neutrophils), the specific immunopathology is thought 
to be different from asthma.3 Short-term treatment with both inhaled and systemic 
corticosteroids may have some beneficial effects on symptoms and lung function level 
in subgroups of COPD patients, in particular those with partially reversible airways 
obstruction.4 Two long-term uncontrolled and retrospective studies have shown that 
systemic corticosteroids slowed down the progression of deline in lung function in 
patients with moderate and severe COPD.5'6 The effects o f prednisone were observed 
after 6-24 months, the effects being larger with doses o f I0 mg and higher.5,6 Especially 
in the long term, however, systemic corticosteroids may cause serious side effects. I f
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long term treatment with corticosteroids is needed, it would therefore be preferable to 
replace systemic by inhaled corticosteroids.I,2
Thus far, three long term prospective clinical trials on inhaled corticosteroids in 
COPD have been published in full,7-9 and two in abstract form.I0'II All studies showed 
more or less beneficial effects of inhaled corticosteroids on the decline in lung function. 
In two of these studies it was shown that patients with ‘asthma features’ - that is, high 
bronchodilator response and bronchial responsiveness - may respond better to inhaled 
corticosteroids.4^2 However, the inclusion o f ‘asthmatic’ COPD patients in each of 
these studies may have caused an overestimation of the beneficial effects of inhaled 
corticosteroids. It would be interesting to re-analyse the effects o f inhaled corticosteroids 
only in the patients with clearly defined COPD, preferably by a cumulative analysis to 
avoid, as far as possible, underestimations of the effects of inhaled corticosteroids by 
subgroup analysis of each separate study.
We have therefore performed a meta-analysis of the original individual patient 
data from these studies, selecting only patients with a strict diagnosis o f COPD. The 
primary question was: ‘Are inhaled corticosteroids able to slow down the decline in 
lung function?’ Secondary questions were: ‘What is the point in time when inhaled 
corticosteroids start to have a significant effect on the course o f lung function?’, ‘Is there 
a dose-effect relationship?’, and ‘Which clinical characteristics predict the effect?’
Methods
selection of studies for the meta-analysis
A Medline search covering the period from I983 to I996 with the ‘free-text’ words 
‘COPD’, ‘chronic airflow obstruction’, ‘obstructive airways disease’, ‘chronic airflow 
limitation’, ‘chronic bronchitis’, ‘inhaled corticosteroids’, ‘beclomethasone’, ‘budesonide’, 
and ‘fluticasone’ yielded 94 references. The reference list of these studies was also 
checked for usable studies. We also checked Biosis (I99I-I996), On Line Contents 
(I993-I996), ‘GLIN’ (Grey Literature Netherlands, I982-I996), The Cochrane Library, 
and finally Embase (I993-I996). No new references were found using the keywords 
above. Only studies with a duration of at least 24 months were considered to be long 
enough to assess long term effects of inhaled corticosteroids on the decline in lung 
function. Only five studies met this criterion.7-”  Three studies were published in 
full,7-9 and two as abstracts.I0'II In order to be able to compare the effect o f inhaled 
corticosteroids with that of placebo, only randomised, placebo controlled clinical trials 
were included.7,9^0 Therefore, the self-controlled study o f Dompeling et al8 and the 
therapeutic trial o f Weir et aln were not used in the meta-analysis.
Details of the studies
In Table 7.I patient selection criteria, method, and analysis o f the three studies are 
summarized. Renkema et al7 investigated the effects o f a two years o f treatment with 
inhaled budesonide (I600 |j,g/day) versus inhaled budesonide plus prednisone 
(5 mg/day) versus placebo on decline in lung function, symptoms, exacerbations, and 
drop outs in 58 non-allergic patients with moderate to severe COPD. In the French 
multicenter study by Derenne et alI0 the effects o f inhaled beclomethasone (I500
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Table 7.1: The three placebo-controlled trials on the long-term effects o f inhaled corticoste
Renkema et al7
Inclusion criteria C lin ic a l d i a g n o s is  o f  C O P D  b a s e d  o n  h is to r y  ( p e r s i s t e n t  d y s p n o e a  w ith o u t  
s u d d e n  a t ta c k s  o f  d y p n o e a ; FEV-, < 8 0 %  p re d ; R V > io o % p r e d ;  s p e c i f ic  
c o m p l ia n c e ( C s p) > 1 0 0 %  p re d  a f t e r  b r o n c h o d ila t io n ; n o  s ig n s  o f  a lle r g y  
( n e g a t iv e  sk in  t e s t  r e s u lt s ) ,  to ta l s e r u m  IgE  <  2 0 0  lU /m l, e o s in o p h i ls  in 
p e r ip h e ra l b lo o d  <  2 5 0 x i 0 3 / m l; s t a b le  p h a s e  o f  d i s e a s e ;  ^ - a n t i t r y p s in  
w ith in  n o r m a l ra n g e ; ( e x - ) s m o k e r
Exclusion criteria A g e  >  7 0 ; c o n t in u o u s  c o r t ic o s t e r o id  th e ra p y ; s e v e r e  c o n c o m it a n t  d i s e a s e
Setting C lin ic a l, o n e  c e n tr e
Design D o u b le  b lin d , p la c e b o  c o n tr o lle d , 3  p a ra lle l a r m s
Duration o f  study 2 4  m o n th s
Study drugs B u d  8 0 0  | ig  b d  M D I th r o u g h  N e b u h a l e r ®  +  p la c  l d d  v e r s u s  b u d  8 0 0  | ig  
bd  +  p re d  5 m g  l d d  v e r s u s  p la c  b d  +  p la c  ld d
Concomitant drugs A n t ic h o lin e r g ic s ,  0 2  a g o n is t s ,  th e o p h y llin e  o r  a n t ih is t a m in ic s
O utcom e FE V 1 d e c l in e ; s y m p t o m s ;  d u r a t io n  o f  e x a c e r b a t io n s
Criteria pulm onary dropout > 3  e x a c e r b a t io n s  w ith in  3  c o n s e c u t iv e  m o n t h s ; s e v e r e  p r o g r e s s iv e  
d e te r io r a t io n  o f  lu n g  fu n c t io n  leve l
Definition exacerbation In c r e a s e d  c o m p la in t s  o f  d y s p n e a  a n d / o r  c o u g h  a n d / o r  s p u t u m  w ith (o u t)  
fe v e r
Treatment o f  exacerbation 7  d a y s  p re d  (35 -30 -2 5  m g  e tc ) ,  a n d  a  c o u r s e  o f  a n t ib io t ic s  i f  n e c e s s a r y
Method o f  allergy m easurem ent S k in  t e s t s ,  s e r u m  Ig E , e o s in o p h il  c o u n t
Com pliance check W e ig h in g  c a n is t e r s ;  c o u n t in g  t a b le t s
Statistical analysis:
Overall method E x p la n a to ry  a n a ly s is  o f  v a r ia n c e
Subgroup? N o
M easurem ent o f  FEV1 decline L in e a r  r e g r e s s io n ,  >  3  m e a s u r e m e n t s  n e e d e d
Financial support A s t r a  P h a r m a c e u t ic a ls
bud = budesonide, plac = placebo, pred = prednisone, becl = beclom ethasone, terb = terbutaline, ipra = ipratropium
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jids in COPD: Inclusion and exclusion criteria, method and analysis.
Derenne et al10 Kerstjens et al9 (subgroup)
A g e  <  7 5 ; ‘c h r o n ic  b r o n c h i t i s ';  FE V 1 3 0 - 6 0 %  p re d ; 
r e v F E V 1 < i o %  p re d ; P a O 2  > 55  m g  H g ; u s u a l  t r e a t m e n t  
w ith o u t  c o r t ic o s t e r o id ; n o  e x a c e r b a t io n  in th e  la s t  
t h r e e  m o n t h s ; w r it te n  in fo r m e d  c o n s e n t
A g e  1 8 - 6 0 ;  ‘s y m p t o m - b a s e d  d i a g n o s is  o f  C O P D ';  
F E V 1 < F E V 1 p r e d .- 1 .6 4 S D  a n d  > 1 .2 ! ;  P C 2 0 h is t a m in e  
< 8  m g /m l
O th e r  p u lm o n a r y  d i s e a s e s ;  c o r t ic o s t e r o id s  p a s t  15  
d a y s ;  u n a b le  to  fo llo w  p r o to c o l; p r e g n a n t  o r  la c ta t in g  
w o m e n ; s to m a c h  u lc e r  w ith o u t  t r e a tm e n t , p u lm o n a r y  
t u b e r c u lo s is ;  Ig E  >  2 0 0 lU / m l  a n d  e o s in o p h i ls  
> 500x i 0 3 /m l
M a in te n a n c e  t r e a t m e n t  w ith  c o r t ic o s t e r o id s ;  a s t h m a t ic  
a t ta c k s
C lin ic a l, m u lt ic e n tr e C lin ic a l, m u lt ic e n tr e
D o u b le  b lin d , p la c e b o  c o n tr o lle d , 2  p a r a lle l a r m s D o u b le  b lin d , p la c e b o  c o n tr o lle d , 3  p a r a lle l a r m s
2 4  m o n th s 3 0  m o n t h s
B ec l 1 5 0 0  | ig  M D I v e r s u s  p la c T erb  2  m g  +  b e c l 8 0 0  | ig  M D I v e r s u s  te r b  2  m g  +  ip ra  
1 6 0  | ig  v e r s u s  te rb  2  m g  +  p la c
A n tic h o lin e rg ic s , 0 2  a g o n is t s ,  th e o p h y llin e , m u c o ly t ic s , 
a lm it r in e
S a lb u t a m o l 4 0 0  | ig  o n  d e m a n d
Level o f  FE V 1 ; le v e l o f  P E F ; d u r a t io n  o f  c o r t ic o s t e r o id  
c o u r s e
D ro p -o u ts ; le v e l o f  F E V 1 ; F E V 1 d e c l in e ; le v e l o f  P C 2 0
In s u ff ic ie n t  e f fe c t iv e n e s s D o c t o r 's  in it ia t iv e : > 2  c o r t ic o s t e r o id  c o u r s e s / 3  m o n th s  
o r  > 4 / y e a r ;  p a t ie n t 's  in it ia t iv e : » s y m p t o m s
(1)  in c r e a s e  o f  d y s p n e a  a n d / o r  (2) p u r u le n t  s p u t u m  
a n d  fe v e r
In c r e a s e d  s y m p t o m s  a n d  > 4  a d d it io n a l 
s a lb u t a m o l/ d a y
(1)  c o u r s e  o f  p re d  a n d / o r  (2) c o u r s e  o f  a n t ib io t ic s  
<  15  d a y s
1 2  d a y s  p re d  (3 0 -3 0 -2 5 -2 5  m g  e tc)
S e r u m  IgE  a n d  e o s in o p h il  c o u n t S k in  t e s t s ,  s e r u m  Ig E , e o s in o p h il  c o u n t
V erb a l c h e c k W e ig h in g  c a n is t e r s
R e p e a te d  m e a s u r e m e n t  a n a ly s is ,  e x p la n a to r y  a n a ly s is A n a ly s is  o f  v a r ia n c e , e x p la n a to r y
N o Y e s
R e p e a te d  m e a s u r e m e n t L in e a r  r e g r e s s io n  fr o m  m o n th  3  o n , > 4  
m e a s u r e m e n t s  n e e d e d
G la x o W e llc o m e  Inc. N e t h e r la n d s ' H e a lth  R e s e a r c h  P r o m o t io n  P r o g r a m  
( S G O ) . P h a r m a c e u t ic a l  c o m p a n ie s :  A s t r a  
P h a r m a c e u t ic a ls ,  B o e h r in g e r  In g e lh e im , G la x o
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|Jg/day) versus placebo on lung function level and the duration o f exacerbations were 
assessed during two years in 194 patients with moderate to severe COPD. Kerstjens et 
al9 investigated the effects o f 800 |j,g inhaled beclomethasone and placebo on lung 
function level and decline and bronchial responsiveness during 30 months in a group 
of 274 patients with moderate asthma or COPD. A subgroup analysis was performed in 
51 patients with a symptom based diagnosis o f COPD.
selection of patients for the meta-analysis
In order to be able to exclude patients with ‘asthma features’ in the analyses and also to 
maximise the contribution o f individual patient data, we used the original clinical data.
Firstly, rigid diagnostic criteria were framed based on the most recent guidelines 
on COPD.1-2 The protocols and data bases o f the three studies concerned were 
then collected. Thirdly, the investigators of the studies were sent an output of the 
baseline characteristics and follow up data of their own study, in order to avoid 
misinterpretations o f their study data.
Inclusion criteria for individual patients in the meta-analysis
(1) Pulmonary symptoms compatible with the diagnosis of COPD (chronic breathlessness 
especially on exertion and/or (productive) cough during > 3 months per year in two 
successive years).
(2) Aged 40 and over.
(3) FEVj following treatment with fë2 agonist (> 400 |j,g salbutamol or > 500 |j,g 
terbutaline) < FEV: predicted - 1.64SD.
(4) Bronchodilator response to fë2 agonist (> 400 |j,g salbutamol or > 500 |j,g terbutaline) 
< 9% of FEVj predicted.
(5) Previous or current smoker.
Exclusion criteria of individual patients in the meta-analysis:
(1) ^-Antitrypsin deficiency.
(2) History o f asthma.
effect parameters for the meta-analysis
The primary effect parameter was prebronchodilator decline in FEVI measured at two 
monthly7 or three monthly intervals9^0 according to the recommendations o f the 
ERS.^ All FEVI measurements were made in a stable state - that is, in the absence o f an 
exacerbation.
The secondary effect parameters were postbronchodilator decline in FEVI, the number 
o f drop outs, and the number o f exacerbations. FEVI after inhalation o f ipratropium 
bromide was not assessed in all studies so only post-£2 agonist FEVI values were used. 
In two studies FEVI following treatment with £ 2 agonist was only assessed annually,7^0 
and in one study six monthly.9 In the study o f Kerstjens et al9 a higher dose o f £ 2 
agonist was used (i mg terbutaline) than in the other studies (500 |j,g terbutaline7 and
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400 |j,g salbutamol10). Because o f these differences within the studies in frequency, 
dosage and type o f bronchodilator used to measure postbronchodilator FEVP the 
prebronchodilator but not the postbronchodilator FEVI was used as the primary effect 
parameter in the meta-analysis.
In all three studies the number o f drop outs and the reasons for drop out were 
recorded. The reasons for drop out were divided into ‘worsening o f disease’, ‘adverse 
effects’ and ‘other’ (personal reasons, unspecified reasons).
The number o f exacerbations was recorded in all three studies. An exacerbation was 
defined similarly - that is, a doctor’s diagnosis o f increasing repiratory symptoms 
requiring a short course o f systemic corticosteroids7'9 and/or antibiotics.10
Bronchial hyperresponsiveness was not used as a dependent variable or as a 
determinant of corticosteroid response because this clinical characteristic was not 
assessed in all studies. Also symptoms were not used as dependent variables because of 
too large variations in registration between the studies.
baseline characteristics for the meta-analysis
The continuous variables were age, height, FEVI (litres), FEVI (expressed as a percentage 
o f FEVI predicted), FEVI/IVC (%), airway reversibility (bronchodilator response to £ 2 
agonist, expressed as a percentage o f FEVI predicted), smoking history (number of 
pack years (cigarettes/day x years smoked divided by 20)), number o f cigarettes/day, 
and allergy (total IgE, expressed as IU/ml). Dichotomic variables were sex, smoker 
(current/ex), regular use o f anticholinergics, £ 2 agonists, theophylline, mucolytics or 
almitrine (Vectarion, a respiratory stimulant).
analysis of data
The SAS statistical package was used in all analyses.14 IgE values were log10(x+i) 
transformed in the analysis. The main independent variable was the inhaled corticosteroid 
versus placebo. In the study by Kerstjens et al patients were treated with 800 |j,g 
beclometasone,9 in the other studies with 1500 |j,g beclomethasone or 1600 |j,g 
budesonide.7,10 Dosages o f 1500 |j,g beclomethasone and 1600  |j,g budesonide were 
considered as equal dosages for analytical purposes. The prednisone + budesonide 
group in the study by Renkema et al was excluded from analysis as it was presumed that 
the effects of oral corticosteroids, if  present, would overrule the effects of inhaled 
corticosteroids. The patients o f the study by Kerstjens et al who were treated with 
ipratropium bromide were considered as a placebo group since no long term effects 
other than the acute bronchodilating effect o f ipratropium bromide were observed.15
Since the duration o f the study by Kerstjens et al was 30 months and the two other 
studies took 24 months, only patient data up to 24 months o f study were used.
In the study by Renkema et al two monthly FEVI measurements were performed 
compared with three monthly measurements in the two other studies. In all the analyses 
the average individual FEVI values o f the measurements o f 2 and 4, 8 and 10, 14 and 16, 
and 20 and 22 months were therefore used as estimates for the FEVI at 3, 9, 15 and 21 
months, respectively.
Differences in drop out percentages and reasons for drop out during the trial between
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Table 7.2: Subject selection (numbers o f subjects are given).
R e n k e m a 7 
(b u d  1 6 0 0  | ig /  
b u d + p r e d  
/  P la c )
D e r e n n e 1 0  
(b e cl 1 5 0 0  | ig  
/  P la c )
K e r s t je n s 9  
(b e cl 8 0 0  | ig /  
ip r a /  p la c )
O r ig in a l n u m b e r T o ta l: 58 T o ta l: 1 9 4 T o ta l: 51
2 1  /  1 9  /  1 8 1 0 0  /  9 4 1 9  /  1 1  /  2 1
M e e t in g  in c lu s io n  c r ite r ia  m e ta -a n a ly s is :
S y m p t o m s  c o m p a t ib le  w ith  d i a g n o s is  o f  C O P D 58 194 51
A g e  >  4 0  y e a r s 55 1 9 2 39
F E V n p o s t  0 2  a g o n is t  <  FEV-, p re d . - 1 . 6 4 S D 47 18 5 29
A ir w a y  re v e rs ib ility  ( 9 %  p red .F E V ., 43 1 7 8 29
(E x - ) s m o k e r s  ( > 0  p a c k  y e a r s ) 53 173 51
N o t  m e e t in g  1 in c lu s io n  c r ite r io n 2 2 36 25
N o t  m e e t in g  2  in c lu s io n  c r ite r ia 6 6 8
N o t  m e e t in g  3  in c lu s io n  c r ite r ia 0 0 3
N o t  m e e t in g  > 4  in c lu s io n  c r ite r ia 0 0 0
M e e t in g  e x c lu s io n  c r ite r ia  m e ta -a n a ly s is :
a i-A n t i t r y p s in  d e f ic ie n c y 0 0 0
A s t h m a  h is to ry 0 0 0
E lig ib le  fo r  m e ta -a n a ly s is : 30  (6 /  1 4 *  /  1o ) 1 5 2  (81 /  7 1 ) 15 (8 /  3T /  4)
b u d  =  b u d e s o n id e ,  p la c  =  p la c e b o , p re d  =  p r e d n is o n e , b e c l =  b e c lo m e t h a s o n e ,  ip ra  =  ip r a tr o p iu m  
^ E x c lu d e d  fr o m  a n a ly s is  b e c a u s e  o f  t r e a t m e n t  w ith  o r a l c o r t ic o s t e r o id s  
-¡- C o n s id e r e d  a s  ‘ p la c e b o ' in th e  m e t a -a n a ly s is
the inhaled corticosteroid and the placebo groups were tested with the X2 test. 
Differences in the number o f exacerbations per year between both groups were tested 
univariately with the Student’s t test.
The effect o f inhaled corticosteroids (independent o f the dose) on prebronchodilator 
and postbronchodilator FEV: (litres) was measured with a multiple repeated measurement 
technique in which patient and time effects on FEV: were separately investigated in an 
intention-to-treat analysis. Preliminary analysis demonstrated no measurement*treatment 
interaction. For that reason a random coefficient model was chosen in which all available 
individual time points o f FEV: measurements were incorporated and analysed. In a first 
model the effect o f inhaled corticosteroids, irrespective o f the dose used, on the course 
o f FEVj was compared with placebo. In a second analysis the dose effects o f the inhaled 
corticosteroid (800 |j,g beclomethasone (‘low dose’) versus 1500 |j,g beclomethasone or 
1600 |j,g budesonide (‘high dose’)) on the course o f FEV: were investigated by adding 
one dummy.
In order to correct for possible confounders and to be able to assess which clinical 
characteristics may predict the influence o f inhaled corticosteroids on the change in 
FEVP the baseline variables o f age, height, sex, FEVP airway reversibility, pack years, 
smoking, IgE, anticholinergics, £ 2 agonists, theophylline, mucolytics, and almitrine
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were introduced into the model. The number o f exacerbations during the study was also 
introduced into the model. In addition, data on the number o f cigarettes smoked daily 
during the study (assessed at each visit) were incorporated into the analysis at each time 
point o f measurement. Only baseline data o f the number o f cigarettes smoked daily 
were available from the study by Renkema et al. However, smoking behaviour was 
shown to be remarkably constant during the study.7 Compliance rates and a complete 
registration of all adverse effects during the studies were not available for all three studies.
First, all possible interaction terms o f the independent variables with treatment were 
incorporated into the model. Secondly, in a backwards procedure variables with the 
highest p value were subsequently deleted until only variables with p< 0.05 remained.
No analysis was performed with linear regression based measurement o f FEV: 
decline. Preliminary analysis demonstrated a non-linear course in the FEV:: the explained 
variance o f individual linear regression analysis o f FEV: was only 24% on average (SD 
24%, range 0 to 99%).
Results
subject selection
The selection procedures o f subjects for the meta-analysis are presented in Table 7.2. 
The most important reasons for exclusion were ‘mild obstruction’ (FEV: > FEV: predicted 
- 1.64 SD, 42 o f original 303 patients) or ‘reversible obstruction’ (> 9% o f the FEV: 
predicted, 53 o f 303 patients). Twenty eight o f the 58 subjects (48%) in the study 
by Renkema et al were excluded from the meta-analysis, 15 because o f reversible 
obstruction. From the study by Derenne et al 42 (17%) o f the 194 patients were excluded 
from the meta-analysis, 21 because they were never-smokers. Subjects in the study by 
Kerstjens et al were younger and had less severe airway obstruction than in the other two 
studies. Therefore, only 15 (29%) o f the 51 subjects in this study were eligible for the 
meta-analysis. Within each study the baseline characteristics between the patients in the 
inhaled corticosteroids group and the placebo group eligible for the meta-analysis did 
not differ significantly in all relevant parameters.
Baseline data
Table 7.3 shows the combined baseline characteristics o f the 183 subjects selected. 
No statistically significant differences between the inhaled corticosteroids group and 
placebo group were present in the relevant parameters.
Effects of inhaled  corticosteroids on FEV j (repeated measurement analysis)
In Figure 7.1 the effect of two years of treatment with inhaled corticosteroids, irrespective 
o f their dose, on the prebronchodilator FEV: is presented versus placebo, and in Table 
7.4 the results are presented after adjustment o f variables with p< 0.05. The estimate 
was +0.034 l/year (95% confidence interval (CI) 0.005 to 0.063), which was statistically 
significant (p = 0.026). I f  the dose o f inhaled corticosteroids was included in the model, 
the estimate was +0.002 l/year (95% CI -0.061 to +0.065) for the low dose o f inhaled 
corticosteroids and +0.039 l/year (95% CI 0.008 to 0.070) for the high dose (p=0.043).
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Table 7.3: Mean (SD) baseline characteristics and exacerbation and drop out rates o f 
patients using inhaled corticosteroids (irrespective o f the dose) or placebo.
Inhaled Corticosteroids
(n =  95)
Placebo
(n =  88)
A g e  (y e a rs ) 6 1 (7) 6 1 (7)
H e ig h t  (cm ) 1 70  (7) 1 6 8  (7)
M a le  (n) 8 9 79
F E V 1 (l) M 2  (° . 47) 1 . 3 0  (0 .3 8 )
F E V 1 (%  p red ) 4 6  ( 1 1 ) 44  ( 1o )
F E V 1 / IV C  (% ) 49  ( 13) 47  ( 1 1 )
A irw a y  re v e rs ib il ity  (%  o f  FE V 1 p red ) 3.2  (2 .7) 2.9 (2.5)
P a c k  y e a r s 4 0  ( 2 5) 43 (24)
S m o k e r  (c u rre n t/e x ) 32 /6 3 34/54
C ig a r e t t e s / d a y  (n) 17 ( 12 ) 1 7  ( 1 1 )
L° g i o (|g E + l)  ( Iu / m l) W  (° . 59) 1 . 6 7  (0 .5 0 )
R e g u la r  u s e  o f  (%  o f  p a t ie n t s ) :
A n t ic h o lin e r g ic s 25 32
S h o r t a c t in g  ß 2  a g o n is t s 6 0 6 2
T h e o p h y llin e 56 53
M u c o ly t ic s 33 40
A lm it r in e 1 0 13
D u rin g  th e  s tu d y :
E x a c e r b a t io n s / y e a r 0.9  (0 .9 ) 1 .o  ( 1 .3)
D ro p  o u t s  (n) 35 29
R e a s o n  f o r  d r o p  o u t  (n ):
W o r s e n in g  o f  th e  d i s e a s e 4 9
A d v e r s e  e f fe c t s 1 7 1 2
O th e r  r e a s o n s 14 8
The same procedure with postbronchodilator FEV: showed a two year treatment 
effect for the inhaled corticosteroid group versus the placebo group o f +0.039 l/year 
(95% CI -0.006 l to 0.084 l, p=0.095) (Table 7.4, Figure 7.2), which was maintained 
only in the high dose group i f  the dose o f inhaled corticosteroids was taken into account.
Determinants of lung function slope and corticosteroid response
Table 7.4 shows an independent effect o f the following two variables on a beneficial
course in FEV: : the use o f short-acting £ 2 agonists and a higher baseline FEVr  No
interaction o f any o f the variables analysed with the inhaled corticosteroid treatment was
observed.
E ffe c t  o f in h aled  co rtico stero id s on exacerbations and drop-outs 
During the study the mean (SD) number o f exacerbations per year was 0.9 (0.9) in the 
inhaled corticosteroid group, and 1.0 (1.3) in the placebo group (p>0.05; Table 7.3). The 
drop out rate during the study was 36% in the inhaled corticosteroid group and 32% in 
the placebo group (Table 7.3). In the placebo group twice as many patients dropped out 
due to worsening o f the disease compared with the actively treated group (9/88 versus
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4/95  patients, p=0.ii). No patients dropped out in the low dose inhaled corticosteroid 
group. Comparison o f the baseline characteristics between those who fulfilled the 
protocol and the drop outs within each trial group showed no indications o f selective 
drop out or ‘survivor effect’ .
A dverse effects
In the inhaled corticosteroid group 17 o f the 95 subjects dropped out because of adverse 
effects compared with 12 o f 88 in the placebo group(X2=0.62, p=0.43). All these drop 
outs were in the study by Derenne et al. An additional investigation o f the adverse effect 
files of these patients showed that in six o f the 95 subjects in the active group the adverse 
event leading to drop out may have been related to the treatment (cough, dysphonia, 
sore throat, anorexia, problems with taste and the nasal organ, and headache). In the 
placebo group the cause o f drop out in two o f the 88 subjects could have been related to 
treatment (cough, dysphonia, sore throat) (X2=i.78, p=0.i8). No serious adverse effects 
related to the treatment occurred.
Table 7.4: Influence o f inhaled corticosteroids compared with placebo on the change 
in prebronchodilator and postbronchodilator FEVj (l) by repeated measurement 
analysis. The model presents only variables with p<0.05.
Two-year SE  p value (Pr>F)
estim ate (l/year)
Prebronchodilator:
T r e a tm e n t  e f fe c t  ( in h a le d  c o r t ic o s t e r o id s  v e r s u s + 0 .0 3 4 0 .0 1 5 0 .0 2 6
p la c e b o , n = i8 3 )
FE V 1 b a s e l in e  (l) + 0 .9 7 0 .0 2 7 0 .0 0 0 1
P 2  a g o n is t s  (yes) + 0 .0 6 3 0 .0 2 5 0 . 0 1 2
A lm itr in  (yes) -0 .0 7 5 0 .0 3 8 0 .0 4 8
P o s t b r o n c h o d ila t o r :
T r e a tm e n t  e f fe c t  ( in h a le d  c o r t ic o s t e r o id  v e r s u s + 0 .0 3 9 0 .0 2 3 0.095
p la c e b o , n = i8 3 )
H e ig h t  (m ) + 0 .6 4 0 .2 2 2 0 . 0 0 4
R e v e r s ib ility  F E V 1 (a s  %  o f  p r e d ic te d  F E V 1 ) + 0 . 0 1 4 0 .0 0 5 0 .0 0 3
F E V 1 b a s e l in e  (l) + 0 .9 2 0 .0 3 6 0 .0 0 0 1
P 2  a g o n is t s  (yes) + 0 .0 5 8 0 .0 2 7 0.034
Discussion
We combined the original data o f three published long term intervention studies with 
inhaled corticosteroids in moderately severe COPD, selecting only patients with clearly 
defined disease. The meta-analysis showed a significant beneficial effect o f inhaled 
corticosteroids compared with placebo on the course o f the prebronchodilator FEVI 
during two years o f treatment (+0.068 l), whereas only a tendency towards an effect of 
inhaled corticosteroids on postbronchodilator FEVI was shown. However, the latter 
results pertain to only three data points. A specific measurement*treatment effect was
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lacking. A daily dose o f 1500/1600 |jg o f the inhaled corticosteroid was more effective 
than 800 |j,g. No beneficial effect was observed on the exacerbation rate or drop out 
rate. Finally, no interaction effect o f the variables assessed on the response to inhaled 
corticosteroids was found.
When the three original studies contributing to the meta-analysis were considered, 
no heterogeneity was seen in the beneficial effect o f inhaled corticosteroids on the FEVr  
Renkema et al demonstrated a median decline o f FEV: o f 60 ml/year in the placebo 
group and 30 ml/year in the budesonide group.7 Due to large interpatient variations this 
difference was not significant. Kerstjens et al found the FEV: to increase significantly by 
+7.4% (3,1) % predicted in the beclomethasone group compared with the placebo 
group after the first six months o f study.9 The study by Derenne et al demonstrated an 
improvement in FEV: o f +1.44% from baseline in the experimental group compared 
with -0.62% in the placebo group (p=0.05) during the two-year study.10 Subjects of 
these three studies who were excluded from our meta-analysis were patients who had 
features o f asthma in addition to COPD. An interesting finding was that, although we 
selected only patients with clearly defined COPD for the analysis, a beneficial effect of 
inhaled corticosteroids on the course o f FEV: remained present.
Several shortcomings o f the study should be mentioned. Firstly, we presented the 
results o f a ‘re-analysis’ using studies with a duration o f only two years. Secondly, 
compliance data and the doses of concomitant drugs were not incorporated and corrected 
for in the analysis. Thirdly, cost effectiveness was only assessed in the study by 
Kerstjens. Rutten-van Mölken et all6 found that ‘addition o f an inhaled corticosteroid to 
a ß agonist leads to significant benefits in respiratory function and restricted activity 
days with relatively low additional health care costs’. However, an interaction analysis in 
this study showed that inhaled corticosteroids were most beneficial in patients with the 
‘classic’ asthma profile (allergy, reversibility, non-smoking and mostly young). Longer 
term and larger studies with more detailed registration o f compliance, drug use during 
the trial, and cost effectiveness are therefore required to confirm the conclusions o f our 
study.
In two retrospective studies with oral prednisone in a group o f patients with 
moderate and severe COPD it has been suggested that the time to reach a response to 
oral corticosteroids in COPD is 6-24 months.5>6 In our meta-analysis with inhaled 
corticosteroids no specific time point o f response was observed, but a sustained effect 
o f inhaled corticosteroids on the course o f FEV: took place during the two years. In a 
self-controlled study in 26 patients with moderate COPD Dompeling et al investigated 
the effects o f 800 |j,g beclomethasone on the course o f FEVr 8 The prebronchodilator 
FEVj increased during the first six months o f the trial with no further effect on the 
decline in FEV: after that. The study by Kerstjens et al showed that a response had 
already been achieved after three months.9 In both studies inclusion o f COPD patients 
with some ‘asthmatic features’ such as airway reversibility and allergy in both studies 
might have contributed to this early response. Preliminary results o f the EUROSCOP 
study, a large three-year study in mild COPD with 800 |j,g budesonide, have also shown 
an effect o f inhaled corticosteroids, especially during the first three months o f the study 
(oral presentation, Congress o f the European Respiratory Society, 1997). Further 
analysis is needed to show whether this early effect o f inhaled corticosteroids may 
indicate ‘asthmatic features’ in the group o f patients with COPD selected. Moreover, in
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the light o f the previous studies by Postma et al5>6 with systemic corticosteroids, the 
delay in reaching ‘the response’ in our study may suggest a relationship to a true effect 
o f inhaled corticosteroids on COPD.
The course o f postbronchodilator FEVI tended to differ from prebronchodilator FEVI, 
especially after one year and to the advantage o f the placebo group. In Figure 7.2 it 
appears that the FEVI in the placebo group increased considerably after one year o f the 
study. This may be explained partly by the fact that ‘all’ participants (including drop 
outs) were plotted. The drop outs in the placebo group, most o f which dropped out 
during the first year o f the study, had a lower baseline FEVI % predicted than those who 
fulfilled the protocol o f the placebo group (4I% versus 47% of FEVI predicted, 
p<0.0I74). It was shown that the course o f postbronchodilator FEVI in patients in the 
placebo group who finished the study was reasonably stable during the first year o f the 
study.
A daily dose o f I500 |jg beclomethasone or I600 |jg budesonide was more effective 
than 800 |jg beclomethasone, with effects on the prebronchodilator FEVI o f 0.039 
l/year and 0.002 l/year, respectively. However, in the analysis the group o f patients 
treated with 800 |jg beclomethasone was relatively small (n = 8) and therefore this 
result has to be interpreted with great caution. On the other hand, in short term studies 
with inhaled corticosteroids in patients with moderately severe COPD daily dosages of 
at least I500 |jg seemed to be necessary to achieve significant improvements in FEVI.4 
Watson et al found no beneficial effects on the level o f lung function in a nine month 
single blind follow up study with I200 |jg budesonide daily.I7 In a long term therapeutic 
trial (mean duration 26 months) o f oral and inhaled corticosteroids in I2I patients with 
non-asthmatic chronic airway obstruction, beclomethasone 750 |jg twice daily seemed 
to slow down the decline in FEVr n Unfortunately this study was not placebo controlled 
and is only published in abstract form. In patients with moderate asthma, daily doses of 
800 |jg inhaled corticosteroids are often sufficient to achieve disease control. In the light 
o f our study we hypothesise that, in patients with moderate to severe COPD, differences 
in the type and site o f inflammation in asthma and COPD might lead to the need of 
higher dosages o f inhaled corticosteroids in COPD. In COPD the largely neutrophilic 
and lymphocytic inflammation seems to take place in the peripheral airways while in 
asthma the predominantly eosinophilic inflammation is located mainly in the central 
airways.3 These two considerations might explain the need for a higher dosage o f inhaled 
corticosteroids in moderate to severe COPD compared with moderate asthma. I f  we 
consider the preliminary results of the EUROSCOP, the dosage of inhaled corticosteroids 
(800 |jg budesonide daily) may have been too low to be sufficient. Two other large long 
term multicenter European studies o f COPD will soon present the long term effects 
o f a low to medium dosage o f inhaled corticosteroids in mild COPD (800-I200 |jg 
budesonide daily; Copenhagen City Lung Study) and a relatively high daily dose in 
severe COPD (I000 |jg fluticasone; ISOLDE). This may help us to understand better the 
minimal daily dose o f inhaled corticosteroids required to prevent progression o f the 
decline in lung function in COPD.
The beneficial course of FEVI in patients treated with inhaled corticosteroids compared 
with placebo was not accompanied by a lower number o f exacerbations. Bacterial 
superinfection is a common cause of acutely aggravating COPD^ It might not be expected 
that inhaled corticosteroids protect the bronchial wall o f the host against bacterial
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colonisation in patients with COPD. However, this result has to be treated with caution 
because the definition o f exacerbation varied between the three studies o f the meta­
analysis (see Table 7.I).
Several variables influenced the course o f prebronchodilator FEVI independently. The 
regular use o f both oral and inhaled £ 2 agonists was related independently to an overall 
change in both prebronchodilator and postbronchodilator FEVI o f +0.063 l/year after 
two years. This result strongly contrasts with the general opinion that regular use o f £ 2 
agonists cannot delay the progression of COPD.I>2 However, the route of administration, 
dosages and drug names o f the £ 2 agonists were not specified in the largest study^0 Our 
result therefore has to be interpreted with caution.
Contrary to others,4 the meta-analysis did not show a relationship between higher 
levels o f IgE or airway reversibility and a better response to inhaled corticosteroids in 
COPD. As already mentioned, allergy was an exclusion criterion in two o f three studies. 
Also, subjects with reversible airway obstruction were excluded from the analysis. Both 
factors may explain the absence o f an interaction effect o f relatively low levels o f IgE 
and airway reversibility on the response to inhaled corticosteroids. No other variables 
interacted with the effect o f inhaled corticosteroids.
Up to now, smoking cessation has been shown to be the only intervention able to 
improve the long term morbidity and mortality due to COPD, next to supplemental 
oxygen in hypoxaemic patients.I'2>I5 The results o f this study indicate that, in patients 
with moderate COPD (FEVI 45-55% of predicted), relatively high doses o f inhaled 
corticosteroids (> I500 |jg) may also improve the long term prognosis. Dosages above I 
mg may cause systemic side effects, as assessed by cortisol levels^8 However, an 
additional investigation o f the side effect reports from the studies by Derenne 
and Renkema with high doses o f inhaled corticosteroids demonstrated symptoms 
which could have been related to the treatment (especially cough and dysphonia) in 
approximately 20%  of the subjects, with no difference between the active and the 
placebo groups. There were no indications o f high intolerability o f the study drug in any 
o f the three studies, not even in high doses.
In conclusion, this is the first study o f a group o f patients with strictly defined 
moderate to severe COPD showing a preservation o f the FEVI during two years of 
treatment with relatively high dosages o f inhaled corticosteroids (I500 |jg beclomethasone 
or I600 |jg budesonide daily).
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Dr van Grunsven et alI refer to our study comparing inhaled beclomethasone 750 |jg 
twice daily with placebo in the long term management o f COPD (their reference ii) 
and were unable to find the full report. Its reference is Bronchitis V edited by D S 
Postma and J Gerritsen, published by Van Gorkum, Assen in I994 (pages 240-4).
Our study followed up 74 patients at approximately two and five years after a double 
blind steroid trial. The mean (SE) decline in FEVI in those taking beclomethasone was 
35 (2I.5) ml/year at the two year follow up and 65 (I0.3) ml/year at the five year follow 
up (not significant). In those not receiving inhaled steroids the mean (SE) decline in 
FEVI was ii2  (23.3) ml/year at the two year follow up, decreasing significantly to 25.3 
(I9.5) ml/year at the time o f the second follow up when they were given inhaled 
beclomethasone dipropionate. There was no relationship between the response to 
the initial steroid trial and the subsequent decline in FEVI.
P Sherwood Burge 
Occupational Lung Disease Unit,
Birmingham Heartlands Hospital,
Bordesley Green East,
Birmingham B9 5ST, UK
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Author’s reply
We thank Dr Sherwood Burge for his comments on our study. Indeed, the results of 
their study have been presented not only in abstract form but also more in detail.1 We 
apologise for this omission. As we stated in the discussion section o f our study,2 Weir 
et al investigated the long term effect o f inhaled beclomethasone 1500 |j,g daily on the 
decline in FEV: in a therapeutic trial. This (uncontrolled) treatment followed an 
original randomised controlled trial o f 107 patients including a group o f patients with 
moderately severe COPD (FEV: <70% predicted), comparable to our study. In their 
original study patients were treated with prednisone 40 mg daily, inhaled 
beclomethasone 1500 |j,g daily and placebo in a crossover design to assess the short 
term steroid response (defined as an increase in FEVP FVC or PEF o f > 20%  from 
baseline). Seventy four patients were reassessed approximately two and five years after 
this original trial. Thirty two patients received beclomethasone only during the second 
follow up period, the remaining patients were treated with beclomethasone during the 
whole follow up period. In the former group o f 32 patients the authors showed that 
the decline in FEV: decreased significantly when the first follow up period (without 
the use o f inhaled beclomethasone) was compared with the second follow up period 
(during treatment with inhaled beclomethasone). This result, although not achieved 
in a randomised controlled design and therefore excluded from our meta-analysis, 
supports our finding o f a significant two year treatment effect o f inhaled 
beclomethasone or budesonide in a daily dose o f 1500/1600 |j,g compared with 
placebo o f +0.034 l/year.2
Dr Sherwood Burge also pointed to the absence o f a relationship between the 
response to the initial steroid trial and the subsequent decline in FEV: in their study. 
Indeed, an interesting finding o f their study was that, although the majority (75%) of 
the original 23 steroid responders had been treated with beclomethasone during the 
whole follow up period, the mean (SE) decline in FEV: o f 51.5 ( 10.3) ml/year did 
not differ from the 51 non-responders o f which only 50% were treated with 
beclomethasone during the whole follow up period (53.1 (8.7) ml/year). The authors 
therefore concluded that the acute steroid response did not seem to be an adequate 
predictor o f the long term response to inhaled steroids in patients with moderate to 
severe COPD. In our meta-analysis2 only patients in the study by Renkema et al had 
been treated with a course o f 40 mg daily during the eight days preceding the trial in 
order to assess steroid responsiveness (response as defined by an increase in FEV: of 
> 20%  from baseline). In their study only three steroid responders (of 58 patients with 
severe COPD) were identified.3 In two studies in patients with mild to moderate 
COPD the presence o f ‘asthmatic features’ such as allergy and reversibility of 
obstruction resulted in a better long term treatment effect with inhaled 
corticosteroids.4'5 In our meta-analysis we did not find this relationship.2 This result 
could be explained by our selection o f subjects with strictly diagnosed 
non-asthmatic and irreversible COPD, comparable to the subjects in the study of 
Weir et al. Forthcoming data o f the ISOLDE trial which was initiated by Dr Sherwood 
Burge (ISOLDE is a three year randomised placebo controlled trial in 990 patients 
with severe COPD treated with 1000 |j,g fluticasone daily), may give an more definite 
answer to the question o f the predictive value o f a short course o f oral prednisone
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(or other asthmatic features such as reversibility and allergy) on the clinical effects 
o f long term treatment o f patients with moderately severe COPD with inhaled 
corticosteroids.
PM van Grunsven 
CP van Schayck
Department o f General Practice and Social Medicine,
University o f Nijmegen,
6500 HB Nijmegen,
The Netherlands
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Abstract
Context In spite o f many trials, the role o f inhaled steroids in the management o f COPD 
has not yet been defined precisely, and evidence o f their benefit remains a matter of 
debate.
Objective To determine the clinical effects and safety o f a two-year treatment with I500 
|j,g inhaled beclomethasone daily in stable moderate COPD.
Design A two-year randomized placebo controlled multicenter study was performed.
Setting Twenty-eight outpatient lung clinics in France.
Patients Eligibility criteria were: age below 75; chronic bronchitis with the baseline 
prebronchodilator FEVI 30 to 60%  predicted. The increase in FEVI i0  minutes after 
administration o f 400 |j,g aerosolized salbutamol had to be less than i5% o f predicted 
FEVI.
Intervention Beclomethasone dipropionate (Becotide™) metered dose inhaler I500 
|j,g daily (three puffs o f 250 |j,g, twice daily) versus placebo.
Main Outcome Measures The change in the prebronchodilator FEVI was the primary 
outcome measure. The main secondary outcome parameters were the postbronchodilator 
FEVI, arterial blood gases, courses o f antibiotics and/or oral steroids, dyspnea and 
adverse effects o f beclomethasone.
Results Multi variate repeated measurement analysis showed a significant increase in 
prebronchodilator FEVI by +38 mL/yr(SE i8, p=0.03i) in the beclomethasone group 
in comparison with placebo during two years. The postbronchodilator FEVI in the 
beclomethasone group increased by +I49 mL/yr(SE 70, p=0.035) in comparison with 
the placebo group. The number and duration o f steroid and antibiotic courses were 
comparable in the two study groups. Blood oxygen saturation improved by +0.5(SE 
0.2)%/yr (p=0.02) under beclomethasone as compared with placebo. Seventeen percent 
o f the patients in the beclomethasone group experienced an oropharyngeal side effect of 
the trial drug, versus i5% o f the patients o f the placebo group.
Conclusions This study shows a clear beneficial effect o f I500 |j,g beclomethasone 
MDI daily during two years compared with placebo on the two-year course o f FEVI in 
patients with stable moderate COPD.
List o f Abbreviations
FEVI Forced Expiratory Volume in One Second 
VC Vital Capacity
MEF25 Mid Expiratory Flow at 25% of the VC
MEF50 Mid Expiratory Flow at 50% of the VC
FEF25-75 Forced Expiratory Flow, at (mean from) 25-75% of the VC
PEF Peak Expiratory Flow
FRC Forced Residual Capacity
RV Residual Volume
TLC Total Lung Capacity
MDI Metered Dose Inhaler
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Introduction
Up to now smoking has been considered as the only potentially useful intervention to 
limit lung function decline, hence morbidity and mortality, in patients with chronic 
obstructive pulmonary disease (COPD).I>2 Unfortunately, smoking cessation programs 
and campaigns are only partly successful.3
In spite o f many trials, the role o f steroids in the management o f COPD has not yet 
been defined precisely, and evidence o f their benefit remains a matter o f debate.4 Over 
the years, short-term trials have indeed shown functional benefits o f (inhaled) steroids 
in a substantial proportion o f non-asthmatic COPD patients.5-7 On the basis o f these 
results, COPD guidelines recommend the use o f inhaled steroids in patients showing 
some degree o f improvement after a trial period o f steroid treatment.3'8 There is now a 
large body of evidence demonstrating that COPD has an inflammatory component. This is 
strongly suggested by the presence of inflammatory cells, including polymorphonuclear 
neutrophils and activated lymphocytes in the airway mucosa o f smokers and COPD 
patients.9^3 Inhaled steroids are preferred to oral steroids because o f the systemic 
side-effects o f the latter treatment, and have recently been shown to reduce the number 
o f neutrophils in the bronchial mucosa o f patients with COPD.H The use o f inhaled 
steroids is widespread.4 However, in spite o f pathophysiologic arguments, short-term 
clinical evidence and the effect o f inhaled steroids in COPD patients on a long-term 
basis remain ill documented.
Four long-term studies in moderateI5-I7 and severe COPDi8 suggest that treatment 
with inhaled steroids in both moderate and relatively high doses during two years could 
abate the progressive lung function decline^9 A meta-analysis of randomized controlled 
studies on the long-term effects o f inhaled steroids in distinct COPD showed a 
preservation o f the FEVI during two years o f treatment, especially in higher doses.20 
Recently, Paggiaro et al showed that daily treatment with I000 |j,g inhaled fluticasone 
propionate during 6 months in 28I patients with moderate COPD caused a significant 
decrease in the number o f exacerbations and an improvement in lung function, with 
few local and systemic adverse effects.2I However, the period o f observation in this last 
study was relatively short (six months). On the other hand, another recent six-month 
study o f 79 patients with severe COPD showed no beneficial effect o f I600 |j,g 
budesonide on lung function.22
Here, we present the results o f a randomized placebo-controlled multicenter trial in 
stable moderate COPD performed in France.23 The purpose o f the study was to assess the 
clinical effects and safety o f a two-year treatment with I500 |j,g inhaled beclomethasone 
daily.
Methods
Background
This study was originally coordinated by one o f the co-authors (J.P. Derenne) in 
cooperation with GlaxoWellcome France. So far, its results have only been presented in 
abstract form23 and have not been published in full. The study was selected for a 
meta-analysis o f published and unpublished studies on the long-term effects o f inhaled 
steroids in COPD.20 Here, we present the full analysis o f the original raw data to avoid 
publication bias and the restrictions imposed by the meta-analysis.24 The trial report 
complies with the CONSORT statement.25
a s t h m a  a n d  c o p d  -  t r e a t m e n t  w i t h  in h a l e d  c o r t ic o s t e r o id s
Patient selection
Between I5 May I989 and 9 February I990, 28 outpatient lung clinics in France were 
approached and each was asked to recruit 8 patients with COPD for the present trial. 
The main eligibility criteria were tested by a pulmonologist during the pretrial visit (visit 
I). Patients were eligible i f  their age was below 75 and i f  they were suffering from 
chronic bronchitis (cough and sputum on most days during at least three consecutive 
months in two consecutive years, according to the criteria o f the American Thoracic 
Society26). The baseline (prebronchodilator) FEVI had to be 30 to 60%  of the predicted 
value (according to the reference values o f Quanjer27). The increase in FEVI i0 
minutes after administration o f a bronchodilator (400 |J.g o f aerosolized salbutamol) 
had to be less than i5% o f the predicted FEVI. Exclusion criteria were: a history o f 
severe exacerbation o f COPD in the past 3 months, a diagnosis o f lung cancer or bullous 
emphysema, a diagnosis or a clinical history strongly suggestive o f asthma in the past 
i0  years, chronic use o f (inhaled) steroids, administration o f oral steroids in the past I5 
days, inability to follow the protocol, participation in another trial, pregnancy or 
lactation, stomach ulcer without treatment, pulmonary tuberculosis, and inability to use 
an inhaler. Patients who met the inclusion criteria entered a two-week pretrial period 
during which their usual treatments (anticholinergics, beta2 agonists, theophylline, 
mucolytics, almitrine) were maintained. The baseline assessment (visit 2) was made at 
the end o f this period. I f  the prebronchodilator FEVI did not differ more than i0%  from 
the pretrial FEVI at visit i, IgE was less than 200 IU and/or blood eosinophils were less 
than 500/mm3, and PaO2 was at least 55 mm Hg, the subjects were definitely included 
and randomized. The study gained the approval o f the Ethical Committee. All 
participants received verbal and written information, and signed an informed consent form.
Study design
The treatment regimen in this two-year randomized controlled multicenter study was 
beclomethasone dipropionate (Becotide™) MDI I500 |j,g daily (three puffs o f 250 |j,g, 
twice daily) versus placebo. Furthermore, a block randomization was performed. Each 
of the 28 investigators was given a set o f 8 sealed envelopes containing the assignment 
codes. The code could be broken in the event o f a serious adverse effect. Patients were 
seen at the clinic with three-monthly intervals during the two-year study (visit 2 to I0), 
and were also instructed to come to the clinic in case o f an exacerbation (defined as 
mucopurulent sputum and fever). At each visit, a box with 8 M DI’s, sufficient for three 
months, was supplied. In case o f an exacerbation the investigators prescribed a course 
o f antibiotics for a maximum of I5 days. I f  the investigator judged it necessary (e.g. in 
case o f increased dyspnea) a course o f oral prednisone was prescribed. I f  patients 
dropped-out, a specific registration form was filled in, describing the reason for 
drop-out (adverse events, ineffectiveness o f the drug, personal reasons, etc.).
Measurements
Patient characteristics and smoking behavior
General and clinical patient characteristics (see Table 8.i) were registered during visit i. 
Smoking history was registered at baseline, and actual smoking behavior was assessed 
at each visit.
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Table 8.1: Baseline characteristics. Variables between the treatment groups were 
tested. Only p-values <0.05 are represented. Standard deviations are given in parentheses.
Beclom ethasone 150 0  m g/day
n = i o o
Placebo
n=94
A g e  (y r) 6 2  (7) 6 3  (8)
H e ig h t  (cm ) 1 6 8  (8) 167 (7)
M a le  (n) 85 8 6
B o d y  M a s s  In d e x  ( k g / m 2 ) 2 5.4 (3.9) 24.5 (4 .3)
F E V n P r e b r o c h o n d ila t o r  (L) 1 .36 ( o .4 l ) * 1.25 (0 .35)
F E V n P reb r. (% p r e d .) 4 8  ( 1 1 ) * * 44  ( 1 1 )
< 3 5  % p r e d .  ( n u m b e r  o f  p a t ie n ts ) 17 21
3 5 -5 0  % p r e d .  ( n u m b e r  o f  p a t ie n ts ) 41 47
> 5 0  % p r e d .  ( n u m b e r  o f  p a t ie n ts ) 42 25
F E V n/ V C  (% ) 52  ( 13) 49  ( 12 )
F E V 1 P o s t b r o n c h o d ila t o r  (L) (p re tr ia l v is it) M 4  (° . 43) 1.35 (0 .37)
F E V n P o stb r . ( % p r e d .) ( p r e t r ia l  v is it) 51 ( 12 ) 4 8  ( 1 1 )
R e v e r s .F E V n ( % p r e d ) 3.4 (3.o ) 3 .8  (3 .6 )
P a c k  Y e a r s 37 (27) 4 1  (28 )
S m o k e r s  ( c u r r e n t / fo r m e r / n o n -s m o k e r s ) 2 7 / 6 2 / 1 1 2 8 / 5 6 / 1 0
C ig a r e t t e s / d a y 14  (9) { n = 2 7} 15 (9) { n = 2 8 }
lo g i o (|g E+ l) ( IU / m l) 1.74 (0 .57) 1.68 (0 .4 9 )
Ln E o s in o p h il  C o u n t / m m 3 4 . 1 8  ( 1 .95) 3.89 (2 .0 9 )
C o n c o m it a n t  D r u g s  ( c o n t in u o u s  u s e ) :
A n t ic h o lin e r g ic s 1 9 %  (%  o f  s u b je c t s ) 2 2 %
B e t a 2  m im e t ic s
os95 6 1 %
T h e o p h y llin e
os85 55%
M u c o ly t ic s 4 0 % 48%
A lm itr in e 1 0 % 17%
* p = 0 .0 4 4 ,  * * p = o . o o i 8
Pulmonary function and blood gases
At each visit, lung function measurements were performed according to the criteria of 
the European Respiratory Society.27 All measurements were taken with the same 
apparatus, and i f  possible, with the same technician and at the same hour o f day. In case 
patients had acute rhinitis, sinusitis or an exacerbation, the taking o f measurements was 
postponed. Bronchodilators were not allowed within six hours prior to the assessment. 
The measurements o f FEVP VC, M EF^, MEF50, F E F ^ ^ , PEF were performed every 
three months. The FRC, RV and TLC were assessed every half year, and reversibility in 
FEVj (as a percentage o f FEV: predicted) was assessed annually. Reversibility was tested 
by measuring FEV: 10 minutes after 4 puffs o f 100 |jg salbutamol (Ventolin™- MDI) 
had been administered.
Arterial blood gases (PaO2 , PaCO2 , pH, saturation, bicarbonates and HbCO) were 
measured annually.
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Steroid and antibiotic courses
Prescribed courses o f antibiotics or oral steroids and the number o f days treated were 
registered at each follow-up visit.
Dyspnea and ‘general well-being
Dyspnea was assessed at baseline, and after 3, 6, 12, 18 and 24 months according 
to Fletcher (i=no dyspnea, 2=no dyspnea when walking on flat ground, 3=no 
dyspnea when walking slowly, 4=dyspnea even when walking slowly, 5=dyspnea while 
undressing).28
At the same time, the patients were asked to rate their ‘general well-being’ on a 
visual analog scale (VAS) (100 mm unticked vertical line, uppermost boundary (100) 
corresponding to the patient’s worst possible self-perception o f his/her well-being 
(‘I have never felt that bad’) and lowermost boundary (0) corresponding to the best 
possible status (‘I have never felt so good’).29
Every three months, the physician in charge subjectively assessed and recorded the 
clinical status o f the patient (good, moderate or bad).
Hospitalization, consultation
Hospitalization (including the number o f days) and the number o f unplanned 
intermediate consultations were recorded at each visit.
Adherence to treatment and safety
At each visit, the patients were asked i f  they had succeeded in taking the prescribed 
drugs regularly or not. I f  they had not succeeded in this, the investigators insisted on 
explaining the importance o f regular use o f the trial drug. Also at each visit, the subjects 
were asked i f  the drug o f treatment was well tolerated and i f  not, the investigator had to 
fill in a standard (serious) adverse event form.
Study end points
The main outcome parameter was the change in the prebronchodilator FEVI. Secondary 
outcome parameters were the postbronchodilator FEVI (which was only assessed 
annually), IVC, MEF2j , M EFj0, F E F ^ ^ , PEF, FRC, RV, TLC, the number o f courses of 
antibiotics and/or oral steroids, the number o f hospitalizations (in days), arterial blood 
gases, the physician’s subjective assessment o f clinical status and the patients’ 
self-assessment o f well-being.
Power A ssessment
The estimated number o f evaluable participants in each trial group was 108. This 
calculated number was based on the hypothesis that the minimal detectable difference 
in decline in (prebronchodilator) FEVI between the two trial groups had to be 0.04 L/yr 
(0.02 L/yr in the beclomethasone and 0.06 L/yr in the placebo group), with the SD of 
FEVI o f 0.1 L and using a unilateral t-test with alpha=0.05 and beta=0.i.
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A nalysis
At the time o f data collection, all data were manually checked and then computerized. 
After computerization, a 5% sample was rechecked. For the purpose o f the analysis 
presented in this article, a further sample o f 5% o f the original patient records were 
again compared with the computer draw-outs. This routine check showed full reliability 
o f the data. The analysis was performed with the statistical package o f SAS (SAS 
Institute Inc., Cary, NC, USA).3°
An intention-to-treat analysis was performed. The effect o f beclomethasone (versus 
placebo) on prebronchodilator and postbronchodilator FEVI was measured with a 
multiple repeated measurement technique, in which patient and time effects on FEVI 
were investigated separately. A preliminary analysis had shown no interaction between 
measurement and treatment. Therefore, a random coefficient model was chosen in 
which all available individual time points o f FEVI measurements were incorporated and 
analyzed.31 Patients were only analyzed i f  they attended at least one follow-up visit. 
Effects on other lung function parameters (postbronchodilator FEVP M EF^, MEF50, 
FEF25-75, PEF, static volumes), and on blood gases, dyspnea, clinical status, VAS score, 
‘nutritional status’ , were also assessed with the same kind o f model. Correction for 
baseline values was performed in all models.
Differences between the beclomethasone and placebo group concerning dichotomous 
dependent variables (e.g. the number o f courses o f antibiotics and oral steroids, the 
number o f hospitalizations because o f pulmonary disease) were tested using logistic 
regression analysis.
For prebrochodilator and postbronchodilator FEVI more extensive analyses were 
performed as well. In order to correct for possible confounders o f the effect o f inhaled 
beclomethasone on the change in (prebrochodilator or postbronchodilator) FEVP the 
baseline variables o f FEVP age, height, gender, FEVP airway reversibility, pack years, IgE 
(log10(x+i) transformed), eosinophils (ln transformed), the concomitant drugs used 
(anticholinergics, beta2 agonists, theophylline, mucolytics and almitrine) were introduced 
in the models with the FEVI as dependent variable. The number of steroid and antibiotic 
courses during the study were introduced in the model as well. In addition, data about 
the number o f cigarettes smoked daily during the study (assessed at each visit) were 
incorporated into the analysis at each time point o f measurement. In a backwards 
procedure, variables with the highest p-value were subsequently deleted until only 
variables with p<0.05 remained in the multivariate model (‘final models’).
In the final models o f prebrochodilator and postbronchodilator interaction, terms of 
possible predictors o f the effect o f beclomethasone with FEVI were incorporated (FEVI 
at baseline as a continuous variable or as a class variable (<35, 35-50, >50 % pred.), sex, 
reversibility, pack years and (logI0)IgE).
Results
Randomization
Figure 8.1 shows the trial profile. Data from 100 patients in the beclomethasone group 
and from 94 in the placebo group were obtained and analyzed (Table 8.1). In spite of 
a slightly higher baseline FEVI in the beclomethasone group, the repartition of 
the patients in the American Thoracic Society severity classes3 was not significantly
1 1 9
Figure 8.1: Trial profile o f the study.
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different within both groups (Table 8.1). All the analyses on FEVI were corrected for the 
small difference in baseline FEVI between the two treatment groups.
W ithdrawals
The mean study duration was 1.55 (range 0-2.18) years in the beclomethasone group and 
1.60 (range 0-2.16) years in the placebo group (unpaired t-test, p=o.64). In the actively 
treated group, 62 patients completed the study protocol, compared to 63 in the placebo 
group. Reasons for drop-out (Figure 8.1) did not differ between both groups. In 7 out 
o f 19 cases in the beclomethasone group, the drop-out due to an adverse event was 
considered to be related to the trial drug, compared to 4 out o f 17 in the placebo group.
Effect on FEV i
Figure 8.2 shows the course o f the prebronchodilator FEVr  Intention-to-treat analysis 
showed an increase in the uncorrected prebronchodilator FEVI o f +16 mL/yr in the 
beclomethasone treated group, compared to a decline o f -13 mL/yr in the placebo group. 
Repeated measurement analysis, which corrected for possible confounders like baseline 
FEVP showed a statistically significant increase in the prebronchodilator FEVI o f +38 
mL/yr(SE 18, p=0.03i) in the beclomethasone group in comparison with placebo during 
two years. Postbronchodilator FEVj tended to increase during the first year o f follow-up
Figure 8.2: Course o f prebronchodilator FEVj (L) o f the Beclomethasone group 
versus that o f the Placebo group. BEC = Beclomethasone group, PLA = Placebo group. The solid 
lines represent all available data (intention to treat). Standard errors and the number of patients at each 
point in time in the study have been added. The dotted lines represent the subgroup of patients having 
finished the study per protocol (explanatory analysis). The difference between the two trial groups in 
terms of baseline prebronchodilator FEVI does not exist in the explanatory analysis.
0  3  6 9 12 15 18 21 24
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in both groups. This tendency was sustained over the second year in the beclomethasone 
group, whereas it was lost in the placebo group. As a result, after correction for possible 
confounders like baseline postbronchodilator FEVP repeated measurement analysis 
showed a statistically significant increase in the postbronchodilator FEV: in the 
beclomethasone group during the two-year treatment in comparison with the placebo 
group (+149 mL/yr(SE 70, p=0.035), Figure 8.3).
Effect on other lung function indices
Table 8.2 shows that the MEF2j as an index o f obstruction of the small airways improved 
significantly during treatment with beclomethasone compared to placebo (estimate 
+o.o67(L/sec)/yr, SE 0.023, p=0.003). There were no significant differences between 
treatments regarding other lung function parameters.
Effect on arterial blood gases
The arterial blood oxygen saturation, which was subnormal in both trial groups at 
the start o f the study, improved significantly by +o.5(SE o.2)%/yr (p=0.02) during 
beclomethasone therapy compared to placebo (Table 8.2). Also, (subnormal) PaO2
1 22
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Table 8.2: Overall estimates o f lung function indices, arterial blood gases, dyspnea, 
VAS score and clinical status during the study. Univariate repeated measurement analysis 
was performed on all parameters, correcting for baseline differences. Data of time*treatment models are 
represented.
Baseline values Estimate SE P-value
Beclomethasone Placebo Pl£cleSi
Secondary dynam ic lung 
function indices
MEF25 (L/sec) 0.511 0.448 +0.067/yr 0.023 0.003
MEF50 (L/sec) 0.871 0.759 +0.002/yr 0.026 0.93
FEF25-75 (L/sec) 0.812 0.681 +0.026/yr 0.018 0.14
PEF (L/sec) 3.60 3.50 +0.004/yr 0.058 0.94
VC (L) 2.694 2.635 +0.020/yr 0.026 0.43
Statistic lung volum es
FRC (L) 3.900 4.020 -0.071/yr 0.072 0.32
RV (L) 3033 3.227 -0.058/yr 0.070 0.40
TLC (L) 5.867 5.986 -0.061/yr 0.077 0.43
Arterial blood gases
PaO2 (mm Hg) 71.1 71.8 +1.4/yr 0.7 °.°53
PaCO2 (mm Hg) 38.6 40.1 -0.36/yr 0.31 0.24
ph 7.4 7.4 -0.002/yr 0.004 5.60.
O2 saturation (%) 93.6 93.5 +°.5/y 0.2 0 .02
Bocarbonate (mmol/L) 25.0 25.3 +0.067/yr 0.334 0.84
Sem iquantitative m easures
Dyspnea score 
(mean from 1-5)
2.03 2.20 +°.°45/yr 0.053 0.39
Self-rated well-being 
VAS score (0-100 mm)
40.1 43.3 -0.61/yr 1.44 0.67
Physician related clinical 
status (mean from  1-3)
1.27 1.46 +0.03/yr 0.04 0.44
increased with + i .4(SE o.7)%/yr in the beclomethasone treated group compared to 
placebo, which was o f borderline significance (p=0.053).
Effect on the n um ber  and duration of steroid and antibiotic courses 
Table 8.3 shows the number o f steroid and antibiotic courses in both groups. Logistic 
regression analysis performed on these variables showed no statistical significance 
when the beclomethasone was compared with the placebo group (steroid course: 
RR=o,8o {95%c.i. 0.23-2.80, p=o.34}, antibiotic course: RR=o,72 {95%c.i. 0.30-1.71,
p = ° . ° 9 }).
During the study, the duration o f steroid courses tended to be shorter in the 
beclomethasone group, this difference reaching significance from 7 to 9 months 
(Table 8.3). The total number o f days o f steroid courses was 530 (of 56,949 days of 
treatment) in patients o f the beclomethasone group compared to 568 (of 55,149 days of 
treatment) in the placebo group (p=0.90, Z-score, Wilcoxon Rank-test).
123
Effect on
dyspnea and ‘g e n e ra l w ell-bein g ’ 
In the beclomethasone group, the 
overall dyspnea improved in 24 o f the 
88 patients (27%) (with at least two 
dyspnea score assessments), in the 
placebo group in 27 o f 83 patients 
(32%) (X2 test, p=o.96). Repeated 
measurement analysis showed that 
dyspnea, the self-perceived well­
being status, VAS score and the 
physician’s subjective rating of clinical 
status were not influenced by the 
treatment (Table 8.2).
Effect on intermediate 
consultations and hospitalization 
During the study, the patients o f both 
trial groups were given a comparable 
number o f intermediate consultations 
(1.3) due to pulmonary problems. In 
the beclomethasone group, 13 patients 
were hospitalized due to pulmonary 
problems, compared to 16 patients in 
the placebo group. The total number 
o f days o f hospitalization was more 
than twice as much in the placebo 
group (376 days) compared to the 
beclomethasone group (152 days). 
After correction for the total number 
o f days o f treatment (56,949 in the 
beclomethasone and 55,149 in the 
placebo group), this difference was 
not found to be significant (Z-score =
0.93, Wilcoxon Rank test).
Predictors of
the effect of beclomethasone 
None o f the variables o f baseline 
FEVj (both as a continuous variable 
and class variable), sex, reversibility 
o f obstruction, pack years and serum 
IgE did interact with the effect o f 
beclomethasone on the prebrochodilator 
or postbronchodilator FEV: compared 
to placebo.
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A dverse effects, safety and compliance
In the beclomethasone group, 98 adverse events were reported (of which 27 were 
serious) and in the placebo group 94 (of which 33 were serious). One event (bronchitis 
in one patient o f the beclomethasone group) was reported as a serious adverse event. In 
the beclomethasone group, 23 adverse events occurred that possibly related to the trial 
drug (in 17 o f 100 patients), compared to 14 events in 13 o f 94 patients in the placebo 
group (X2=2.o6, p=o.i5). Ninety-seven percent o f the patients stated to tolerate the trial 
drug well, and 84% of the subjects stated to be compliant at each three-monthly visit. 
No differences in these parameters were found between the two trial groups.
Discussion
In this study, 1500 |j,g beclomethasone MDI daily administered during two years to 
patients with moderate COPD had a significantly beneficial effect on the course of 
FEVi, compared to placebo. Beclomethasone therapy did better than slowing down the 
progressive decline in FEVi predicted by the natural history o f the disease1: it actually 
reversed it. There were no clear positive effects of beclomethasone as compared to 
placebo in terms o f symptoms and oral steroid and antibiotic courses.
M ethodological issues
Studies o f this type require that careful attention is paid to methodological issues before 
interpreting the results, particularly when some results are more or less surprising. In 
the present study, several points deserve to be mentioned.
An increase in FEVi over two years in a COPD population can be considered a 
surprise. The effect of beclomethasone, compared to placebo, on the postbronchodilator 
FEV i (approximately +150 mL/year) was even larger than on the prebronchodilator 
FEVi. This is important because postbronchodilator FEVi is generally considered as a 
more accurate estimate o f lung function (decline) in COPD than prebronchodilator 
FEVi. However, the corresponding results only pertain to three measurements. Also, 
due to missing values in the multivariate model, which corrected for possible confounding 
variables, the number o f measurements which were to be included was strongly reduced. 
The better result in terms o f postbronchodilator FEVi compared to prebronchodilator 
FEV i should therefore be considered with due caution.
After one year o f study, a sudden increase in FEVi was observed in both treatment 
groups (Figures 8.2 and 8.3). Additional analysis showed that all the corresponding 
measurements were equally distributed throughout the year, which indicated that there 
were no seasonal effects. However, it appeared that, during months 9 to 12, less oral 
steroids and antibiotics had been prescribed, probably indicating a lesser number of 
exacerbations, and possibly explaining a higher average FEV i at the end o f this period. 
Such types o f events, probably coincidental, justify the need for longer observation 
periods where therapeutic interventions in COPD are concerned.
Considering the rate o f decline o f FEVi in COPD described in the literature (-60 to 
-80 mL/yr)1, the mean uncorrected decline in FEVi in the placebo group o f this study 
was less (-20 mL/yr) than expected, and was in fact ‘physiological’ . This can probably 
partly be explained by the participants’ smoking behavior. Smoking cigarettes is the
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most important contributor to a progressive lung function decline in COPD. It has been 
shown that, in people who have stopped smoking, this progressive decline decreases to 
near normal rates.2 A relatively low percentage o f patients (approximately 30%) smoked 
at the start o f our study. In addition, the current smokers in both groups smoked less 
cigarettes a day at the end o f the study than they did at the beginning (a decrease from 
14 to 8 cigarettes in the beclomethasone group {p=0.005, Wilcoxon Rank Test}, and 
from 15 to 12 in the placebo group {p=0.043}), although no specific smoking cessation 
intervention had taken place before or during the study. The reduction o f tobacco 
consumption in both groups may be due to a positive ‘in care effect’, and probably 
contributed to the evolution o f FEVI in both cases.2
Retrospective analysis o f the inclusion criteria o f all 194 patients randomized, showed 
that approximately 5% o f the patients had a FEVI below 30% of the predicted value, and 
7% had a FEVI o f more than 60%  of the predicted value. Strictly considering all the 
other inclusion criteria (airway reversibility < 15% predicted, stable FEVI {< 10%  
difference between pretrial and baseline visit}, IgE < 200 IU and/or eosinophil count 
< 500/mm3, PaO2 at least 55 mm Hg), it was found that another 20%  o f the patients did 
not fulfill these. A possible explanation for this important restriction to the study is that 
inclusion o f patients proved more difficult than expected, so that the criteria o f inclusion 
were sometimes enlarged by the investigators. Nevertheless, there was the same 
number of patients not fulfilling all the inclusion criteria in both groups, and re-analysis 
restricted to the patients who fulfilled all inclusion criteria (70 beclomethasone, 71 
placebo) yielded comparable positive results in favor o f beclomethasone versus placebo 
(+47(SE 17) mL/yr improvement of prebronchodilator FEVP p= 0.006, postbronchodilator 
FEVP +50(26) mL/yr improvement, p=0.056).
Approximately one out o f three patients dropped out o f the study, with no difference 
between the two trial groups. The drop-outs o f the placebo group had a lower baseline 
FEVj%pred than the placebo patients who completed the study {40.4(8.6)% compared 
to 45.8(10.9)% (p=0.0i8)}. Because a lower baseline FEVI is known to lead to the risk of 
a steeper decline in FEVI, the drop-out within the placebo group may have caused an 
underestimation o f the effect o f beclomethasone versus placebo on the course o f FEVI. 
However, explanatory analysis showed roughly the same effects o f beclomethasone 
versus placebo on FEVI, and thereby the possibility o f selective drop-out was excluded.
Discussion of outcomes
FEVI was taken as the main outcome in this study. This is often the case in COPD 
studies, because FEVI is a well known index, considered simple to measure and follow 
up, and because it ‘speaks clearly to the mind’ o f COPD oriented physicians. However, 
there are many other issues to consider.
In COPD, inflammatory changes have been shown to be present, especially in the 
small airways.32 Inhaled steroids should therefore theoretically improve lung function 
indices reflecting obstruction in the small airways. In this view, the very significant 
improvement o f MEF25 noted in the treatment group here is an important finding. It 
might attest to the reality o f the anti-inflammatory effect o f beclomethasone in 
the treated group, and supports the validity o f the analysis in terms o f FEVI. 
Pathophysiologically speaking, the reduced degree o f airway obstruction, and particularly
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of small airway obstruction, should be associated with a decrease in the degree of 
hyperinflation. Indeed, RV and FRC tended to decrease over time in the beclomethasone 
group.
In line with the increase in MEF2. under beclomethasone, the novel finding of 
improved oxygenation levels can hypothetically be viewed as the result o f an improved 
ventilation/perfusion equilibrium deriving from a lower degree o f inflammation in the 
distal airways. Nevertheless, it should be noted that PaCO2 did not decline significantly 
during treatment with inhaled beclomethasone. When analyzing a number o f 
clinical effect parameters, the risk o f finding a significant effect by mere chance does 
normally increase. The putative effect o f beclomethasone on PaO2 should therefore be 
considered with due caution.
No effects o f beclomethasone (versus placebo) were observed on the intensity of 
dyspnea. This may be viewed as a discrepancy given the improvement in FEVi, but 
subjective clinical measures as dyspnea are known to correlate poorly with the severity 
o f obstruction in asthma or COPD.33 In addition, it is now well recognized that the relief 
o f dyspnea that is induced in COPD, for example, by bronchodilators, is much more the 
result o f a reduction in hyperinflation than o f increased expiratory flow.34 Since 
beclomethasone had no significant effect on static lung volumes in this study, the lack 
o f improvement o f dyspnea is a logical finding. Several explanations can be proposed, 
including 1) the heterogeneity o f the population in terms o f the severity o f obstruction, 
with a minority o f severely hyperinflated patients and 2) the fact that a great majority of 
patients received bronchodilators on a regular basis (Table 8.1), which may have masked 
hypothetical benefits o f beclomethasone in terms o f hyperinflation related dyspnea.
The patients’ self-perceived well-being and the physician’s subjective assessment of 
clinical status were not modified by beclomethasone as compared to placebo. This is not 
surprising i f  one considers that dyspnea is probably one o f the main determinants o f the 
quality o f life in COPD. It should be kept in mind that the indices studied are relatively 
rough: principally due to the time o f its realization, this study did not include a 
sophisticated assessment o f the quality o f life.
Beclomethasone did not affect the number o f oral steroid or antibiotic courses 
significantly, nor did it affect the total number o f days spent under oral steroids or 
antibiotics. A possible explanation may be that the criteria for the prescription o f these 
treatments were left to the decision o f the physician in charge o f the patient rather than 
being defined by the protocol. In the literature, the long-term effect o f inhaled steroids 
on exacerbations in COPD is not clear. Renkema et al found no decrease in the number 
o f exacerbations during two-year treatment with 1600  |j,g budesonide daily18, whereas 
Paggiaro et al found a decrease in the severity o f exacerbations with 1000  |j,g 
fluticasone/day.35 The limited duration o f this study (6 months) makes it difficult 
to draw any conclusions regarding exacerbations. It is noteworthy that 60 o f 160 
patients with stable COPD (38%) had an exacerbation o f COPD within eight weeks after 
they had stopped with inhaled steroids (wash-out period) because o f participation in a 
trial with inhaled fluticasone.36 Not finding a sparing effect o f inhaled steroids 
regarding oral steroids in our study may be viewed as a disappointment in the light of 
the increasingly well described side-effects o f oral steroids in COPD. As opposed to 
what is observed in asthma, this points to the notion that exacerbations o f COPD are 
probably not predominantly due to increased airway inflammation, but may proceed
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from many non- inflammatory mechanisms (e.g. left heart failure or bacterial infection). 
It again raises the unresolved question o f the appropriateness o f oral steroid therapy in 
acute exacerbation o f COPD.37
The majority o f the adverse events considered to be related to the inhaled steroid drug 
in our study were local side-effects (oral candidiasis, cough after inhalation, dysphonia, 
pharyngitis, dry mouth), which are the result o f oropharyngeal deposition o f inhaled 
steroids.38 No significant difference between the trial groups was shown. Also note that 
the patients in our study used M DI’s as inhaler devices and not spacer devices as these 
were not yet used on a regular basis at the time o f this study. The use o f spacer devices 
is likely to decrease oropharyngeal deposition and systemic availability significantly, and 
thus to further improve the benefit-risk balance o f inhaled steroids.39
Approximately I5% o f the subjects o f our study perceived one or more (especially 
oropharyngeal) adverse events that were considered to be related to the trial drug. 
Systemic side-effects like a decrease o f bone density, a decrease o f serum cortisol, or 
skin bruising may occur with high doses o f inhaled steroids.38'40 At the time o f the 
study, the assessment o f bone density was not as easy and accurate as now. Moreover, 
because o f the difficulty o f obtaining urinary samples, it was agreed not to proceed with 
cortisol measurements. In addition, the phenomenon o f skin bruising was not well 
recognized at the time o f the study. As systemic side-effects were not specifically 
studied, it is not possible to fully comment on the long-term safety o f beclomethasone 
dipropionate I500 |ig daily in the COPD patients from this study.
Inhaled steroids and COPD
That inhaled steroids can have a positive effect on lung function in COPD, including in 
non-reversible forms o f the disease, is not disputable on a short-term basis^9 As three 
major studies on the topic are pending publication, there is still doubt about the 
long-term clinical effects o f inhaled corticosteroids in COPD.4^9 Indeed, among these 
studies, '... the Copenhagen study showed no benefit from inhaled budesonide 800 jig daily 
(with 1.2 mg for the first six months) on any outcome measure. The EUROSCOP study 
showed non-significant benefit in terms o f FEV1 decline with budesonide 800 fig daily, whilst 
the ISOLDE study showed benefit in terms of quality o f life, along with non-significant 
improvement in FEV1 decline, with fluticasone propionate 1 mg daily' (quoted from 4 1). In 
addition, exacerbations were significantly reduced in the ISOLDE group.4
Our study, conducted among a much smaller population, which, nevertheless, was 
probably large enough to draw valid conclusions, yielded results that seem to be at 
variance with those o f the three above-mentioned ones. It does show a statistically 
significant difference in (prebronchodilator) FEVI o f approximately +40 mL per year 
during treatment with beclomethasone compared to placebo on the FEVI, which may be 
o f clinical relevance. In a recent meta-analysis, in which I52 o f the patients from our 
present study were included, a comparable two-year effect o f inhaled steroids on FEVI 
was shown.20 This difference may be due to differences in the population studied, for 
instance, a greater proportion o f more severe cases in our study (inhaled steroids being 
likely to be more efficient in the most severe forms o f the disease). It could also be a 
dose related effect, I.5 mg o f inhaled beclomethasone daily represents one o f the higher 
doses used on a long-term basis in COPD. In this view, it is interesting to note that the
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ISOLDE study used a significantly higher relative dose than the Copenhagen study and 
EUROSCOP.
Conclusion
In conclusion, we showed that a high dose o f beclomethasone o f 1500 |jg daily 
beneficially modified the course o f lung function beneficially during two years in 
patients with stable moderate COPD. This can raise safety concerns and certainly 
implies that efforts should be made to define selection criteria, which might lead to a 
rationalized prescription o f inhaled steroids in COPD. Indeed, it will probably become 
apparent from other studies that inhaled steroids ‘are unlikely to be the ideal drugs for 
this disease’41, but our study suggests that they may indeed have a place in therapeutics, 
given the limited therapeutic scope that is available for COPD.
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Part Three

Chapter 9
Summary, General Discussion and Final Conclusions/ 
Recom m endations
Summary
Chapter 1 presents an introduction containing the general background, and the contents 
o f the studies reported in this thesis. Asthma and chronic obstructive pulmonary disease 
(COPD) have a relatively high prevalence in general practice. Because inflammation of 
the bronchial wall plays more or less a key role in both disease entities, anti-inflammatory 
treatment seems a logical treatment option. In the long-term, both in asthma and in 
COPD, irreversible changes take place in the lower airways, as a consequence o f the 
chronic inflammatory process. It seems therefore essential that anti-inflammatory 
treatment is started as early as possible. Inhaled steroids have already proven their 
beneficial anti-inflammatory action, especially in asthma. Mild cases o f asthma or 
COPD are mostly treated in general practice. General practice is therefore the most 
suitable domain to study the efficacy and effectiveness o f treatment with inhaled 
corticosteroids as early as possible (may be even before the full clinical presentation of 
the disease).
Treatment o f patients with (mild signs of) asthma or COPD with inhaled corticosteroids 
is the central theme o f the research in this thesis. Part One o f the thesis contains 
original data from the DIMCA study, a large general-practice-based study on Detection, 
Intervention, and Monitoring o f patients with mild signs o f COPD and Asthma. Several 
aspects o f early intervention with the relatively new inhaled corticosteroid fluticasone 
propionate {F lixotide®} in patients with mild signs o f asthma or COPD without a clear 
diagnosis are investigated, such as ‘fear o f corticosteroids’ (Chapter 2), clinical effects 
(Chapter 3) and compliance o f treatment (Chapter 4). In Part Two related questions are 
presented concerning the dosage and duration o f treatment with inhaled corticosteroids
135
a s t h m a  a n d  c o p d  - t r e a t m e n t  w i t h  in h a l e d  c o r t ic o s t e r o id s
in patient with diagnosed mild asthma (Chapter 5 and 6) and in patients with diagnosed 
moderate to severe COPD (Chapter 7 and 8).
Part one (data from the DIMCA programme)
The reasons o f patients with early signs o f asthma or COPD for refusing to participate 
in early treatment with fluticasone propionate are investigated in Chapter 2. Screening, 
monitoring and the three interventions with fluticasone in DIMCA showed on average 
25 to 35% refusers. For those invited to one o f the three drug intervention studies, 
‘dislike o f medication’ was the most important reason for non-participation (33%, 45% 
and 67% of the refusers). ‘Fear o f corticosteroids’ was the specific reason for non­
participation in only 8% of the refusers who had a ‘dislike o f medication’. We concluded 
that a specific fear o f corticosteroids was not a major obstacle for early intervention with 
inhaled corticosteroids.
Chapter 3 decribes the clinical effects o f fluticasone propionate in subjects believed to 
be at the very onset o f developing obstructive airways disease, i.e. before a reliable 
diagnosis could be made. Two randomized placebo-controlled trials were conducted 
after a two-year monitoring o f lung function and symptoms. In the first trial ('mild signs 
o f COPD’), 48 subjects with a moderate increase in decline in FEVI o f more than 
0.04L/yr were invited for a 2-year trial with fluticasone propionate 500 |jg daily. In 
the second (i-year) trial ('mild signs o f asthma’), 29 subjects with signs o f bronchial 
hyperresponsiveness were treated. In the COPD trial, the overall course o f FEVi during 
the study did not improve for the better by fluticasone compared to placebo. In the 
asthma trial, bronchial hyperresponsiveness was also not influenced by fluticasone 
compared to placebo. In both trials there were no significant differences in symptoms 
between the fluticasone- and placebo-treated patients. We concluded that there is no 
ground for screening subjects with mild signs o f asthma or COPD without a clear 
clinical diagnosis for reason o f treatment with inhaled corticosteroids.
Chapter 4 assesses the two-year compliance to inhaled fluticasone during the trials 
described in Chapter 3. It was hypothesized that compliance would be low in these 
patients without a clinical diagnosis o f asthma or COPD and hence with few symptoms. 
Fluticasone had to be inhaled twice daily with the use o f a dry powder inhalator 
(Rotadisks®) during one year (in the asthma group) or two years(in the COPD group). 
All full and empty disks returned were counted manually. In a telephone survey, the 
patients were asked about perceived effects and/or side-effects o f the trial drug. The 
mean overall individual compliance rates o f 72% (range: 7 to i02%) in the COPD trial 
and 7i%  (range: 8 to 99%) in the asthma trial were maintained throughout the study. 
The willingness o f patients to use the trial drug in daily practice i f  efficacy would have 
been shown was positively related to compliance during the trial (p=0.0i7). It was 
concluded that compliance rates were high in spite o f the ‘mild stage’ o f the disease. 
The results also emphasize the importance o f patient education in establishing early 
treatment with inhaled corticosteroids in case o f proven efficacy.
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Part two
Chapter 5 describes the literature search and subsequent meta-analysis o f the effect of 
inhaled corticosteroids on bronchial responsiveness in corticosteroid-naive asthma. The 
study was set up in response to recent consensus reports advocating early introduction 
o f high doses o f inhaled corticosteroids in asthma to reduce the bronchial inflammation 
as quick as possible. Because o f the possibility o f adverse effects during long-term 
treatment with high doses o f inhaled corticosteroids, it is also advised to reduce the dose 
as soon as the clinical state is stable. However, these recommendations are not supported 
yet by clinical evidence. Bronchial responsiveness, which is closely related to bronchial 
inflammation and can be measured by a bronchial provocation test (for example with 
histamine), was taken as the main effect parameter. Eleven studies were selected. In 
most of the studies relatively high doses of inhaled corticosteroids were used (on average 
1000 |j,g daily). The overall effect size of inhaled corticosteroids versus placebo treatment 
was +1.16 (95%c.i. +0.76 to +1.57) doubling dose o f the bronchoconstricting agent. This 
effect remained when only the short-term studies (of 2 to 8 weeks) were analysed. We 
demonstrated that high doses o f inhaled corticosteroids were able to control inflammation 
in corticosteroid naive asthma already within 2 to 8 weeks. On the basis o f this meta­
analysis it remained unclear whether there is a dose-response relationship between 
inhaled corticosteroids and the effect on bronchial hyperresponsiveness. For this 
moment, following the recent guidelines o f ‘start high, go low’ is mandatory.
In an observational study (Chapter 6), the aim was to investigate whether long-term 
therapy with inhaled corticosteroids can be discontinued in mild asthma when patients 
are in a clinically stable phase o f the disease. Data were derived from a two-year 
randomized controlled bronchodilator intervention study in general practice during 
which no inhaled corticosteroids were allowed. The experimental group consisted o f 19 
mild asthmatic patients who had used inhaled corticosteroids daily during at least the 
year preceding this study. The control group consisted o f the 70 patients with asthma, 
who had not used corticosteroids in the year preceding the study. In the experimental 
group, 12 of the 19 patients (63%) dropped out during the study because of dependency on 
corticosteroids. In the control group, only 8 o f the 70 patients dropped out for this 
reason (11%). This difference was significant (Chi-square= 20.1, p<0.000i). In the 
patients o f the experimental group (ex-corticosteroid users), the annual FEVI decline 
was much larger than in the control subjects (0.165 versus 0.040 L/yr, p=0.022). From 
these secondary analyses it was concluded that stopping maintenance treatment with 
inhaled corticosteroids is not advisable on a routine base in patients with mild asthma 
even when the disease seems stabilized. When discontinuing inhaled corticosteroids is 
considered, patients should be closely observed and followed by the general physician.
Chapter 7 deals with the assessment o f the long-term clinical effects o f inhaled 
corticosteroids in COPD. There is much debate about this topic. We therefore performed 
a meta-analysis o f the original data-sets o f three placebo-controlled studies on this 
subject (of at least 24-month duration). Patients with ‘asthmatic’ features such as 
reversibility o f bronchial obstruction were excluded from the analyses. Patients had 
moderately severe COPD (FEVI = 45% of predicted). Ninety five selected patients were 
treated with inhaled corticosteroids (87 with 1500 or 1600  |j,g inhaled beclomethasone
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or budesonide daily, and 8 with 800 |jg beclomethasone daily) and 88 with placebo. 
The estimated two-year difference in prebronchodilator FEVi was +0.034L/year 
(95% confidence interval +0.005 to +0.063, p=0.26) to the advantage o f the inhaled 
corticosteroid group compared to placebo. Compared with the low-dose treatment, 
the high-dose treatment resulted in a more beneficial course o f FEVi (+0.039L/jaar vs. 
+0.002L/yr, p=0.043). The exacerbation rate was not influenced by treatment with 
inhaled corticosteroids. No possible predictors o f the response to inhaled corticosteroids 
(such as smoking behaviour) were found. We concluded that, in patients with 
clearly defined moderately severe COPD, a beneficial course o f FEVi was evident after 
long-term treatment with relatively high doses o f inhaled corticosteroids.
As a result o f the good cooperation with the French research group while working 
on the meta-analysis (Chapter 7), we were allowed to analyse the original data from 
the (yet unpublished) French study. Chapter 8 contains the results o f this study. In a 
group o f i94 patients with stable moderate to severe COPD, the clinical effects and 
safety o f a two-year treatment with i500 |jg inhaled beclomethasone (Becotide® MDI) 
daily versus placebo were assessed. During the study a significant increase in the 
prebronchodilator FEVi of+0.038L/yr(SE 0.0i8, p=0.03i) in the beclomethasone group 
was shown in comparison with placebo. The postbronchodilator FEVi showed a 
comparable change. The number and duration o f steroid and antibiotic courses were 
comparable in both components o f the study. Blood oxygen saturation improved by 
+0.5(SE 0.2)%/yr (p=0.02) under beclomethasone therapy as compared to placebo. 
Seventeen percent o f the patients in the beclomethasone group had experienced 
an (especially oral) side effect o f the trial drug, versus i5% o f the patients o f the 
placebo group. This study showed a beneficial and relatively safe effect o f i500 |jg 
beclomethasone MDI daily during two years in comparison with placebo in patients 
with stable moderate to severe COPD.
General Discussion
Inhaled corticosteroids are often prescribed in general practice, both in asthma and in 
COPD^ However, a number o f questions have not been resolved yet, such as: ‘At what 
stage should these anti-inflammatory drugs be introduced?’, and ‘What should be the 
dose and duration o f treatment in diagnosed subjects?’ .
Part One o f this thesis contains data on several aspects o f the experimental treatment 
of patients with mild signs of ashma and COPD (without a clear diagnosis) with inhaled 
corticosteroids. Questions to be answered were: ‘Are inhaled corticosteroids effective in 
very early stages o f asthma or COPD’?, and ‘What are barriers in prescribing inhaled 
corticosteroids in this group o f patients?’. In order to identify early stages in the
development o f asthma or COPD, data from a large Detection, (early) Intervention 
and Monitoring programme on COPD and Asthma in general practice (DIMCA
programme) were presented in this part.
In Part Two o f the thesis we investigated clinical effects o f inhaled corticosteroids in 
diagnosed groups o f asthma and COPD patients.
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Part one (data from the DIMCA Programme)
Detection o f an early stage of COPD
The increased FEVi decline during the two-year monitoring period o f DIMCA was the 
central feature for detecting patients with an increased risk o f developing COPD. There 
are two reasons why one may doubt the relevance o f the measurement o f an increased 
FEVi decline as risk factor for COPD in patients with near normal lung function. Firstly, 
an increased FEVi decline is a well-known feature o f diagnosed COPD. It remains 
hypothetical to suppose that patients with a progressive lung function decline during 
two years o f monitoring but with (near) normal lung function develop COPD. Secondly, 
the individual significance o f the assessment o f FEVi decline can be doubted. Moreover, 
in our study, the mean standard deviation o f the individual decline was high (at least
0.065 L/yr).2 However, the frequency and duration o f the FEVi measurements (three- 
monthly during two years) seemed sufficient to detect a reliable decline in patients with 
an observed FEVi decline o f >0.08 L/yr.3
Detection o f an early stage of asthma
During the same two-year monitoring period o f DIMCA we also selected patients 
without a FEVi decline but with signs o f (asymptomatic) bronchial hyperresponsiveness 
(i.e. a decreased PC20 histamine and/or a reversible bronchus obstruction on a few 
occasions). We hypothesized these items were useful precursors o f asthma. Zhong et 
al showed that i0  out o f a group o f 50 students with asymptomatic bronchial 
hyperresponsiveness developed asthma in the following two years.4 On the other hand, 
Kolnaar showed that asymptomatic bronchial hyperresponsiveness in adolescence did 
not show the asthma-related characteristics (such as allergy) compared to symptomatic 
bronchial hyperresponsiveness.5
‘Fear of corticosteroids'
Groups identified as having mild signs o f COPD and asthma were invited to participate 
in early intervention with 500 |jg fluticasone propionate daily. Chapter 2 states the 
reasons for non-participation in this early intervention. Fear o f side-effects o f the 
drug and the absence o f symptoms were frequently mentioned as reasons for non­
participation. However, a specific fear o f inhaled corticosteroids seemed not to be 
the major obstacle for participation. Maybe the full explanation o f possible action 
and side-effects o f fluticasone that was given at the start o f the study reduced the 
expected ‘fear o f corticosteroids’ . In a self-treatment programme involving 22 adult 
asthmatic patients, Van der Palen et al hypothesized that the reluctance o f patients to 
double inhaled corticosteroids i f  necessary seemed to reflect indirectly the ‘fear of 
corticosteroids’ .6 They suggested more efforts should be made to educate patients 
with asthma about both the effects and side-effects o f inhaled corticosteroids.
Clinical effects of inhaled corticosteroids in subjects with mild signs of COPD or asthma 
We investigated i f  inhaled fluticasone (500 |jg daily) was capable to reverse a slightly 
progressive FEV: decline during two years in subjects with this mild sign o f COPD.
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We also assessed the effect o f the same dose o f inhaled fluticasone on bronchial 
responsiveness during one year in subjects with this possible sign o f asthma. We 
hypothesized that each o f the two signs would be the result o f early inflammation o f the 
bronchial wall. Chapter 3 showed no clear effects o f inhaled fluticasone 500 |j,g daily on 
lung function and symptoms in both groups. Thus, in these patient groups secondary 
prevention o f the disease seemed not to be possible through early treatment with a 
mean dose o f inhaled corticosteroids. This result indicates that there is no ground for 
recommending early detection o f all patients with mild signs o f asthma or COPD 
without a clinical diagnosis (including symptoms) followed by treatment with inhaled 
corticosteroids. However, in a group o f 3i patients with undiagnosed but c lin ic a l 
obstructive airways disease, early treatment with 500 |j,g fluticasone daily compared 
with placebo during one year (another DIMCA trial) did show significant improvements 
in FEVi and PC20 histamine.7 At an early date, results o f the START study will provide 
more evidence about the optimum time to begin treatment with inhaled corticosteroids.8 
In the START study the clinical effects o f inhaled budesonide (200-400 |j,g daily during 
three years) versus placebo are assessed in nearly 7,000 patients with newly diagnosed 
asthma.
As I have already mentioned, the inclusion criterion o f bronchial hyperresponsiveness 
in the asthma trial does not necessarily indicate (pre)asthma.5 This may be one o f 
the explanations for the lack o f effect o f inhaled corticosteroids on bronchial 
hyperresponsiveness in the asthma trial.
On the basis o f a review o f clinical predictors o f the effect o f inhaled corticosteroids 
in COPD9 , we expected the lung function to be more preserved by treatment with inhaled 
corticosteroids in comparison with placebo when ‘asthmatic features’ such as allergy, a 
higher reversibility, a higher bronchial hyperresponsiveness and a lower consumption 
of tobacco were present. However, in our experimental study in both trials, no 
subgroups with an enhanced effect o f inhaled corticosteroids were identified. A 
possible explanation might be the relative ‘healthy state’ o f the patients, so that the room 
for improvement was too small. The number o f patients could also have been too small 
to show a significant effect in subgroups.
Non-drug treatment options in patients with mild signs of asthma or COPD?
As I have stated in the introduction, treatment should probably be multifactorial. This 
thesis, however, focusses only on one particular early intervention, i.e. treatment with 
inhaled corticosteroids. In patients with mild signs o f asthma or COPD, other treatment 
options may therefore also be more or less effective.
In COPD, giving up smoking is the most effective intervention to prevent further 
deterioration o f the lung function. In the Lung Health Study, a multicentre 5-year 
study on the effects o f ipratropium bromide on the FEVi in patients with mild COPD 
during 5 years, a smoking cessation intervention at the start o f the study resulted in a 
physiological decline o f FEVi in the placebo group during the study^0 Logically, the best 
way to prevent the development, or further development, o f COPD is not to start 
smoking, and for patients who do smoke, to stop smoking as soon as possible. Recent 
guidelines are meant to assist the general practitioner to help patients with smoking 
cessation, for example by prescribing nicotine replacement therapy.n
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In asthma, avoidance o f exposure to allergens is a tool to minimize bronchial 
hyperresponsiveness and thus symptoms. Household mite avoidance measures in 29 
patients with an isolated allergy to household mite without clinical asthma (of which i3 
patients received placebo treatment) showed improved peak flow parameters and 
symptoms after six weeks.i2 Health insurance companies are increasingly reimbursing 
the purchase costs o f matrass covers when an allergy to household mite has been 
demonstrated, also in absence o f the full clinical presentation o f asthma or rhinitis.
Early detection of ‘high-risk’ patients?
From a general practitioner’s point o f view, one important question is w hich  patients 
from the general population may be considered to run a ‘high risk’ of developing clinical 
asthma or COPD and how they can be detected (and treated) as soon as possible.
Several possible risk factors for the occurrence o f aeroallergen sensitization - and 
thus asthma - in children were identified, such as atopic family history, food antibodies 
and early atopic dermatitis.^ However, the sensitivity o f these factors for aeroallergen 
sensitization was low.^ It is therefore not easy to predict whether or not a child will 
develop allergic asthma. Also in adulthood, atopy is a well-known risk factor for the 
occurrence o f asthma.H Until more specific predictors o f high-risk for asthma become 
available, general practitioners should give extra attention to patients with prolonged 
cough or wheezing from atopic families.
The most common risk factor for COPD is cigarette smoking. However, only i5% 
o f the smoking patients develop COPD.^ Furthermore, COPD may aggregate in 
families.^ Measurement o f the FEVi/VC may help to identify smokers susceptible to 
the development o f chronic airflow limitation^6 Stanescu et al found that middle-aged 
smokers are at no evident risk o f functional deterioration i f  their FEVi/VC ratio is 
normaLi6 Until more specific research on detection o f high-risk patients with COPD is 
available, it might be appropriate to offer all smokers o f 50 years and over (especially 
when COPD was diagnosed in the family) a one-time spirometry containing data about 
the FEVi and VC.
Compliance
Rates o f compliance to inhaled fluticasone in the trials in patients with early signs of 
asthma or COPD were relatively high (72%), although the results show that side-effects 
o f the drug seemed to outweigh the clinical effects (Chapter 4). One possible explanation 
o f this high compliance rate may be the ongoing communication with the patient 
during the study, as they were asked about their general well-being and the possible 
effects and side-effects o f the drug and encouraged to continue the measurement 
schedule o f the study. In a trial with 50 adult patients with moderate to severe asthma, 
compliance to a twice-daily dosing schedule with inhaled corticosteroids was monitored 
electronically during 6 weeks.i7 A good patient-clinician communication was strongly 
related to compliance (mean rate 63% of prescribed).i7 This stresses the importance 
o f a good relationship between the patient and the doctor as a major condition for 
adherence to therapy^8
Our study also showed that compliance was higher in patients who were willing to 
use the drug in daily practice when efficacy would be proven. Education plays a key role
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in improving compliance and motivating patients to be treated.i9
The patients’ own responsibility regarding the treatment is considered to be a major 
factor in improving compliance in asthma cases. Implementation o f guided self­
treatment plans in the general practice is more and more advised.20 Van der Palen 
showed a small increase o f compliance from 83 to 92% in 2i asthma patients when a 
self-treatment guideline was introduced during four weeks.6 Although the clinical 
benefits o f guided self-treatment are not yet entirely clear, the shift towards more 
personal responsibility for the treatment o f the disease may be encouraged. This may 
also lead to more ‘equality’ and thus probably to a better patient-doctor relationship.2I
Part two
Top-down strategy of inhaled corticosteroids in ‘corticosteroid-naive' mild asthma 
Chapter 5 described a meta-analysis o f the effect o f inhaled corticosteroids on bronchial 
responsiveness in patients with asthma who had never used inhaled corticosteroids. In 
this way a ‘clean’ effect o f inhaled corticosteroids on the early inflammation o f the 
bronchial wall could be assessed indirectly by measuring bronchial hyperresponsiveness. 
Bronchial provocation testing, known as an indirect measure o f inflammation, was the 
main outcome parameter o f the meta-analysis. We concluded that high doses o f inhaled 
corticosteroids (i000 |j,g daily) reduced bronchial responsiveness significantly within 
2-8 weeks. We therefore found sufficient reason to support the ‘start high’ strategy in 
the recent concensus reports on asthma.22
VanderMolen et al found that a four-week treatment o f 9 i patients with corticosteroid- 
naive asthma with 800 |j,g versus 200 |j,g budesonide daily improved lung function 
and decreased peak expiratory flow variability in both groups equally.23 However, no 
bronchial provocation testing for the assessment o f bronchial responsiveness was done 
in their study and therefore the study was not included in the meta-analysis. Although 
it is also believed that peak expiratory flow variability is a reliable and simple indicator 
o f bronchial responsiveness, a recent study with data from the DIMCA programme 
showed a poor correlation between peak expiratory flow rate and bronchial provocation 
testing.24 A recent review showed a number o f studies in which no correlation was 
shown between bronchial provocation testing and direct measures o f inflammation 
(BAL, induced sputum or bronchial biopsy).25 These results reflect the difficulty of 
finding the ‘golden standard’ for noninvasive assessment o f bronchial inflammation. 
Recent evidence suggests that nitric oxide in exhaled air also may reflect the presence 
and severity o f airway inflammation, but due to large ranges o f the level o f nitric oxide 
its use as a marker o f inflammation is not yet justified.26
Stopping treatment with corticosteroids in asthma
The general opinion is that inhaled corticosteroids have to be used daily over a long 
period. Adverse effects such as oropharyngeal complaints are relatively common.27 
Also, the occurrence o f systemic side-effects o f inhaled corticosteroids, especially in 
higher doses, such as effects on bone, growth, skin thinning and bruising, cataract and 
glaucoma27 may warrant reducing or stopping treatment once the disease is ‘under 
control’ .
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Chapter 6 showed that i2 o f i9 subjects with mild stable asthma had a deterioration 
o f their asthma (increased decline o f FEVi ) especially in the first six months after they 
stopped inhaling corticosteroids. Haahtela et al also showed that stopping with i200  |j,g 
inhaled budesonide after a two-year treatment caused a relapse o f the steady clinical 
state o f mild asthma during the following year (decrease o f PD^ histamine after one 
year, decrease in morning peak flow and increase in symptoms after 3 months), while a 
gradual reduction to a lower dose caused no deterioration.28 Two other studies also 
indicated that discontinuation o f treatment with inhaled corticosteroids in mild 
asthma does not result in a deterioration o f the clinical condition.29>3°  It is not yet 
clarified which patients are at risk o f asthma deterioration when stopping with inhaled 
corticosteroids. Therefore, i f  a general practitioner considers to stop treatment with 
inhaled corticosteroids, a close monitoring o f lung function and symptoms is advisable, 
especially in the first six months.
Inhaled corticosteroids in COPD
There exists a certain overlap between patients with a clinical diagnosis o f COPD and 
asthma. Because inhaled corticosteroids have proven their value in the treatment in 
asthma but not in COPD, it would be mandatory to assess the clinical effect in patients 
with clear COPD without ‘asthmatic features’ such as reversible airway obstruction. 
This starting-point, as well as the general doubt about the clinical effect o f inhaled 
corticosteroids in COPD, was the basis o f Chapter 7. A meta-analysis was performed of 
all published and known unpublished studies providing results o f long-term treatment 
with inhaled corticosteroids in patients with strictly diagnosed COPD (i.e. with a 
irreversible bronchus obstruction). Inhaled beclomethasone/budesonide (daily dose 
approximately i500 |j,g) caused a modest but significant preservation o f lung function 
during two years o f treatment in comparison with placebo. One o f the studies that 
attributed the majority o f data to the meta-analysis was an unpublished French study. 
We had the opportunity to analyse the original data from this study (Chapter 8), of 
which the conclusions are comparable with those o f the meta-analysis. As the data from 
the two studies overlap, this was not very surprising. On the other hand, we expected the 
analysis o f the original data-set o f the French study, also including COPD patients with 
‘asthmatic features’ , to result in a larger effect on the FEVi than that which was 
actually found. As in the meta-analysis, and in contrast to other studies, no predictors 
o f the effect o f inhaled corticosteroids such as reversibility o f obstruction and allergy 
could be identified.9
Although our study showed a small beneficial effect o f a relatively high dose of 
inhaled corticosteroids in moderate to severe COPD, the debate about its precise role in 
COPD will undoubtedly continue.3i The results o f the three large unpublished but 
already finished trials (EUROSCOP32, ISOLDE, and the COPENHAGEN CITY LUNG 
study), assessing the effect o f inhaled corticosteroids in COPD, are not very promising.33 
See Table 9.i for a brief overview o f the three studies mentioned (the data in the studies 
were derived from oral presentations at the i997 congress o f the European Respiratory 
Society in Berlin and the i998 congress in Geneve33). On the basis o f our meta­
analysis there were indications that a dose o f 800 |j,g o f the inhaled corticosteroid 
(beclomethasone) was insufficient to inhibit the progressive lung function decline
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Table 9.1: Preliminary results o f three long-term multicenter trials on the effects o f 
inhaled corticosteroids in COPD.33
EUROSCOP ISOLDE COPENHAGEN CITY LUNG
Participants 1,277 751 2 9 0
Duration 3  y e a r s 3  y e a r s 3  y e a r s
Intervention b u d e s o n id e  
8 0 0  | ig  v s . 
p la c e b o
f lu t ic a s o n e  
1 0 0 0  | ig  
v s . p la c e b o
b u d e s o n id e  ( 1 2 0 0  | ig  0 -6  
m o n th s )  8 0 0  | ig  
v s . p la c e b o
Baseline FEV1 7 7 % p r e d . 5 0 % p r e d . 8 6 % p r e d .
Long-term effect on FEV1 
decline
n o n o n o
Effect on 
exacerbations
n o  d a ta y e s n o
Effect on quality o f  life/ 
functional status
n o  a s s e s s m e n t y e s n o
during two years in our patients with moderate to severe COPD (mean FEVi 50% pred.). 
This may partly explain the absence o f the effect o f a three-year daily treatment with 
800 |j,g budesonide on the long-term lung function decline in patients with (mild) 
COPD (FEVi 77% pred.) in the EUROSCOP study, and with 800-i200 |j,g budesonide 
in patients with (mild) COPD (FEVi 86% pred.) in the COPENHAGEN CITY LUNG 
study. On the other hand, a three-year trial with a higher dose o f inhaled corticosteroids 
(i000 |J.g fluticasone daily) in patients with severe COPD (FEVi 50% pred.) participating 
in the ISOLDE trial did not show a different long-term lung function decline between 
the active and placebo group either. Only in the ISOLDE trial did the number of 
exacerbations decrease during active treatment. The same trial showed a significant 
increase in the quality o f life.
On the basis o f our results and all these preliminary findings, the conclusion must be 
that only a small beneficial long-term effect o f inhaled corticosteroids, in a high dose, 
has been demonstrated in patients with moderate to severe COPD. This stresses 
the importance o f future development o f new treatment options in COPD. In the mean 
time, the most effective intervention in COPD, i.e. giving up smoking, has to be 
encouraged more. Recent international recommendations for physicians may help to 
encourage patients to ban the cigarette from their lives.n ‘The four A’s’ seem the 
central tool in these recommendations: Ask about smoking at every opportunity, Advise 
all smokers to stop, Assist the smoker to stop (for example by prescribing nicotine 
replacement therapy) and Arrange follow-ups.n
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Future asthma and COPD drug therapy - some options
Inhaled corticosteroids are undoubtfully the most effective anti-inflammatory treatment 
o f asthma. However, in the light o f the possible (systemic) side-effects o f these anti­
inflammatory drugs, other treatment options may be considered, especially in mild 
stages o f asthma. Leukotriene receptor antagonists (such as montelukast, zafirlukast) 
and leukotriene synthesis inhibitors (such as zileuton) are newly developed oral drugs 
directed against leukotrienes as part o f the inflammatory components in the airways in 
asthma.34 As a consequence, leukotriene modifiers have shown to decrease bronchospasm, 
eosinophil recruitment and bronchial hyperresponsiveness in patients with asthma.34 
Clinical studies in patients with mild to moderate asthma have shown that leukotriene 
modifiers, compared with placebo, improve lung function, decrease the need o f £  
agonists and decrease symptoms o f asthma, especially at night.35 Reported adverse 
effects were relatively mild, although it must be said that long-term clinical studies have 
not yet been performed. The oral administration o f leukotriene receptor antagonists 
may also have the advantage o f a better compliance than inhaled anti-asthmatic drugs. 
Huse et al showed that, during a one-year registration o f anti-asthmatic prescriptions 
in 455 patients, the compliance with oral anti-asthmatic medication was 70% in 
comparison with inhaled medication (52%, p<0.000i).36
In COPD, free (oxygen) radicals from cigarette smoke or activated neutrophils are 
known to cause irreversible lung tissue damage.37 Anti-oxidant drugs therefore become 
increasingly important in the treatment o f COPD. Some clinical studies showed that 
oral acetylcysteine decreased the number o f exacerbations38 and days o f illness.39 One 
study suggested a decrease o f the FEVi decline as a result o f acetylcysteine.40 This study 
was only published as an abstract, however. It was hypothesized that anti-oxidant 
treatment might be more effective among those COPD patients who respond less well 
to inhaled corticosteroids (low reversibility and heavy smoking).4J Further studies will 
have to evaluate the precise role o f acetylcysteine in the treatment o f COPD. However, 
Dutch general practitioner’s guidelines for the treatment o f COPD recommend a trial of 
acetyl-cysteine in case o f frequent exacerbations.42
Main  conclusions of the general discussion
-It remains doubtful i f  an increased FEVi decline in subjects with near normal 
lung function and without symptoms or with few symptoms is a precursor o f the 
development o f COPD, and that bronchial hyperresponsiveness in subjects without 
symptoms or with few symptoms is a precursor o f the development o f asthma. 
-Education about the possible action and side-effects o f inhaled corticosteroids may 
reduce the ‘fear o f corticosteroids’.
-The absence o f a beneficial effect o f inhaled fluticasone in subjects with mild signs of 
asthma was possibly caused by the relatively ‘healthy state’ o f the patients, so that the 
room for improvement was too small.
-In subjects with mild signs o f COPD, smoking cessation seems the best measure to 
prevent a (further) development o f COPD.
-In order to detect patients with a ‘high risk’ o f (further) developing COPD, a one-time 
spirometry could be offered to all smokers o f 50 years and over.
-A good patient-doctor relationship on the basis o f ‘equality’ may be a key factor in 
enhancing compliance to the treatment.
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-The bronchial provocation testing is considered as the ‘golden standard’ for measuring 
bronchial inflammation until more specific non-invasive measurements become 
available.
-Future investigations will have to indicate which patients with asthma who stop 
treatment with inhaled corticosteroids run the risk o f the disease deteriorating.
-Clinical evidence shows that, in COPD, inhaled corticosteroids are moderately effective in 
relatively high doses in moderate to severe stages o f the disease. It remains unclear what 
clinical characteristics predict the effect most.
-In the light o f the possible adverse effects o f inhaled corticosteroids, future research 
will have to determine the value o f leukotriene modifiers in the drug treatment of 
patients with mild asthma.
-Future research may demonstrate i f  anti-oxidant drugs (such as acetylcysteine) are an 
alternative treatment option for patients with COPD and frequent exacerbations.
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Final Conclusions/Recommendations
The main findings as described in this thesis resulted in the following conclusions and 
recommendations for the general practice:
-Presently, there is insufficient evidence to recommend detection o f all patients with 
mild signs o f asthma or COPD without a clinical diagnosis, followed by treatment with 
inhaled corticosteroids. It is likely that some selected cases may benefit, but more 
research is needed to identify the appropriate target group ('high risk’ group).
-General practitioners do not have to be afraid that the ‘fear o f corticosteroids’ will tip 
the scale in favour o f non-participation in early intervention with inhaled corticosteroids 
in asthma and COPD. Educational efforts such as instruction about effect and side- 
effect o f inhaled corticosteroids may improve participation further.
-High long-term compliance rates to inhaled corticosteroid/ fluticasone propionate can 
be achieved in asthma and COPD, also in patients with early signs o f the disease and 
thus with few symptoms. Repetition, instruction and education about the disease and 
the (side-)effects o f treatment with inhaled cortiocsteroids, as well as a good patient- 
doctor relationship seem valuable tools to improve and sustain compliance. This is 
compatible with a pro-active monitoring approach. The general practitioner and 
practice nurse play an important role in fulfilling this task.
-When general practitioners consider to introduce inhaled corticosteroids in asthma 
patients for the first time, it is advisable to ‘start high’, and to ‘go low’ as soon as control 
has been achieved. In a stable phase o f the disease, it is even possible to stop treatment 
safely in a number o f patients. However, accurate supervision o f symptoms, use of 
bronchodilators and lung function is necessary -especially in the first six months after 
the reduction or cessation o f treatment- to avoid unexpected exacerbation o f the disease.
-High daily doses o f inhaled corticosteroids slightly modify the progressive course of 
lung function in moderate to severe COPD beneficially. The role of lower doses o f inhaled 
corticosteroids remains unclear. Furthermore, future investigations will have to 
reveal which COPD patients may benefit most from long-term treatment with inhaled 
corticosteroids. In the meantime, a better implementation o f smoking cessation 
strategies is highly recommended.
149
Chapter 10
Scientific Publications
-Bottema BJAM, Fabels EJ, Van Grunsven PM, et al. NHG-Standaard CARA bij 
Volwassenen: Diagnostiek. Huisarts Wet 1992;35:430-36.
-Dompeling E, Van Grunsven PM, Van Schayck CP, Folgering H, Molema J, Van Weel 
C. Treatment with inhaled steroids in asthma and chronic bronchitis; long-term 
compliance and inhaler technique. Fam Pract 1992;9:161-6.
-Dompeling E, Van Grunsven PM, Molema J, Verbeek ALM, Van Schayck CP, Van 
Weel C. Early detection o f patients with fast progressive asthma or chronic bronchitis 
in general practice. Scan J  Prim Health Care 1992;10:143-50.
-Dompeling E, Van Schayck CP, Van Grunsven PM, et al. Slowing the Deterioration of 
Asthma and Chronic Obstructive Pulmonary Disase observed during Bronchodilator 
Therapy by Adding Inhaled Steroids. A 4-year prospective study. Ann Int Med 
1993;118:770-8.
-Grunsven PM van, Dompeling E, Schayck CP van, Folgering H, Molema J, Weel C 
van. De lange adem van de CARA-patiënt. Een observatie van de inhalatietechniek. 
Huisarts Wet 1994;37:14-6.
-Grunsven PM van, Harbers R, Froeling PGAM, Muytjens HL. Een erysipelas- 
epidemie in het verpleeghuis; ziekenverzorgenden schraapt uw keel! Vox Hospitii
i 9 9 4 ;3:3-5.
-Ad hoc-consensusgroep ‘diagnostiek van astma/chronisch obstructieve longziekte 
door de huisarts’ . De diagnostiek van asthma bronchiale en chronisch obstructieve 
longziekte door de huisarts. Ned Tijdschr Geneesk 1995;139:1966-71.
-Grunsven PM van, Schayck CP van, Smeele I, Weel C van. Zelfbehandeling van 
astma met inhalatiecorticosteroïden. Een literatuuronderzoek. Huisarts Wet 
i 9 9 6 ;3 9 :56 -6 0 .
-Grunsven PM van, Dompeling E, Schayck CP van, et al. Treatment o f mild asthma 
with inhaled corticosteroids: is discontinuation o f therapy possible? Fam Med 
1996;28:46-51.
-CP van Schayck, PM van Grunsven, R. Dekhuijzen. Do patients with COPD benefit 
from treatment with inhaled corticosteroids? Eur Resp J  1996;9:1969-72.
-PM van Grunsven. Behandeling van acute, ernstige dyspneu bij astma en COPD in 
de huisartspraktijk. Een literatuuronderzoek. Huisarts Wet 1997;40:54-62.
-SG van Gunst, SAJJ Rikken, PM van Grunsven. NHG-bouwsteen: Piekstroommeting in 
de huisartspraktijk. (brochure) Utrecht: Nederlands Huisartsen Genootschap, 1997.
-PM van Grunsven. Behandeling astma door de huisarts gemakkelijker dan 
diagnostiek. Caravisie 1997;10:84-86.
-van Grunsven PM, van Schayck CP, van Kollenburg HJM, et al. The role o f ‘fear of 
corticosteroids’ in nonparticipation in early intervention with inhaled corticosteroids 
in asthma and COPD in general practice. Eur Respir J  1998;11:1178-81.
-Van Grunsven PM, Dompeling E, van Schayck CP, et al. Abrupt stoppen
150
c h a p t e r  lol SC IENTIF IC  PUBLICATIONS
inhalatiecorticosteroïden niet zonder risico. Pharm Weekblad 1998;133:724-727. 
-Folgering HThM, van Grunsven PM, van Herwaarden CLA. Intercollegiaal 
consult- Longfunctie: spirometrie. Alphen a/d Rijn: Van Zuiden Communications
B.V., 1998(1).
-van Grunsven PM, van Schayck CP, Derenne JP, et al. Long-term effects o f inhaled 
corticosteroids in chronic obstructive pulmonary disease- a meta-analysis. Thorax
i 9 9 9 ;54 :7 -i4 .
-van Grunsven PM, van Schayck CP, Molema J, Akkermans RP, van Weel C. Effect of 
inhaled corticosteroids on bronchial responsiveness in patients with ‘corticosteroid 
naive’ mild asthma: a meta-analysis. Thorax 1999;54:316-22.
-van Grunsven PM, van Schayck CP. Letter to the Editor. Thorax 1999;54:655-6.
-PM van Grunsven, C Derikx, BJP Crul. Kan de huisarts patiënten met neiging tot 
chronisering van pijnklachten in een vroeg stadium opsporen? Chronisch Pijn 
Spreekuur i999;2(3):4-5.
-van Grunsven PM. The magnitude o f ‘fear o f adverse effects’ as a reason of 
non-participation in drug treatment- a short review. J o f Asthma 2000;37(in press).
1 51
Chapter ii
Other Publications
-Anoniem. De ‘blijfbeller’. Praktijkperikelen. Med Contact 1992)47:602.
-Pierre M. van Grunsven. Welke inhalaties gebruikt u? (CARA-MORGANA’S) 
CaraVisie 1997)10:30.
-Pierre van Grunsven. Diploma terug op de zwembroek van jonge zwemmers. (De 
Discussie) De Gelderlander, 29-08^98.
-Pierre van Grunsven. To comply or not to comply..... (CARA-MORGANA) CaraVisie 
1998)11:66.
-P. van Grunsven. Chronische pijn bij de huisarts. (Gastcolumn) Tijdschrift voor 
Geneeskunde en Ethiek 1998;8:99-100.
-Pierre van Grunsven. Docteur en vacances.... (CARA-MORGANA) CaraVisie
1998)11:82.
-Pierre van Grunsven. Lang leve het ‘hackey’! (CARA-MORGANA) CaraVisie
I9 9 9 ; i2 :i4 .
-Pierre van Grunsven. Jan met de mooie achternaam. (CARA-MORGANA) CaraVisie
1999)12:62.
152
Chapter 12
In Dutch: Samenvatting en Slotconclusies/Aanbevelingen
Samenvatting
Hoofdstuk 1 behandelt een algehele introductie van de achtergrond, doel en inhoud van 
de studies die in dit proefschrift besproken worden. Astma en chronisch obstructieve 
longziekte (COPD) zijn frequent voorkomende chronische longziekten in de 
huisartspraktijk. Daar ontsteking van de luchtwegwand (bronchiale inflammatie) bij 
beide ziektebeelden in min o f meerdere mate optreedt, lijkt anti-inflammatoire 
behandeling een zinvolle behandelingsoptie. Op lange termijn treden bij astma en 
COPD onomkeerbare veranderingen in de lagere luchtweg op, waarschijnlijk ten 
gevolge van die chronische ontsteking. Het vroegtijdig starten van anti-inflammatoire 
behandeling lijkt dan ook essentieel. Inhalatiecorticosteroïden hebben hun anti­
inflammatoire werking reeds bewezen bij astma, bij COPD is de positie nog 
onduidelijk. Patiënten met een lichte vorm van astma o f COPD worden voornamelijk 
door de huisarts behandeld. De huisartspraktijk is dan ook meest aangewezen locatie 
om onderzoek te verrichten naar het effect van een zo vroeg mogelijke behandeling met 
inhalatiecorticosteroïden, zelfs nog voordat de volledige klinische diagnose is gesteld.
Het thema van dit proefschrift is de behandeling van patiënten met (lichte tekenen van) 
astma en COPD met inhalatiecorticosteroïden. Deel 1 van het proefschrift bevat data van 
de DIMCA studie, een groots opgezette studie in de huisartspraktijk over vroegtijdige 
opsporing (Detection), behandeling (Intervention), en Monitoring van patiënten met 
vroege tekenen van COPD en Astma. Verschillende aspecten van vroegtijdige interventie 
met het relatief nieuwe inhalatiecorticosteroïd fluticason propionaat {F lixotide®} in 
deze patiëntengroepen zonder een duidelijke diagnose worden onderzocht, zoals 
‘steroïdangst’, (Hoofdstuk 2), klinische effecten (Hoofdstuk 3) en therapietrouw 
(Hoofdstuk 4). In Deel 2 van dit proefschrift worden andere openstaande vragen beantwoord, 
waarbij onderzoeksgegevens worden gepresenteerd van groepen patiënten met 
gediagnostiseerd (licht) astma o f COPD. De onderzoeksvragen hebben betrekking op de 
dosering en duur van behandeling met inhalatiecorticosteroïden bij patiënten met 
(licht) astma (Hoofdstuk 5 en 6) en bij patiënten met matig ernstig COPD (Hoofdstuk
7 en 8).
Deel 1 (resu ltaten  van h e t ‘DIMCA’ programma)
In Hoofdstuk 2 worden redenen onderzocht om deelname aan vroegtijdige behandeling 
met fluticason propionaat te weigeren bij patiënten met lichte tekenen van astma of 
COPD zonder een duidelijke diagnose. De screening, monitoring en de (drie) 
interventiestudies met fluticason in DIMCA lieten 25 tot 35% weigeraars zien. ‘Aversie 
tegen medicatie’ was de belangrijkste reden van weigering tot deelname aan een van de 
interventies met fluticason (33%, 45% en 67% van de weigeraars). Specifieke ‘steroïdangst’
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was slechts bij 8% van de weigeraars die een hekel aan medicatie hadden een reden om 
niet deel te nemen. ‘Steroïdangst’ lijkt dus geen obstakel te zijn voor vroege interventie 
met inhalatiecorticosteroïden.
Hoofdstuk 3 beschrijft de klinische effecten van fluticason propionaat bij patiënten met 
lichte tekenen van astma o f COPD zonder dat de volledige klinische diagnose is gesteld. 
Twee gerandomiseerde placebo-gecontroleerde trials werden uitgevoerd na een twee jaar 
durende monitoring van longfunctie en klachten. In de eerste trial ('lichte kenmerken 
van COPD’) werden 48 patiënten met een matig versnelde achteruitgang van de 
longfunctie (FEVI > 0.04 L/jaar) gedurende twee jaar behandeld met fluticason propionaat 
500 |j,g/dag. In de tweede trial ('lichte kenmerken van astma’) werden 29 patiënten met 
tekenen van bronchiale hyperreactiviteit gedurende i jaar behandeld. In de ‘COPD’ 
groep werd het verloop van de FEVI gedurende de studie niet beïnvloed door 
behandeling met fluticason vergeleken met placebo. In de ‘astma’ groep werd de 
bronchiale hyperreactiviteit niet beïnvloed door behandeling met fluticason versus 
placebo. Ook trad er geen verandering in het aantal klachten op. Geconcludeerd werd 
dat er onvoldoende reden is om patiënten zonder een duidelijke klinische diagnose van 
astma o f COPD te screenen en vervolgens gedurende langere tijd te behandelen met 
inhalatiecorticosteroïden.
In Hoofdstuk 4 wordt de therapietrouw aan fluticason gemeten in de in Hoofdstuk 3 
genoemde onderzoeken. De hypothese was dat de therapietrouw laag zou zijn in een 
groep patiënten zonder een klinische diagnose van astma o f COPD en dus met weinig 
bronchiale klachten. Fluticason moest gedurende een jaar (in de ‘astma’ groep) o f twee 
jaar (in de ‘COPD’ groep) tweemaal daags geïnhaleerd worden met een droge 
poederinhalator (Rotadisk®). Alle teruggebrachte volle en lege schijfjes werden 
handmatig geteld. Door middel van een telefonische enquête werden vragen gesteld 
over ervaren werking o f bijwerking van het medicijn. De gemiddelde therapietrouw was 
72% (spreiding 7 tot 102%) in de ‘COPD’ trial en 71%  (8 tot 99%) in de ‘astma’ trial. De 
bereidheid van patiënten om het studiemedicijn in de dagelijkse praktijk te gebruiken 
als de werking bewezen zou zijn, was positief gecorreleerd aan de therapietrouw 
gedurende de trial (p=0.0i7). Geconcludeerd werd dat de therapietrouw hoog was 
ondanks het vroege stadium van de ziekte. De grote bereidheid om inhalatie- 
corticosteroïden te gebruiken indien de werking bewezen zou worden, was volgens de 
onderzoekers het gevolg van de duidelijke uitleg (educatie) aan de patiënten over het 
doel, werking en bijwerking van het studiemedicijn.
D eel 2
Hoofdstuk 5 beschrijft een meta-analyse naar het effect van inhalatiecorticosteroïden op 
bronchiale hyperreactiviteit in patiënten die voor de eerste maal inhalatiecorticosteroïden 
kregen voorgeschreven ('corticosteroid-naive’). Volgens consensusrapporten zou met 
een hoge dosering moeten worden begonnen, en zou de dosering snel kunnen worden 
verlaagd als de inflammatie onder controle zou zijn. Dit advies wordt echter niet 
ondersteund door klinisch bewijs. Bronchiale hyperreactiviteit, als maat voor de 
inflammatie en gemeten met behulp van een bronchiale provocatietest (bv. met
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histamine), was de belangrijkste effectparameter. Elf studies werden geselecteerd. In de 
meeste studies werden relatief hoge doseringen inhalatiecorticosteroïd (1000 |j,g/dag) 
gebruikt. Het totale effect van inhalatiecorticosteroïden versus placebo was +1.16 (95% 
betrouwbaarheidsinterval +0.76 to +I.57) verdubbelingsdosis van het bronchus- 
vernauwende middel. Dit effect bleef aanwezig als alleen de kortetermijnstudies werden 
geanalyseerd (2-8 weken). Op basis van deze resultaten was het onduidelijk of lagere 
doseringen hetzelfde resultaat zouden hebben bereikt. Vooralsnog lijkt het volgen van 
het adagium ‘start hoog, en verlaag’ gerechtvaardigd.
In een observationele studie (Hoofdstuk 6) werd gemeten o f langdurige behandeling 
met inhalatiecorticosteroïden kon worden gestopt wanneer patiënten met een lichte 
vorm van astma in een stabiele fase van hun ziekte waren. De onderzoeksgegevens 
werden ontleend aan een twee jaar durende in de huisartspraktijk gesitueerde 
gerandomiseerd gecontroleerde interventie waarbij patiënten alleen met luchtwegverwijders 
werden behandeld. De experimentele groep bestond uit 19 patiënten met (lichte) astma die 
gedurende het jaar voorafgaande aan genoemde studie inhalatiecorticosteroïden hadden 
gebruikt. De controlegroep bestond uit 70 patiënten met astma die geen 
inhalatiecorticosteroïden hadden gebruikt in het jaar voorafgaande aan de studie. In de 
experimentele groep vielen 12 van de 19 patiënten (63%) uit gedurende de interventie- 
studie wegens afhankelijkheid van corticosteroïden. In de controlegroep vielen slechts
8 van de 70 patiënten uit om die reden (i i %). Dit verschil was significant (Chi-kwadraat 
= 20.i, p<0.000i). Ook het longfunctieverlies in de experimentele groep (ex-steroïd- 
gebruikers) was groter dan in de controlegroep (FEVi daling 0 .i 65 versus 0.040 L/jaar, 
p=0.022). Stoppen met een onderhoudsbehandeling met inhalatiecorticosteroïden kan 
niet routinematig geadviseerd worden bij patiënten met licht astma, ook al lijkt de ziekte 
onder controle. Als toch overwogen wordt om behandeling met inhalatie- 
corticosteroïden te stoppen, dan dient dit onder zorgvuldige medische controle te 
gebeuren.
Over de klinische langetermijnseffecten van inhalatiecorticosteroïden bij patiënten met 
COPD bestaat nog veel discussie. In Hoofdstuk 7 werd een meta-analyse van de originele 
datasets van drie placebo-gecontroleerde studies (met een studieduur van minstens 24 
maanden) verricht. Patiënten met astmatische kenmerken (zoals reversibiliteit van de 
luchtwegobstructie) werden niet geanalyseerd. De patiënten hadden matig tot ernstig 
COPD (FEVi = 45% van voorspeld). Vijfennegentig geselecteerde patiënten waren 
behandeld met inhalatiecorticosteroïden (87 met i 500/i 600 |j,g beclomethason of 
budesonide per dag, 8 met 800 |j,g beclomethason per dag), en 88 met placebo. Het verschil 
in de prebronchodilatoire FEVi over twee jaar was +0.034 L/jaar (95% betrouwbaarheids­
interval +0.005 tot +0.063, p=0.026) in het voordeel van de met inhalatiecorticosteroïden 
behandelde groep vergeleken met placebo. De hoge dosering resulteerde in een beter 
verloop van de FEVi dan de lage dosering van het inhalatiecorticosteroïd (resp. +0.039 
L/jaar vs. +0.002 L/jaar, p=0.043). Het aantal exacerbaties werd niet beïnvloed door de 
behandeling. Er werden ook geen voorspellers van het effect gevonden (zoals 
bijvoorbeeld het rookgedrag). Patiënten met duidelijk gedefinieerd matig tot ernstig COPD 
hadden een beter verloop van de FEVi bij behandeling met relatief hoge doseringen 
inhalatiecorticosteroïden.
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Door de goede samenwerking met de Franse onderzoeksgroep naar aanleiding van de 
meta-analyse in Hoofdstuk 7 kwam er een aanbod om de volledige data van de (nog niet 
gepubliceerde) originele Franse studie te analyseren. Hoofdstuk 8 beschrijft de resultaten 
van deze studie. In een groep van i94 patiënten met matig tot ernstig COPD werden de 
behandelingseffecten en eventuele bijwerkingen van een twee jaar durende dagelijkse 
behandeling met beclomethason i500 |j,g (versus placebo) onderzocht. Gedurende de 
studie nam de prebronchodilatoire FEVi in de beclometasongroep vergeleken met de 
placebogroep significant toe met +0.038 L/jaar(SE 0.0i8, p=0.03i). De postbroncho­
dilatoire FEVi liet een vergelijkbare verandering zien. Het aantal prednison- en 
antibioticakuren was vergelijkbaar gedurende de studie in beide behandelgroepen. De 
zuurstofsaturatie verbeterde met +0.5(SE 0.2)% /jaar (p=0.02) gedurende 
beclometasonbehandeling vergeleken met placebo. Zeventien procent van de patiënten 
in de beclometasongroep hadden (niet ernstige, veelal oropharyngeale) bijwerkingen 
van het onderzoeksmedicijn, versus i5% van de patiënten van de placebogroep. Deze 
studie toonde aan dat behandeling van patiënten met stabiel matig tot ernstig COPD 
met beclomethason in een dosering van i500 |j,g per dag gedurende twee jaar relatief 
veilig was en resulteerde in een voordelig verloop van de longfunctie.
Slotconclusies/Aanbevelingen:
-Vooralsnog is er onvoldoende bewijs om vroege detectie en vervolgens behandeling 
met inhalatiecorticosteroïden aan patiënten met lichte tekenen van astma en COPD aan 
te bevelen. Het is mogelijk dat er in selecte gevallen sprake is van een voordelig effect, 
maar er is meer onderzoek nodig om de doelgroep (‘high risk’ groep) te identificeren.
-(Huis)artsen hoeven niet te vrezen dat ‘steroïdangst’ bepalend is voor het weigeren om 
deel te nemen aan vroege behandeling met inhalatiecorticosteroïden bij patiënten met 
astma en COPD, zeker niet indien een duidelijke uitleg van de (bij)werking heeft 
plaatsgevonden. Dit laatstgenoemde educatieve element kan deelname aan behandeling 
nog verder bevorderen.
-Een hoge graad van therapietrouw aan geïnhaleerd fluticason propionaat kan bereikt 
worden bij patiënten met astma en COPD, ook bij patiënten met vroege tekenen van de 
ziekte en dus weinig symptomen. Herhaling, instructie en educatie over de (prognose 
van de) ziekte en de (bij)werkingen van behandeling met inhalatiecorticosteroïden lijken 
waardevolle instrumenten om therapietrouw te verbeteren en te waarborgen. Deze 
benadering sluit aan bij het principe van pro-actief monitoren. De (huis)arts o f de 
praktijkverpleegkundige kan een belangrijke rol spelen in het vervullen van deze taak.
-Als (huis)artsen overwegen om patiënten met (licht) astma voor het eerst met inhalatie­
corticosteroïden te gaan behandelen, dan is het aanbevelenswaardig om met een hoge 
dosering te starten, en de dosering a f te bouwen als controle van de inflammatie is 
bereikt. In een stabiele fase van de ziekte is het bij een aantal patiënten zelfs mogelijk 
om de behandeling veilig te stoppen. Echter, dit dient te gebeuren onder adequate 
periodieke controle van de arts op symptomen, gebruik van luchtwegverwijders en 
longfunctie, vooral in de eerste zes maanden na stoppen o f afbouwen. Hiermee wordt
1 56
c h a p t e r  12: SAM ENVATTING EN CO NCLUSIES
voorkomen dat de ziekte onverwacht verergert.
-Hoge dagelijks doseringen van inhalatiecorticosteroïden lijken het progressief 
longfunctieverlies bij patiënten met matig ernstig COPD enigszins te kunnen 
verminderen. De rol van lagere doseringen inhalatiecorticosteroïden blijft onduidelijk. 
Verder onderzoek zal ook moeten uitwijzen welke COPD patiënten het meeste baat 
hebben bij langdurige behandeling met inhalatiecorticosteroïden. Intussen is een 
betere implementatie van ‘stoppen met roken strategieën’ noodzakelijk.
157
Chapter 13
In Dutch: Dankwoord
De afgelopen vijf jaar heb ik met veel inzet gewerkt aan dit proefschrift. Ik wil graag een 
aantal mensen bedanken die het mogelijk hebben gemaakt dat ik dit proefschrift in deze 
periode kon vervaardigen, ondanks mijn werkzaamheden als praktizerend huisarts. 
Allereerst wil ik graag mijn promotoren bedanken. Onno van Schayck, jij bedankt voor 
alle bijstand in de meest ruime zin des woords, en altijd weer de positieve spirit om 
probleempjes te helpen oplossen. Chris van Weel, bedankt voor je goede en snelle 
adviezen bij ieder manuscript, en de bereidheid om samen ‘even’ naar Parijs te gaan om 
het contact met mede-onderzoekers te versterken. Cees van Herwaarden, dank voor 
onze vaak aan filosofie grenzende discussies in de wandelgangen van buitenlandse 
congressen over longziekten. Statistiek is een boeiend maar soms moeilijk onderdeel 
van de verwerking van de resultaten van dit proefschrift. Zonder de uitstekende en niet 
aflatende hulp van Reinier Akkermans was ik dan ook ongetwijfeld blijven steken in een 
X2-toets. Bedankt voor je hulp. Lea Peters was mijn steun en toeverlaat bij de 
dataverzameling en correctie. Zij was tevens een zeer nauwgezette intermediair tussen 
mij en de patiënt, vooral in de periode dat mijn ‘schrijfwerk’ moest beginnen. Twanny 
Rouwhorst verzorgde vaak mailings, de produktie van Figuren o f tabellen, en tot slot ook 
de lay-out van dit proefschrift. Allebei veel dank hiervoor. Lilian Bierman was als 
longfunctie-assistente een onmisbare en zeer betrouwbare schakel in de data­
verzameling, evenals Victoria Verwaaijen-Larsson. Veel dank voor jullie hulp. Guido van 
den Boom, jou wil ik graag dankzeggen voor je waardevolle en kritische opmerkingen met 
betrekking tot het gehele DIMCA project en je humor als kamergenoot. Mede dankzij jou 
is DIMCA geworden wat we beoogden. Ook de andere naaste collegae van DIMCA, José 
Donkers, Ans Janssen, Marjolein van der Star en Prasanna Tirimanna, allemaal bedankt 
voor de kritische en gelukkig ook regelmatig luchtige noten waar nodig om het project 
tot een goed einde te brengen. Met jou, Sonja Cloosterman, ook promovendus op dit 
vakgebied, heb ik in de afgelopen jaren menig, soms zeer serieus, gesprek gevoerd over 
onderzoek doen en alles wat dat met zich meebrengt. Ook de rest van de ‘CARA-groep’ 
(excusez le mot!), Bart Thoonen, Ingrid Bijl-Hofland en Tjard Schermer, jullie dank ik 
voor je ondersteuning en collegialiteit. Daarnaast wil ik graag Johan Molema bedanken 
voor zijn zorgvuldige en goed bruikbare commentaren op diverse manuscripten. Hans 
Folgering wil ik dankzeggen voor de theoretische en praktische ondersteuning vanuit de 
longfysiologie, wat nog altijd een moeilijk maar interessant onderdeel is van longziekten. 
Richard Dekhuizen en Pieternel Pasker-de Jong dank ik voor hun kritische noten met 
betrekking tot de meta-analyse in COPD. Verder ben ik Dirkje Postma, Huib Kerstjens 
en Tineke Renkema van het Academisch ziekenhuis Groningen zeer erkentelijk voor 
het verstrekken van de data van hun onderzoek voor dezelfde meta-analyse bij COPD, 
en de prima suggesties ter verbetering van het uiteindelijke manuscript. Professor 
Derenne en Thomas Similowski dank ik voor het vertrouwen dat zij mij gaven dat ik
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hun Parijse data op de juiste manier zou bewerken ter publikatie. Deze dank is ook van 
toepassing op de medewerkers van Glaxo Wellcome France, die mij ondersteunden bij de 
volledige analyse van de Parijse dataset. Uiteraard bedank ik ook de nog niet genoemde 
leden van de begeleidingscommissie voor hun goede methodologische adviezen met 
betrekking tot dit onderzoek, Henk van den Hoogen, Wil van de Bosch en Maureen 
Rutten-van Mölken. Ook Peter Jagt en Hans Tamminga van de firma Glaxo Wellcome 
Nederland wil ik in dit kader graag bedanken voor hun positief kritische houding ten 
aanzien van het DIMCA onderzoek. Ook hiervan heb ik veel geleerd. Zonder mijn 
stagiaires Karin van Bosheide, René van Kollenburg en Mirjam van Deuveren zou de 
klus veel moeilijker geklaard zijn. Ook wil ik de collega-huisartsen en centrum- 
assistentes uit mijn praktijk dankzeggen voor de morele steun die ik vooral in de laatste 
fase van dit onderzoek mocht ontvangen. Dit onderzoek had natuurlijk nooit kunnen 
slagen zonder de hulp van de deelnemende huisartsen, doktersassistentes en hun 
patiënten. Ontzettend bedankt voor jullie medewerking. Pa en ma, bedankt voor jullie 
niet aflatende belangstelling en stimulerende ondersteuning sinds ik begon met deze 
studie. Tot slot dank ik jou, Marion, voor je medeleven en steun, vooral op die momenten 
dat mijn onderzoek wat moeizamer verliep. Kai en Riko, met jullie heb ik ter 
ontspanning menig balletje getrapt. Helaas moesten jullie regelmatig zonder je papa 
spelen omdat ik aan mijn proefschrift moest werken. Maar nu is het dan eindelijk af!
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Chapter 14
In Dutch: Curriculum Vitae
Pierre van Grunsven werd geboren in Nijmegen op 30 september 1962. Na het behalen 
van het eindexamen Gymnasium B in 1980 studeerde hij in verband met uitloting voor 
Geneeskunde gedurende twee jaar Biologie aan de Katholieke Universiteit van 
Nijmegen. In 1981 behaalde hij de propaedeuse Biologie. In 1982 startte hij uiteindelijk 
met de felbegeerde studie Geneeskunde aan de Katholieke Universiteit van Nijmegen. 
In 1989 behaalde hij het artsexamen. In zijn vervangende dienstperiode (1990-1991) 
was hij onderzoeksmedewerker op de Vakgroep Huisartsgeneeskunde te Nijmegen bij 
de onderzoeksgroep astma/COPD (waarvan Prof.dr. C. van Weel hoofd was en Prof.dr.
C.P. van Schayck uitvoerend onderzoeksleider). Hier werd de basis gelegd voor het latere 
wetenschappelijke werk. In 19 9 1 werd hij ingeloot voor de huisartsopleiding op de 
Vakgroep Huisartsgeneeskunde, Katholieke Universiteit te Nijmegen. Ook de 
opleidingsplaats voor huisarts was in Nijmegen (Gezondheidscentrum ‘Het Weeshuis’ , 
bij Mw. B.T.I.M. van der Bom en P.H.J. Giesen, huisartsen). Begin 1994 begon hij als 
huisarts aan het promotieonderzoek waarvan dit proefschrift het resultaat is. In diezelfde 
periode verrichtte hij waarnemingen in en rond Nijmegen. In 1997 vestigde hij zich als 
huisarts in Gezondheidscentrum Lindenholt te Nijmegen. In de toekomst wil hij zich 
richten op de combinatie praktizerend huisarts-universitair docent. In dit laatste kader 
is hij reeds werkzaam bij het Kenniscentrum Pijnbestrijding van het Academisch 
Ziekenhuis Nijmegen. Daarnaast is hij redacteur van CARAvisie en Het Chronisch Pijn 
Spreekuur, en lid van de landelijke werkgroep CAHAG (CARA-huisartsenadviesgroep). 
Hij is gehuwd met Marion Coster en heeft twee zonen, Kai en Riko. Muziek speelt een 
belangrijke rol in zijn leven en zijn werk als dokter, zoals moge blijken uit de omslag 
van het proefschrift en bijgaande CompactDisc (in plaats van stellingen).
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